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Abstract
In England an estimated, 284,000 patients are admitted to NHS hospitals each year due to 
disease caused by smoking. It is estimated that half of all teenagers who are currently 
smoking will die from diseases caused by tobacco if they continue to smoke. An estimated 
one quarter of smokers will die after 70 years of age and one quarter before, with those dying 
before 70 losing on average 23 years of life. It is the addictive nature of nicotine that 
exacerbates the toxi cities of the other components of cigarette smoke. The Royal College of 
Physicians has affirmed that the way in which nicotine causes addiction is similar to drugs 
such as heroin and cocaine. Thus studies of nicotine metabolism are of great importance 
since they determine the extent of which the addictive nature of nicotine can influence 
smoking behaviour and hence the onset of smoking related illnesses.
In this area of research capillary electrophoresis (CE) is still in its infancy. But with its 
high resolution and high number of theoretical plates achieved, CE makes for an attractive 
separating device for coupling with a mass spectrometer (MS). The overall aims of this 
work were to produce a sensitive, highly selective, and simple CE-sample stacking/MS 
assay for the measurement of nicotine and its metabolites in urine, to develop a highly 
sensitive transient isotachophoretic/MS method, that yields detection limits comparable to 
that observed by HPLC/MS and with a separation efficiency to match that of CE-sample 
stacking/MS, and finally to characterise the metabolic activity of cytochrome P450 (e.g. 
CYP2D6) in the placenta, with respect to nicotine, from a representative in-vitro human 
trophoblast-like cell line, BeWo, via HPLC/MS and CE/UV.
Analysis of urine samples was accompanied by sample clean up via SPE to ensure the 
appropriate removal of inorganic salts. An optimised hydrodynamic and electrokinetic 
injection method (HE injection) was used for CE-sample stacking/ MS. HE-sample 
stacking/MS brought about lower detection limits (LODs of nicotine and cotinine, by CE- 
sample stacking/ MS (via HE injection), were found to be 0.11 and 2.25 pg/ mL, 
respectively) when compared to sample stacking/MS via hydrodynamic or electrokinetic 
injection alone. The added selectivity that the selected ion monitoring mode of MS 
provided ensured the clear identification of nicotine and its metabolites in urine. A 
counterflow transient isotachophoresis (tITP) method was developed, with MS detection, 
for the analysis of even lower analyte concentrations. Limits of detection for both nicotine 
(0.03 pg/ mL) and cotinine (0.34 pg/ mL), via HE-tlTP/MS, were considerably lower than 
those obtained by HE injection-sample stacking/MS, suggesting that HE-tlTP/MS could be 
used complementary to HE injection-sample stacking/MS. When HPLC/MS and CE/UV 
were used to analyse cytochrome p450 activity in the human trophoblast-like BeWo cell 
line, it was clear from our data that nicotine metabolism was observed. Thus it is probable 
that CYP mediated processes play an important role in nicotine metabolism in the placenta. 
When compared to HPLC/MS both HE-sample stacking/MS and HE-tlTP/MS exhibited 
higher resolutions and peak efficiencies; with HE-tlTP/MS exhibiting comparable limits of 
detection and quantitation to those obtained by HPLC/MS with respect to nicotine, but not 
cotinine. The major improvements to the coaxial interface performance and sensitivity 
enhancements, has made CE/MS an attractive alternative to HPLC/MS for the 
determination of nicotine and its’ metabolites from biological matrices.
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Chapter 1
Introduction
1.1. A brief history of nicotine and tobacco
In 1492 Christopher Columbus discovered tobacco being smoked in the New World and 
later introduced the habit to Spain; and later in 1550 Jean Nicot, an ambassador to Portugal, 
sent tobacco and tobacco seeds to Paris from Portugal (and nicotine was named after him 
many years later) [1,2].
Native Indians smoked the dried leaf of nicotiana tabacum, which was indigenous to 
tropical America, at the time of Columbus. Tabacum, as it was termed, was subsequently 
used by the Italians, with the English obtaining their tobacco directly from America. Soon 
after, the rest of the world became involved with tobacco use and abuse [3].
Nicotiana tabacum is now cultivated throughout the world for preparation of, cigars, 
cigarettes, pipe and chewing tobacco. Nicotine constitutes approximately 2-8 % of the dry 
weight of the cured leaf (although a much larger range exists in some species), and is the 
major tobacco alkaloid. Other minor tobacco alkaloids, that are present in much lower 
amounts, include anabasine, anatabine and nomicotine (which itself is a metabolite of 
nicotine) [3].
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Since Langley and Dickenson noted the antagonistic behaviour of nicotine towards 
autonomic ganglia, in 1889, this compound has contributed greatly to the understanding of 
pharmacological responses within the human body [3].
In 1950 Sir Richard Doll and A Bradford Hill published the first evidence of a link 
between lung cancer and smoking in the British Medical Journal and in 1964 the US 
Surgeon General Luther Terry announced that smoking causes lung cancer. The British 
government later banned cigarette advertisements on television in the UK, in 1965, and in 
the same year the Federal Cigarette Labelling and Advertising Act required the US Surgeon 
General’s warning on cigarette packets [4]. Since then a variety of studies were carried out 
to determine the health effects associated with smoking and to improve upon the various 
smoking cessation strategies, which include nicotine replacement therapy.
1.2. Chemical properties of nicotine
Nicotine was isolated from tobacco, in 1828, by Posselt and Reimann and its empirical 
formula described, in 1843, by Melsens. Pictet and Crepieux synthesized it, in 1893, and 
Pictet and Rotschy described its chemical isomerism, in 1904. In 1978, Pitner et al. 
identified the special orientation of natural (S)-nicotine [3].
Nicotine has the systematic name 3-(1 -methy 1-2-pyrrolidinyl)pyridine, 1-methyl-2-(3- 
pyridyl)pyrrolidine, and is also known as P-pyridyl-a-N-methylpyrrolidine. It is a 2-(3)- 
substituted analog of N-methylpyrrolidine and is related both structurally and 
biosynthetically to nomicotine, cotinine and norcotinine. It has an empirical formula of 
C10H14N2, a molecular weight of 162.23, and a density of 1.0097 g/mL. In the majority of 
alkaloids, one heterocyclic ring is aromatic, and the other is saturated, or contains a single
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double bond, with additional conformation flexibility within the saturated ring. Nicotine is 
thought to exist in solution primarily in a conformation in which the N'-methyl group is 
trans to the pyridine ring, with the pyrrolidine ring in an envelope conformation, and the 
relative orientation of the pyridine and pyrrolidine ring is essentially orthogonal [3].
Figure 1.1. Nicotine (adapted from Gorrod and Jacob ID) [3].
Nicotine exists primarily in the S-(-)-enantiomeric form in nature but, to a lesser extent, 
may also be present as the R-(+)-isomer in nicotiana plant species. Both enantiomers are 
pharmacologically active, but the effects and potency of the (+)-2'R-nicotine enantiomer 
are still relatively unknown. Smokers may be exposed to both enantiomers, due to pyrolytic 
racemisation of the S-(-)-isomer during smoking. As much as 11 % of the R-(-)-isomer has 
been found in smoke condensate from cigarettes [3].
With two tertiary amino centres, nicotine is reported to have relative pKas of 
approximately 3.0-4.0, for the pyridino N, and 8.0-9.0 for the pyrrolidino N. The lower pKa 
value for the aromatic pyridino N is due to sp2 hybridisation on base strength, since it is 
more towards ‘s’ in character and hence electrons in that orbital are bound more tightly to 
the nucleus. The opposite is true for the pyrrolydino N. Under physiological conditions the 
N-l-protonated form does not occur, due to the considerably lower basicity of the pyridyl 
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nitrogen compared to the pyrrolidine nitrogen, while the N-l, N-l'-diprotonated species are 
formed predominantly in acidic media (pH < 4.0). At pH 7.4, nicotine exists in both its 
uncharged (lipophilic) and charged (hydrophilic) forms. Nicotine exists with a ratio of 
charged to uncharged forms of approximately 2 to 1 at pH 7.4. The lipophilic form diffuses 
through lipoprotein membranes, whilst the hydrophilic form does not. Thus the charge 
status of nicotine is of great importance when considering its biological actions [3].
1.3. Cigarette and tobacco smoke composition
Nicotine is contained in the moisture of the tobacco leaf. Thus when the cigarette is lit, it 
evaporates, attaching itself to minute droplets in the tobacco smoke inhaled by the smoker; 
and is absorbed by the body very quickly, reaching the brain within 10-19 seconds [5].
Cigarette tobacco is blended from two main leaf varieties: yellowish ‘bright’, also known 
as Virginia where it was originally grown, contains 2.5-3% nicotine; and ‘burley’ tobacco 
which has a higher nicotine content (3.5-4%). US blends are thought to contain up to 10% 
of imported ‘oriental’ tobacco, which is aromatic but relatively low (less than 2%) in 
nicotine. Cigarettes also contain ‘fillers’ which are made from the stems and other bits of 
tobacco, which would otherwise be waste products [6].
Additives are used to make tobacco products more acceptable to the consumer. They 
include' humectants (moisturisers) to prolong shelf life; sugars to make the smoke seem 
milder and easier to inhale; and flavourings such as chocolate and vanilla [6].
In response to the emergence of concern regarding the health problems associated with 
smoking, tobacco companies began to introduce filters. Filters are made of cellulose acetate
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and trap some of the tar and smoke particles from the inhaled smoke. Filters also cool the 
smoke slightly, making it easier to inhale [6].
Tobacco smoke is made up of “sidestream smoke” from the burning tip of the cigarette 
and “mainstream smoke” from the filter or mouth end. Tobacco smoke is composed of 
thousands of different chemicals, which are released into the air as particles and gases. Many 
of these toxic chemicals are present in higher concentrations in sidestream smoke than in 
mainstream smoke (with nearly 85% of the smoke in a room resulting from sidestream 
smoke) [6], The particulate phase includes nicotine, "tar" (itself composed of many 
chemicals), benzene(a)anthracene and benzo(a)pyrene (table 1.1). The gas phase includes 
carbon monoxide (which combines with haemoglobin causing a reduction in oxygen capacity 
in the blood), ammonia, dimethylnitrosamine, formaldehyde, hydrogen cyanide and acrolein. 
Some of these compounds have marked irritant properties, whilst others, including 
benzo(a)pyrene and dimethylnitrosamine, have been shown to cause cancer [7].
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Table 1.1. The major components of fresh, undiluted mainstream smoke of non-filtered 
cigarettes (adapted from K.L. Chambers, PhD thesis, Sheffield Hallam University, 2002)
[«]•
Vapour phase Amount Particular phase Amount
Carbon monoxide 10-23 mg Particulate matter 15-40 mg
Carbon dioxide 20-40 mg Nicotine 1-3 mg
Carbon sulphide 18-42 fig Phenol 60-140 pg
Benzene 12-48 pg Catechol 100-360 pg
Toluene 100-200 pg Hydroquinone 110-300 pg
Formaldehyde 70-100 pg Aniline 360 ng
Acrolein 60-100 pg B enz(a)anthracene 20-70 ng
Acetone 100-250 pg Benz(a)pyrene 20-40 ng
Pyridine 16-40 pg Qinolone 0.5-2 pg
Hydrogen cyanide 400-500 pg 2-Toluidine 160 ng
Nitrogen oxides 100-600 pg Cadmium 100 ng
Acetic acids 330-810 pg Polonium-210 0.03-0.5 pCi
Methyl chloride 150-600 pg Benzoic acid 14-28 pg
In recent decades there has been a shift from the smoking of high-nicotine and high-tar 
cigarettes to lower yield brands. The main reason for smokers choosing light cigarettes 
instead of traditional types is that they think such cigarettes are safer or less addictive than 
high-nicotine and high-tar cigarettes. The addition of ventilation holes and the use of 
reconstituted tobacco, porous cigarette papers, and chemical additives in cigarettes are all 
modifications that tobacco companies “claim” to bring about low yield cigarettes [9]. 
However, a reduction in tar levels does not necessarily lead to the assumed health benefits 
due to the tendency of smokers to compensate for the reduction in nicotine (cigarettes lower 
in tar also tend to be lower in nicotine) by smoking more or inhaling more deeply, which 
would increase the delivery of carcinogens such as nitrosamines and polycyclic aromatic
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hydrocarbons to the peripheral lung, thereby increasing the risk of lung adenocarcinoma 
[9]. Thus, low-tar cigarettes may cause different forms of cancer but not necessarily fewer 
cases.
The size of the cigarette, ventilation characteristics, nicotine and tar ratios, and nicotine 
content influence the way a person smokes the cigarette and, thus, presumably the dose of 
nicotine obtained from the cigarette. The duration of tobacco smoke inhalation, urinary pH, 
tobacco deprivation, stress, and blood nicotine levels are also factors that affect the puffing 
pattern or the number of cigarettes smoked [10].
1.4. Environmental tobacco smoke (ETS)
The size of one’s dwelling affects the internal dose of ETS exposure if the majority of 
exposure occurs in an enclosed area such as one’s home. The health risk of parental tobacco 
consumption might be increased in families living in small dwellings [11]. In a study 
carried out on 295 children, Kohler et al. [12] found passive smoke exposure (via analysis 
of nicotine, cotinine, and trans-3-hydroxycotinine in urine) in 66 % of the children, with 
the frequency in the younger children (82 %) significantly higher than that in children over 
5 years (52 %).
However, parents may be reluctant to consult their physicians about the true extent of 
their smoking habits especially when their children suffer from respiratory tract diseases. 
Thus data obtained from questionnaires has to be supported by environmental and 
biochemical markers used to measure ETS and ETS exposure [13].
Other factors that may influence the extent of passive smoking include room ventilation, 
proximity of non-smokers to smokers, number of cigarettes smoked by the smoker, and
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individual differences in sensitivity to, and/or concern about, the adverse effects of 
environmental tobacco smoke [13].
When a person breathes in air contaminated by tobacco smoke, he or she is described as 
having smoked passively. Passive smoking is associated with increased incidence of lower 
respiratory tract infections in young children and may increase the risk of lung cancer in the 
nonsmoker [14]. It has been established that long-term exposure to environmental tobacco 
increases the risk of lung cancer formation [15,16],
Active and passive smoking expose an individual to the same substances but may differ 
in the relative concentrations of the substances they inhale. Cotinine, the major metabolite 
of nicotine, can be used as a biomarker of environmental tobacco smoke exposure [13]. 
Wall et ah [17] reported higher levels of cotinine in the urine of passive smokers compared 
to non-smokers. They were also able to distinguish active smokers from passive and non- 
smokers using serum, saliva, and urine. In this study the greatest concentrations of cotinine 
were found in urine (table 1.2).
Table 1.2. Mean cotinine levels in serum, saliva, and urine of nonsmokers, passive
smokers, and active smokers (adapted from Wall et al.) [17].
N
Serum
(ng/mL)
Saliva
(ng/mL)
Urine
(ng/mL)
Mean urine 
cotinine + by urine 
creatinine
Nonsmokers
.28 * * 6.0 3.6
Passive smokers
20 * * 9.2 6.3
Active smokers 
lOcgts/day
9 78 66.9 646.8 6.73.4
Active smokers 
>10 cgts/day
40 301.2 283.7 1100.7 1325.5
*Too few subjects with detectable levels for calculation of a mean. N is the number of 
subjects.
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1.5. Other routes o f  administration.
Nicotine can also be introduced to the human body via oral snuff, nasal snuf£ food, and 
nicotine medication. The chemistry of nicotine shows that at pH 7.4 approximately 24 % of 
it is in its non-ionised form, which is more permeable through lipophilic cell membranes. 
Since moist oral snuff has an alkaline pH, nicotine is easily absorbed via the buccal 
mucosa. The amount of nicotine absorbed by the snuff user is dependent upon its 
availability in the product as well as the consumption pattern such as the size of the pinch, 
the site of placement, and the oral treatment of the pinch. Nicotine is absorbed more slowly 
from smokeless tobacco than from tobacco smoke, but peak venous blood concentrations 
after single doses of oral snuffs or chewing tobacco are similar to those for tobacco smoke. 
After smoking nicotine levels rapidly decline, while during and after the use of smokeless 
tobacco nicotine concentrations plateau. Higher levels of cotinine have been observed in 
smokeless tobacco users when compared to those of smokers [3].
Unlike oral snufi£ the absorption of nicotine from nasal snuff is fairly rapid, and levels of 
plasma nicotine concentrations shown by habitual snuff takers are comparable to the 
average increase obtained from a single cigarette by a group of heavy smokers [3].
When ingesting foods, nicotine absorption occurs via the gastrointestinal tract. Foods, 
however, contain only small amounts of nicotine, with probably certain vegetables and teas 
containing the most [3,18]. Thus food is generally considered an insignificant source of 
nicotine exposure [3]. However, because urinaiy cotinine concentrations may range from 
only 0.6 to 6.2 ng/ mL, the use of urinaiy cotinine as a biomarker of exposure to 
environmental tobacco smoke may be compromised by the emergence of cotinine as a
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result of ingesting nicotine containing foods [19]. Thus some workers have suggested that 
background cotinine must be corrected for when analysing environmental smoke exposure 
[20].
Nasal spray, inhaler, nicotine gum, and nicotine patch are all forms of nicotine 
replacement therapy. These therapies are primarily designed to wean people off tobacco 
smoking and habitual consumption of oral and nasal snuffs [21].
1.6. The Metabolism of nicotine
The purpose of metabolism is to decrease the extent to which an exogenous compound 
(such as a drug, dietary chemical, or pollutant) or an endogenous compound is retained 
within the body, by converting that compound into a more water-soluble metabolite, which 
increases the amount that is excreted in the urine or bile.
Metabolism of drugs is carried out by numerous enzymes, which are involved in the 
metabolism of endogenous compounds such as bile acids, fatty acids, steroid hormones, 
and bilirubin. The majority of these enzymes predominate in sites exposed to high 
concentrations of xenobiotics in organs such as the liver, lungs, intestines, kidneys, nasal 
mucosa and even the placenta. By far the greatest knowledge exists in relation to the 
cytochrome P450 (CYP) superfamily of oxidative enzymes [22]. The most prominent CYP 
involved nicotine metabolism is the CYP2A6. Below is a diagram showing the various 
pathways for nicotine metabolism including the conversion nicotine to cotinine via 
CYP2A6 (figure 1.2).
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Figure 1.2. A diagram showing nicotine metabolism (adapted from Gorrod and Jacob ID, 
1999, [3]).
Nicotine isomethonium 
ion
Cotinine glucuromdeN icotine-1 -N-oxide Cotinine methonium 
ion
Nicotine Glucuromde Nicotine Nicotine-A1 (5 ) 
iminium ion
Cotinine-N-oxideCotinine
5*-Hydroxycotinine Trans-3* hydroxycotinine
3-Pyridylacetic acid *r3-Pyridyl-yoxo 
butyric acid
y-3-Pyridyt-^oxo 
N-m ethyl butyr a m i d e
Tra ns-3-hyd roxycoti ni ne 
glucuronide
Chapter 1 Introduction 11
1.6.1. The role of the cytochrome P450
Cytochromes P450 (CYP) are haem-containing enzymes with iron protoporphyrin IX as 
the prosthetic group. CYP mediates biotransformation to polar metabolites, which can be 
excreted by the kidneys [23]. They are thought to bring about the hydroxylation of literally 
hundreds of structurally diverse drugs and chemicals, whose only common feature appears 
to be a reasonably high degree of lipophilicity. CYP is the terminal oxidase component of 
an electron transfer system, present in the endoplasmic reticulum, responsible for many 
drug oxidation reactions. The most intensively studied drug metabolism reaction is the 
cytochrome P450 catalysed mixed-function oxidation reaction [24]
CYPNADPH + H+ + 0 2 + R H    ►NADP+ + H20  + ROH
where NADPH is reduced nicotinamide adenine dinucleotide phosphate and NADP+ is 
nicotinomide adenine dinucleotide phosphate.
CYP consists of a family of closely related isoenzymes that exist in multiple forms of 
monomeric molecular weight of approximately 45000 to 55000 Da. The name cytochrome 
P450 is derived from the fact that the cytochrome exhibits a spectral absorbance maximum 
at 450 nm when reduced and complexed with carbon monoxide [24].
Cytochrome P450 supetfamily 
CYP genes are designated a family number and an asterisk followed by a number for each 
allelic variant (e.g. CYP2A6*2) and are categorised into their families and sub families 
based on their sequence similarities. Those with amino acid sequences showing greater than 
40 % homology belong to the same family, while those greater than 55 % belong to the
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same subfamily. CYP1, CYP2, and CYP3 are mainly involved in the metabolism of 
exogenous compounds [25].
CYP2A6 activity
Approximately 80 % of nicotine is converted to cotinine in vivo by C-oxidation [26]. It is 
thought that CYP2A6 is the major enzyme catalysing this reaction in the liver [26] although 
there are also minor contributions from other CYPs such as CYP2B6 [25], There are 
numerous studies showing the high expression of this enzyme in liver microsomes [26-28]. 
However, Pelkonen et ah [29] reported no such expression of CY2A6 in the kidney, 
duodenum, lung, alveolar macrophages, peripheral lymphocytes, placenta and uterine 
endometrium.
The ability of CYP2A6 to mediate nicotine C-oxidation at both high (500 pM) and low 
substrate concentrations (50 pM), in human liver microsomes, emphasises the major role of 
this enzyme in nicotine conversion to cotinine [30]. Also deletion of the CYP2A6 gene 
results in deficient cotinine formation from nicotine [31].
CYP2A6 is further reported to catalyse the conversion of cotinine to its primary 
metabolites trans-3'-hydroxycotinine [27,32], 5'-hydroxycotinine, and possibly norcotinine 
[32]. Coumarin, a specific and selective CYP2A6 substrate, appears to competitively inhibit 
cotinine formation [26]. Specific inhibitors of CYP2A6 include methoxsalen [33], 
psoralen, naphthoflavone, pilocarpine, and menthofuran [25]. Methoxsalen is an effective 
in vivo inhibitor of CYP2A6 activity [34] and can therefore be used in the treatment of 
nicotine addiction [35-37]. Tyndale and Sellers [37] reported that subjects who received the 
methoxsalen and oral nicotine combination smoked significantly less than those who 
received a placebo. It should be noted that in this study, the methoxsalen/placebo
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combination was more effective than the placebo/nicotine combination (the rank order of 
response was metheoxsalen/nicotine > methoxsalen/placebo > placebo/nicotine > 
placebo/placebo) [37].
When considering inhibitors, there is also the potential for enzymic inducers (e.g. 
phenobarbital, rifampin, antiepileptics) or repressors (e.g. methoxsalen). Both are important 
since the ingestion of these compounds can lead to altered enzyme activity in individuals 
with fully functional alleles [25].
Inter-individual variability in CYP2A6 activity
Polymorphisms in the CYP2A6 gene are thought to be mainly responsible for the 
observed variation in CYP2A6 activity, but environmental factors, such as inducers could 
also contribute. Thus a change in the gene sequence via a point mutation, deletion, or a 
gene conversion, may lead to the overproduction, underproduction, malfunction or absence 
of the enzyme [25]. Poor metabolisers of nicotine (individuals with two inactive gene 
variants) are homozygous for the inactive alleles CYP2A6*4/*4 [38] or CYP2A6*2/*2 or 
CYP2A6*6/*6 or CYP2A6*7. Thus the deficient metabolism of nicotine can result from 
being homozygous for 1 of several CYP2A6 alleles with gene mutations [39]. Extensive 
metabolisers have one or two copies of the active gene (i.e CYP2A6*1/*1), while fast 
metabolisers have two or more copies of the active gene (i.e. gene duplication 
CYP2A6*1/*1 x 2) [39]. Therefore CYP2A6 fast metabolisers that carry more than two 
copies of the active CYP2A6 alleles metabolise nicotine more rapidly, whilst very little 
cotinine is produced from poor metabolisers [25,38,40].
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CYP2A 6 and nicotine metabolism
As well as inter-individual variation, the frequency of CYP2A6 alleles varies between 
different ethnic groups which may result in inter-ethnic differences in the average ability to 
metabolise nicotine [40]. African Americans have a much reduced nicotine to cotinine 
conversion, clearance of cotinine, and metabolic clearance of nicotine to cotinine compared 
with Caucasians [25,41]. Chinese Americans metabolise nicotine more slowly than 
Caucasians [42]. Oscarson et al. [42] reported that high allele frequency of the CYP2A6 
gene deletion [42], found in Chinese subjects (15 % of Chinese subjects expressed the 
CYP2A6del allele), were in part responsible for their slower metabolism of nicotine 
[43,44]. Frequency of the defective CYP2A6 allele of 1-3 % has been observed in Finish, 
Spanish, and Swedish populations [45]. The metabolic ratio of cotinine to nicotine was 
greater in Koreans than the Japanese [25,46], Kwon et al. [46] showed there were ethnic 
differences in the allele frequencies of CYP2A6*1A, CYP2A6*1B, CYP2A6*4 and 
CYP2A6*5 between Koreans (45.7 %, 42.8 %, 11.0 %, and 0.5 %) and Japanese (42.4 %,
37.5 %, 20.1 %, and 0%). Thus it would appear that inter-individual difference in nicotine 
metabolism is closely related to the genetic polymorphism of CYP2A6 [46].
Both inter-ethnic and inter-individual variation in nicotine or cotinine metabolism may 
affect smoking behaviour [37,44], treatment of nicotine addiction, and the effectiveness of 
nicotine replacement therapies [25]. Inter-ethnic and inter-individual variation in nicotine 
or cotinine metabolism may also influence the risk of tobacco related cancers [45], It is also 
known that CYP2 A6 activates a number of structurally unrelated precarcinogens including 
many nitrosamines and aflatoxin B1 [44]. CYP2A6 poor metabolisers may be at lower risk 
of lung cancer development due to a decreased risk of becoming tobacco dependent and
Chapter 1 Introduction 15
less smoking if tobacco dependent, since smoke exposure is exponentially related to cancer 
risk [24]; and also because of their inability to metabolise pre-carcinogens.
CYP2A6 and smoking
It has been reported that genetics is responsible for approximately half of smoking 
initiation. The pharmacology of nicotine suggests that it is the primary compound in 
tobacco that establishes and maintains tobacco dependence. CYP2A6 variants can alter the 
rate of nicotine metabolism and consequently the amount of nicotine maintained in the 
body. Thus it is possible that individuals who are slow metabolisers, who have one or more 
inactive CYP2A6 alleles, differ in their risk for various aspects of smoking behaviour such 
as rates and severity of tobacco dependence, amount smoked regularly, and successful 
cessation. Nicotine levels will remain high for longer periods in slow metabolisers, thereby 
prolonging the adverse affects of nicotine and hence making these individuals less likely to 
become tobacco dependent. However, tobacco dependent slow metabolisers, who smoke 
less, have been shown to experience nicotine withdrawal at greater intervals of time. 
Reports suggest that individuals with extra copies of the active CYP2A6 alleles compensate 
for increased nicotine metabolism by inhaling their cigarettes with greater intensity. The 
reverse is true of slow metabolisers. Further more, it has been demonstrated that individuals 
with inactive CYP2A6 alleles tend to smoke at a later stage (3 years later than fast 
metabolisers) and for a shorter period of time (approximately 9 years) on average. Even 
though these studies have demonstrated the involvement of the CYP2A6 in the regulation 
of smoking behaviour, not all studies have found the same association [25].
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Other CYPs that may be involed in nicotine metabolism
CYP2B6 has been reported to exhibit nicotine C-oxidation activity [22,47]. CYP2B6 
mediates nicotine C-oxidation more effectively at higher substrate concentration (500 pM), 
in the human liver, than a lower substrate concentration (50 pM) [31]. However, CYP2B6 
is not constitutively expressed in human liver and is therefore relatively unimportant in the 
metabolism of nicotine in most individuals [47]. CYP2D6 also appears to be capable of 
mediating the conversion of nicotine to cotinine [30,47]; and similarly exhibits C-oxidation 
more effectively at higher substrate concentration (500 pM) than a lower one (50 pM) [31]. 
This enzyme is constitutively expressed in the liver and is therefore more likely to 
contribute to the C-oxidation of nicotine in humans [47]. 5-10 % of Caucasians exhibit a 
defective gene that codes for this enzyme, which renders them as poor metabolisers of 
many xenobiotics (e.g. coumarin) [47]. CYPs 2E1, 2C19, 1A2, 2C8, 3A4, 2C9, and 1A1 
were all reported to catalyse nicotine C-oxidation, but only at high substrate concentration 
(500 pM) [30]. However, there were no measurable activities for CYPs 1B1, 2C18, 3A5, 
and 4A11, even at 500 pM [30].
It is probable that the inter-individual variability of these enzymes, especially CYP2D6 
[23,48], could have important implications for the ability of individuals to metabolise 
nicotine to cotinine [47].
1.6.2. Phase 1 Metabolism
Nicotine contains both aromatic and aliphatic carbon and nitrogen atoms within its 
structure, providing numerous sites for metabolic oxidation (phase 1) and conjugation
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(phase 2) reactions and in some cases nicotine metabolites may also undergo reductive 
reactions.
Nicotine
The biotransformation of nicotine to cotinine in mammals is a two-step process, the first 
of which suggests the catalysis of nicotine to the intermediate compound nicotine-A1 (5 
iminium ion [49]. This may be brought about by the incorporation of oxygen at the 5' 
position of nicotine, thereby converting the basic pyrrolidine moiety into a cyclic amide 
[49]. This initial metabolic reaction of nicotine may involve electron and hydrogen 
abstraction to produce the intermediate nicotine-A1 (5 ^ iminium ion, which reacts with water 
(which provides oxygen) to yield cotinine (figure 1.2). It has been shown that nicotine can 
form three isomeric iminium ions leading to additional metabolic products [50,51]. Thus 
the formation of cotinine appears more complex than was originally thought and may 
involve electron abstraction to form an aminium radical [52], which may be further 
oxidized to isomeric iminium ions. But even though electron abstraction may be carried out 
by a single cytochrome isozyme, it is possible that the oxidation of isomeric iminium ions 
may involve more than one isozyme. CYP2A6 appears to mediate the formation of 
nicotine-A1 (5 ^ iminium ion and is the same enzyme responsible for the 3'-hydroxylation of 
cotinine. (figure 1.2) [27].
In the second step, the cytosolic molybdenum containing aldehyde oxidase is thought to 
mediate the oxidation of nicotine-A1 (5 ^ iminium ion to yield cotinine (figure 1.2) [53]. 
However, it is less clear as to which enzymes are involved in the oxidation of nicotine- 
A1(2)- and A1 (6 ^ iminium ions, although the latter process is known to yield the N- 
demethylated alkaloid, nomicotine [50].
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Cotinine
Cotinine can be excreted unchanged in most species, but is vulnerable to oxidation at both 
carbon and nitrogen centres. Hydroxylation at the 3'- position yields both cis and trans-3'- 
hydroxycotinine, with the latter form predominating over the former. Thus the trans form 
represents the major urinary nicotine metabolite in humans [54]. Hydroxylation at the 5'- 
position may also give rise to 5'-hydroxycotinine [55]. This metabolite predominates over 
its open chain tautomer 4-(3-pyridyl)-4oxo-N-methylbutyramide [3]. Cotinine and 5'- 
hydroxycotinine are converted to the corresponding N-oxides by oxidation of the pyridyl 
nitrogen (refer to figure 1.2 for cotinine-N-oxide [3].
Cotinine may undergo N-demethylation to give norcotinine in various species, but no 
such activity has been observed in man. It has been reported that cotinine undergoes 
hydroxylation of the N-methyl group to form 1 '-JV-hydroxymethylnorcotinine. This 
metabolite is thought to give rise to norcotinine. However, 1 '-TV-hydroxymethylnorcotinine 
appears to be metabolically stable and does not give rise to norcotinine in vitro. It is 
possible that the major route to norcotinine might be by oxidation of nomicotine [3].
Norcotinine
Regardless of its route of formation, the metabolism of norcotinine has been observed, to 
some extent, prior to excretion, to yield 4-(3-pyridyl)-4-oxo-butyramide [56]. This 
metabolite is the open chain form of 5'-hydroxynorcotinine, a compound found in the urine 
of rats treated with (±)-nicotine [57] but not in the urine of rats treated with (-)-nicotine 
[22]. In human urine the corresponding dehydrated product, demethylcotinine-A4(5)- 
enamine was found with a long half-life of excretion [58]. Norcotinine has been detected in
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the urine of smokers and nicotine treated rats where it has shown to be present at 
approximately 1-2 % of the total nicotine metabolite content [3].
Nomicotine
The metabolism of nomicotine has been studied both in vitro [59] and in vivo [60]. The 
corresponding acid, 4-(3-pyridyl)-4-aminobutyric acid, has also been isolated from the 
urine of dogs treated with nomicotine [60]. It is also possible that during the course of this 
oxidation process a reactive intermediate, analogous to the A1 (3 ^ iminium ion in cotinine 
formation, is produced. Nomicotine may also be sequentially oxidised at the pyrrolidine 
nitrogen to give nomicotine A1 (2)-nitrone via the intermediate T-N-hydroxynomicotine 
[59].
PyridyJbutyric acid derivatives
Cotinine and norcotinine give rise to metabolites possessing a pyridyl moiety attached to 
a modified butyric acid residue [57]. 4-(3-Pyridyl)-4-hydroxybutyric acid has been detected 
in the urine of smokers, as 5 % of the total nicotine metabolites excreted as well as the 
urine of (S)-(-)-nicotine treated rats [61].
The presence of 3-pyridylacetic acid was detected in the urine of animals or man 
following cotinine, nicotine and 4-(3-pyridyl)-4-oxobutyric acid administrations. Thus 3- 
pyridylacetic acid is now generally accepted as an end product of nicotine phase 1 
metabolism in mammalian systems (figure 1.2). It could possibly be derived from 4-(3- 
pyridyl)-4-hydroxybutyric acid by dehydration to 4-(3-pyridyl)-3-butenoic acid followed by 
reduction to 4-(3-pyridyl)-butyric acid and fatty acid degradation [3].
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Oxidation at alicyclic nitrogen
The two nitrogen centres that nicotine possesses can be oxidised chemically to produce 
isomeric nicotine-N-oxides. However, in biological systems only the acyclic pyrrolidine is 
susceptible to metabolic oxidation (figure 1.2) [3]. Nicotine can be oxidised, at the l'-N- 
position, at the l'R- and l'S- configuration, which leads to the formation of two 
diastereoisomers for each nicotine enantiomer [3]. Thus the natural S-(-)-nicotine is 
converted to l'S, l'R,2'S- and rS,2'S-nicotine-l'-N-oxide with the N-methyl group in the 
cis- and /raws-position to the pyridine ring, respectively [3]. The trans stereoisomer is the 
major stereoisomer produced in man [62].
Oxidation is mediated by microsomal flavin containing monooxygenases (FMO). In 
humans it is carried out by FM03 [62], The reduction of nicotine-l'-N-oxide to nicotine 
occurs via the hepatic and extra hepatic systems and by the bacteria of the gastrointestinal 
tract in man [3].
1.6.3. Phase two metabolism of nicotine
Metabolites can be further metabolised by enzymatic transfer to a molecule or molecular 
substructure from endogenous compounds thus forming metabolites with higher molecular 
weights. These are often highly polar, water-soluble compounds and thus aid urinary 
excretion of foreign compounds and their phase 1 metabolites. The main enzymes involved 
are methyltransferases, glucuronosyltransferases, sulfotransferases, glutathione 
transferases, and acetyl transferases [3].
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Methylation
From the urine of dogs Mckennis et al. [63] isolated a quartemary ammonium compound 
derived from nicotine. They identified this metabolite as N-methylnicotinium ion, 
methylated at the pyridine nitrogen. They also isolated, from dogs as well as from the urine 
of a non-smoking man who had orally received large quantities of S-cotinine, N- 
methylcotininium ion, which is also methylated at the pyridine nitrogen [3],
Metabolic N-methylation, in the guinea pig, involves a stereo-specific as well as regio- 
specific pathway for only the R-(+)-enantiomer of nicotine and only methylation at the 
pyridine nitrogen [3]. N-methylated nicotine metabolites account for 15 to 20 % of the total 
urinary metabolites in this species. N-methylnicotinium ion was found as a human 
nicotine metabolite in vivo in the urine of smokers as well as in vitro by incubation of 
either R- or S-nicotine with human liver cytosol [3].
Glucuronidation
Nicotine and cotinine are metabolised by N-glucuronidation to yield N-glucuronides of 
both compounds [41], whereas trans-3'-hydroxycotinine is metabolised by O- 
glucuronidation (figure 1.2) [3]. Studies have shown glucuronides to account for up to 40 
% of the metabolites excreted in urine [3]. There appear to be ethnic differences in N- 
glucuronidation of nicotine and cotinine [41]. Benowitz et al. [41] found blacks to excrete 
significantly less nicotine as nicotine-N-glucuronide and less cotinine as cotinine-N- 
glucuronide than whites, but there was no difference in the excretion of trans-3'- 
hydroxycotinine-O-glucuronide. In this study glucuronidation appeared to be polymorphic, 
with evidence of slow and fast N-glucuronide formers among blacks but unimodal
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behaviour predominating with fast conjugators among whites [41]; and high inter­
individual variation in the urinary metabolite pattern has been observed [64]. Slower 
cotinine metabolism in blacks could be due to both slower oxidative metabolism (via 
CYP2A6) and slower N-glucuronidation [41].
Thus far N-glucuronides of cis and trans-3'-hydroxycotinines have not been found in the 
urine of smokers, even though trans-3-hydroxycotinine-O- P-D-glucuronide was identified 
by both mass spectrometry and NMR, in urine. However, glucuronides of nicotine and 
cotinine have been isolated from smokers’ urine [65].
Cleavage of glucuronides may be obtained by the use of glucuronidase. UDP- 
glucuronidetransferases, of which there are at least two families, comprising at least forty 
isoenzymes, may catalyse glucuronide formation [66]. The isozymes, which are involved in 
N-glucuronidation of nicotine and cotinine and O-glucuronidation of trans-3- 
hydroxycotinine have yet to be identified. High inter-individual variation in glucuronide 
synthesis and the observation that the extent of conjugation of nicotine and cotinine is 
highly correlated, but that neither is correlated with the conjugation of trans-3- 
hydroxycotinine, suggests that the same UGT isozyme may be involved in the formation of 
N-glucuronides of nicotine and cotinine [64]. However, the formation of nicotine-N- 
glucuronide, but not cotinine-N-glucuronide, has been observed in marmoset microsomal 
preparations [67], indicating that nicotine and cotinine are not common substrates of a 
single isozyme.
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1.7. Metabolite distribution
Nicotine enters the body through the lungs, and subsequently the blood stream. It is then 
circulated to various body organs, including the liver and kidneys. It is in the liver where 
major metabolism occurs, after which a small percentage, usually 5-10 percent, of nicotine 
is excreted unchanged into the urine [64]. Approximately 70-80 % of nicotine is converted 
to cotinine, of which only 10-15 % is excreted. The remainder o f cotinine is converted to 
other metabolites, particularly cotinine glucuronide, trans-3-hydroxycotinine and trans-3- 
hydroxycotinine glucuronide (refer to figure 1.3 and table!.3).
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Figure 1.3. Quantitative scheme of nicotine metabolism. Circled compounds indicate 
excretion in urine and associated numbers indicate percent of systemic dose of nicotine. 
Adapted from Benowitz et al. [64].
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Table 1.3. Distribution of urinary nicotine metabolites as percentage of the total amount of 
metabolites excreted during 24 hour (average and standard deviation).
Nicotine
Metabolites
Smokers3 
(n = 91)
Smokeless tobacco 
Smokers users 
(n = 12) (n = 54)
Transdermal nicotine 
(n = 12)
Nicotine 9.4(5.7) 10.4(4.4) 8.3 (5.7) 11.1(4.3)
Nicotine-GlcA 4.5(2.5) 4.6(2.9) 3.0(1.8) 5.3(3.3)
Cotinine 9.2(2.6) 13.3(3.1) 7.9 (2.2) 14.9(4.6)
Cotinine-GlcA 14.0(5.4) 15.8(7.8) 8.9 (4.6) 15.4(7.9)
3HC 36.1(10.6) 39.1(12.5) 41.6(10.6) 37.0(10.8)
3HC-GlcA 22.8(10.0) 7.8(5.9) 19.4(11.0) 7.9(4.7)
NNO 3.0(2.1) 3.7(0.9) 8.6(6.9) 2.7(1.2)
CNO 0.9 (0.9) 4.5(1.5) 2.5(2.3) 5.2(1.5)
Nomicotine 0.65(0.15) 0.41(0.12)
Table 1.3 was adapted from Gorrod and Jacob IU [3].
GlcA -  glucuronide 
NNO -  Ni cotine-1 '-N-oxides 
CNO -  Cotinine-1 -N-oxide 
3HC -  Trans-3'-hydroxycotinine
Superscripts a and b denote results obtained from two different studies.
Since similar excretion profiles were found in smokers, smokeless tobacco users and 
users of transdermal nicotine, it seems likely that the metabolism of nicotine is independent 
of route of administration (table 1.3). However, these profiles of nicotine metabolism have 
not included all metabolites. For example, it is known that 5'-hydroxycotinine is a 
metabolite of cotinine. But to what extent is cotinine metabolised to 5 '-hydroxycotinine? 
This is one of the many questions which need to be addressed [3].
Chapter 1 Introduction 26
1.8. Health effects associated with smoking
In England an estimated 284,000 patients are admitted to NHS hospitals each year due to 
disease caused by smoking, occupying an average of 9,500 hospital beds every day, with 
smoking related illness accounting for 8 million consultations with GPs and over 7 million 
prescriptions each year [68].
It is estimated that half of all teenagers who are currently smoking will die from diseases 
caused by tobacco if they continue to smoke (refer to figure 1.4 for health effects associated 
with tobacco). One quarter will die after 70 years of age and one quarter before, with those 
dying before 70 losing on average 23 years of life. It is estimated that between 1950 and 2000 
six million Britons, 60 million people worldwide, would have died from tobacco-related 
diseases [68].
Nicotine poisoning can cause increased salivation, nausea, vomiting, and cardiac 
palpitation leading to an increase in blood pressure [69]. Nicotine poisoning involves 
central and peripheral effects of the nervous system (refer to table 1.5). Rapid light­
headedness, skeletal muscle weakness, prostration, tremor and convulsions are also 
symptomatic of this poisoning [3], Nicotine may also be associated with cellular stress 
(apoptosis) [70] and cardiovascular disease [71]. Metabolites of nicotine have also been 
reported to be detrimental to the human body [72]. However, nicotine may in turn play a 
part in the beneficial and protective mechanisms against some neurodegenerative diseases 
[73].
As previously mentioned, nicotine is only one of many toxic compounds in cigarette 
smoke. It is the addictive nature of nicotine that exacerbates the toxicities of the other 
components of cigarette smoke. The Royal College of Physicians has affirmed that the way 
in which nicotine causes addiction is similar to drugs such as heroin and cocaine [74].
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Tablel.4. Health effects associated with tobacco smoke (adapted from ASH fact sheet
number 2, www.ash.org, 2003) [68].
Increased risk for smokers
Acute necrotizing ulcerative gingivitis 
(gum disease)
Muscle injuries
Angina (20 x risk) Neck pain
Back pain Nystagmus (abnormal eye movements)
Buerger’s Disease (severe circulatory 
disease)
Ocular Histoplasmosis (fungal eye infection)
Duodenal ulcer Osteoporosis (in both sexes)
Cataract (2 x risk) Osteoarthritis
Cataract, posterior subcapsular (3 x risk) Penis (inability to have an erection)
Colon Polyps Peripheral vascular disease
Crohn’s Disease (chronic inflamed bowel) Pneumonia
Depression Psoriasis (2 x risk)
Diabetes (Type 2, non-insulin dependent) Skin wrinkling (2 x risk)
Hearing loss Stomach ulcer
Influenza Rheumatoid arthritis (for heavy smokers)
Impotence (2 x risk) Tendon injuries
Optic Neuropathy (loss of vision, 16 x Tobacco Amblyopia (loss of vision)
risk)
Ligament injuries Tooth loss
Macular degeneration (eyes, 2 x risk) Tuberculosis
Function impaired in smokers
Ejaculation (volume reduced) Sperm count reduced
Fertility (30% lower in women) Sperm motility impaired
Immune System (impaired) Sperm less able to penetrate the ovum
Menopause (onset 1.74 years early on 
average)
Sperm shape abnormalities increased
Symptoms worse in smokers
Asthma Graves’ disease (over-active thyroid gland)
Chronic rhinitis (chronic inflammation of 
the nose)
Multiple Sclerosis
Diabetic retinopathy (eyes) Optic Neuritis (eyes)
Disease more severe or persistent in smokers
Common cold Pneumonia
Crohn’s Disease (chronic inflamed bowel) Tuberculosis
Influenza
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Lung cancer
Lung cancer can be brought about by exposing the bronchial epithelium to 
environmental carcinogenic compounds of cigarette smoke [75]. Thus the inhalation of 
cigarette smoke together with its harmful byproducts such as benzopyrene will act directly 
on the bronchial tree and the alveoli leading to metaplasia of the bronchial epithelium from 
a columnar pattern to a squamous one and hence dysplasia and carcinoma formation in situ. 
Each time a smoker inhales, the carcinogenic chemicals released touch the inside of the 
lungs (the bronchus, bronchioles and alveoli) leading to the mutation of epithelial cells 
which keep on dividing and eventually form a cancer [76,77]. The disease can spread very 
quickly to other parts of the body and therefore surgery or radiation therapy, targeting 
localized disease, may be relatively ineffective in forestalling mortality. It is usually treated 
with a combination of chemotherapy drugs, and if it has not spread beyond the lung at the 
time of diagnosis, a combination of surgery and chemotherapy may be used [78].
Lung cancer is reported to be three times more prevalent in men than in women [79] and 
is the most common cancer in men [80]. Whilst it is on the increase in females it is now 
decreasing in men due to changes in smoking habits in recent decades [81,82], and by the 
early 1990s was said to have displaced coronary heart disease as the leading cause of death 
among smokers in the US [83]. It has been observed in various countries that regional 
variation in lung cancer mortality is difficult to explain by differences in current smoking, 
and in order to explain lung cancer death rates fully, one has to go further back in time [84].
Approximately 3 million people each year die from smoking in developed countries, half 
of them before 70 years of age [85], which in 40 years time may rise to 10 million [79]. 
There is a strong relationship between smoking and lung cancer, with about 90 % of cases 
may be attributed to tobacco usage [76]. But despite the overwhelming evidence for linking
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lung cancer to smoking, there are other environmental and /or genetic risk factors that may 
be associated with the development of this disease [86],
All cancers
Cigarette smoking is the predominant cause of lung, laryngeal, pharyngeal, oesophageal, 
bladder [87,88], kidney, and pancreatic cancer [89]. Heavy smokers are at risk of up to 30 
percent cumulative lifetime risk of developing cancer, compared to 1 percent of non- 
smokers [90], A study by Schnoll et al. [91] on cancer patients, revealed that continued 
smoking and a reluctance to quit were associated with having relatives at home who smoke, 
a longer time between diagnosis and assessment, completion of medical treatment, greater 
nicotine dependence, and emotional distress.
1.9. Smoking and pregnancy
Approximately one-third of pregnant women in England smoke, and the majority of 
women who smoke during pregnancy are likely to be young, single, and of low social 
standing. The male partner is also likely to smoke. Only one in four women who smoke 
succeed in stopping at some time during pregnancy, and almost two-thirds of women who 
succeed in stopping smoking in pregnancy restart again after the birth of their baby [92].
Babies bom to women who smoke are on average 200 g (8 oz) lighter than babies bom to 
comparable non-smoking mothers. Furthermore, the more cigarettes a woman smokes during 
pregnancy, the greater the probable reduction in birth weight. Recent research suggests that 
cigarettes can reduce the flow of blood in the placenta, which limits the amount of nutrients 
that reach the foetus [93,94]. Low birth weight is associated with higher risks of death and 
disease in infancy and early childhood. Since adverse effects of smoking in pregnancy are 
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due mainly to smoking in the second and third trimesters, if a woman stops smoking within 
the first three months of pregnancy, her risk of having a low-weight baby is dramatically 
reduced [93].
The rate of spontaneous abortion (miscarriage) is substantially higher in women who 
smoke. On average, smokers may experience more complications of pregnancy such as 
premature detachment of the placenta, bleeding during pregnancy, and premature rupture of 
the membranes; there may also be a link between smoking and ectopic pregnancy and 
congenital defects in the offspring of smokers [92].
Exposure of the mother to passive smoking has also been associated with lower birth 
weight, a higher risk of perinatal mortality (still birth) and spontaneous abortion. Still-birth is 
increased by about one-third in babies of smokers. More than one-quarter of the risk of death 
due to Sudden Infant Death Syndrome (cot death) is attributable to maternal smoking 
(equivalent to 365 deaths per year in England and Wales) [92].
Smoking during pregnancy may also have implications for the long-term physical growth 
and intellectual development of the child. It has been associated with a reduced height of 
children of smoking mothers as compared with non-smoking mothers. There is also evidence 
that smoking interferes with women’s hormonal balance during pregnancy and that this may 
have long-term consequences on the reproductive organs of her children [92,95].
It has been known for some time that the offspring of women who smoke during 
pregnancy are likely to have abnormal lung function and associated higher incidences of 
lower respiratory disorders [96-99]. The identification of nicotinic acetylcholine receptors 
(nAChR) in foetal monkey lung suggests that a direct interaction between nicotine and 
nAChR in foetal lung may predispose such infants to postnatal pulmonary abnormalities 
[100].
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Fukuda et al. [101] found that the offspring ratio (male to female) was lower when either 
one or both parents smoked more than 20 cigarettes per day compared to non-smoking 
couples. It was suggested that smoking reduced the offspring ratio around the time of 
conception, rather than imposing a selective disadvantage on male foetuses during later 
pregnancy.
Sasco and Vainio [102] suggest that it may be possible for genotoxic and carcinogenic 
components of tobacco smoke to pass through to the placenta and hence the developing 
foetus. The exposure ofBeWo cells (a human trophoblast-like cell line) to benzo(a)pyrene, 
from cigarette smoke, has been associated with placental toxicity [103].
Animal models have also implicated both nicotine and cotinine in Sudden Infant Death 
Syndrome [104].
1.10. Tobacco policy
The control of lung cancer has been a goal of policies over the years since the 1960s. 
Over time, nicotine replacement therapy (NRT), the development of counter-advertising 
and the introduction of tobacco taxes for the promotion of health has become a part of these 
policies. Many countries were unable to legislate comprehensively but nevertheless 
achieved substantial effects from enthusiastic and active public campaigns. This is most 
evident in the decline in male lung cancer observed in the UK. However, for reasons which 
can be largely attributed to specific advertising targeting women, the decline in male rates 
has been accompanied by an almost universal increase in smoking by women, and
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predictably an increase in the number of female deaths by lung cancer. By 2002, lung 
cancer exceeded breast cancer as a cause of death in women [81].
It was therefore logical for governing bodies to implement the policy of reducing tar and 
nicotine yields, since there was a dose response between cigarette dose and cancer risk as 
well as a reduction of risk with cessation. However, changes in the qualitative nature of tar 
led to increased levels of nitrate (e.g. nitrosamines) in tobaccos and a downward trend in 
benzo(a)pyrene. All this meant was that a decline in squamous cell carcinoma, and an 
increase in adenocarcinoma were observed. Ventilation filters were also introduced, but to 
no avail (as previously described). Nevertheless, the reduction of yields has some beneficial 
effect, but has not delivered the substantial benefits that were expected [81].
An increase in the amount of nicotine was meant to decrease compensatory smoking, but 
did nothing to reduce nicotine addiction. Higher levels of nicotine should have reduced 
inhalation of carcinogens and toxins, but would have been very difficult to sell publicly. A 
reduction in the amount of nicotine should have reduced the addictiveness of cigarettes, but 
would have increased compensatory smoking [81].
A review, which appeared in the 20 May (1998) issue o f New Scientist [106] revealed that 
"in 106 papers published” the major factor associated with concluding that passive smoking 
is not harmful was whether an author was affiliated with the tobacco industry. Therefore it 
can be said that the major problem faced with trying to link smoking with lung cancer is not 
the lack of evidence, but is the power of the major tobacco companies to influence research. 
If these companies recognize the relationship between smoking and lung cancer (or any 
other cancer or disease for that matter) they will have to pay compensation to nonsmokers 
who have developed the disease and bans on smoking in public places will be enforced, 
both of which will cause severe losses to businesses [105], However, the influence of the
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tobacco industry, together with its credibility, is decreasing, probably as a result of 
numerous large compensation payouts to families in the U.S. [81].
Today nicotine replacement therapies (NRTs), such as patches and nasal sprays, help ease 
the withdrawal symptoms many smokers experience when they try to quit and studies have 
shown these products to be useful to those smokers who are have a strong nicotine 
addiction. Smoking in the UK is now less socially acceptable than ever, with the number of 
adult nonsmokers outnumbering those who do by approximately two to one. Long-term 
policy should include a reduction in the attractiveness of the cigarette and as much 
replacement as possible by clean nicotine products (implying the control of additives and 
demonstration of safety in both burnt and unbumt form) [81].
A cessation policy should involve the use of psychological and therapeutic support [106]. 
Unfortunately not all G.P.s are forthcoming with advice. The health service should do more 
to promote NRTs, as such products are widely available in most countries. In Europe, of the 
40-80 % of patients who want to quit, only one-third are advised by their doctor, with 
slightly greater than 10 % given advice as to how to go about it. Despite this set back, the 
epidemic of tobacco-induced mortality is on the decrease in some developed countries, but 
is on the increase in the developing world (where NRTs are too expensive for consumers) 
[81].
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1.11. Pharmacology
Nicotine distributes rapidly into many tissues of the body including foetal tissues as 
shown by studies with pregnant mice [3]. Nicotine initially concentrates in the brain and 
spinal cord and within 15 minutes its concentration in the liver increases. Within 30 
minutes of injection the majority of nicotine is in the liver, the adrenals, the stomach and 
bone marrow, but only a small amount is left in the central nervous system [3].
Nicotine is reported to have some similar actions to acetylcholine, as well as 
parasympathetic and sympathetic nerve stimulation. Acetylcholine, a neurotransmitter, 
affects both muscarinic and nicotinic receptors. The charge similarities of nicotine and 
acetylcholine may account for their similar actions. The pyridino N of nicotine is an 
electron donor that is similar to the keto oxygen of the acetyl group of acetylcholine, and 
the positive charge of the quartemary nitrogen of acetylcholine is similar to the positive 
charge of the pyrrolidino nitrogen (refer to structures in figure 1.4) [3].
Figure 1.4. Charge similarity of nicotine and acetylcholine [3].
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There are at least five muscarinic receptor subtypes (M1-M5) with transduction 
mechanisms to alter second messengers. Specific genes for each of the five subunits of 
several nicotinic cholinergic receptors (nAChRs), which encode a variety of protein 
subunits similar to the skeletal muscle receptor, have been isolated [3],
Since (S)-nicotine is usually more potent than (R)-nicotine it is most probable that 
nAChRs have stereo-selective preference. However, nAChRs do not appear to be the main 
targets of cotinine, the major metabolite of nicotine [107]. The fact that all major organs of 
the body possess nAChRs makes it possible for nicotine to affect all of these. As multiple 
ligand-gated ion channels, these receptors are very complex, involving many presynaptic 
and postsynaptic sites, especially in the central nervous system. An influx of Ca2+ and Na+, 
intracellularly, provides the ionic basis for the release of multiple chemical messengers 
upon receptor depolarisation. But repeated nicotine exposure leads to a rapidly diminishing 
receptor response and to eventual receptor desensitisation (tachyphylaxis), which could 
probably lead to receptor desensitisation to acetylcholine. This may account for the mixed 
stimulant/ depressant actions of nicotine [3].
Behavioural and neurochemical effects of nicotine via the mesolimbic dopaminergic 
system have been documented by Balfour and Benwell [108]. The pharmacological 
antagonism of dopaminergic receptors results in the blockade of locomotor stimulant and 
reinforcing effects of nicotine [109,110].
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Table 1.5. Dose-dependent pharmacological actions of nicotine (adapted from Gorrod and 
Jacob m, 1999) [3].
Pharmacological sites Pharmacological actions of nicotine
Central nervous 
system
Stimulation of brain stem- arousel or wake-up effect.
+ve cognitive effects increasing memory, teaching behaviour 
etc.
Relaxation.
Mixed stimulant/ depressant actions.
Increased orienting response.
Improved gating of relevant stimuli.
Decreased monosynaptic reflexes (e.g. patellar reflex). 
Reinforcing self administration behaviour.
Dependence, addiction, withdrawal.
Stimulation of chemoreceptor trigger zones- nausea and 
vomiting.
Tremor, convulsions and death.
Peripheral nervous 
system
Stimulation and blockade of sympathetic and parasympathetic 
autonomic ganglia.
Peripheral afferent stimulant involving taste and smell.
Aortic and carotid body chemoreceptor stimulation.
Stimulation of gastrointestinal, pulmonary and skeletal muscle 
spindle afferents.
Cardiovascular
system
These include:
Low concentrations- increased heart rate.
High concentrations- decreased heart rate (poisoning). 
Increase in systolic and diastolic blood pressure. 
Cutaneous vasoconstriction.
Therapeutic potential 
of nicotine
Treatment of tobacco addiction and dependence. 
Parkinsons disease.
Alzheimer’s disease.
Schizophrenia.
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Nicotine may also affect the gastrointestinal system, the endocrine system, and hepatic 
and renal systems and lead to a decrease in body weight, an increase in energy expenditure 
and decrease energy consumption [3].
Since many of the metabolites of nicotine are structurally similar it is logical that some 
would also be pharmacologically active. Currently the metabolites of nicotine thought to be 
pharmacologically active are cotinine (to a much lesser extent) and nomicotine. The former 
was reported to oppose the effects o f nicotine on the cardiovascular system, but its effects 
were not blocked by antagonists of nicotinic, muscarinic, histaminic or adrenergic receptors 
[107]. The latter was reported to be behaviourally active, since it has locomotor stimulant 
and reinforcing effects similar to that of nicotine in rats [111]. Nomicotine, like nicotine, 
desensitises nicotinic receptors, but with approximately 12-fold lower potency. It is able to 
bring about cross-desensitization, suggesting the involvement of common nicotinic receptor 
subtypes [111]. Additionally nomicotine was found to increase synthesis and metabolism 
of dopamine, providing evidence that it plays a contributory role in tobacco dependence 
[112]. This is entirely reasonable as nomicotine has a longer half-life than nicotine in 
plasma and brain [113] and therefore reaches a three-fold higher concentration in brain and 
plasma than nicotine [114].
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1.12. Nicotine in biological samples
Most biological materials are complex mixtures consisting of many different components. 
These may include proteins, salts, lipids, nucleic acids, etc [3]. Most of these constituents 
of biological matrices may compromise the analytical procedure [3], Blood or plasma 
levels are important in pharmacokinetic/ pharmacodynamic studies, since they are likely to 
correlate with concentrations at the site of action [115]. The longer half-life of cotinine 
ensures that its concentration in blood is greater and more stable throughout the day than 
that of nicotine [115]. Cotinine concentration, whether measured in plasma, saliva or urine 
has been shown to be the best indicator of smoking status [3].
The most widely used biological materials for nicotine and cotinine measurements are 
whole blood, plasma (or serum), and urine [3]. Other biological materials which have been 
studied include saliva, cerebrospinal fluid, bile, sweat, breast milk, hair, and seminal 
plasma. Cerebrospinal fluid is one of the least problematic fluids to analyse while whole 
blood and tissue are the most difficult [3], Saliva and urine samples are utilised most 
frequently in tobacco cessation studies and epidemiological studies, due to their less 
invasive nature. Generally concentrations of nicotine and cotinine are greater in urine than 
in blood, plasma or oral fluid [17,115].
Whole blood
Blood is made up of a complex mixture of proteins, dissolved fats and solids, and 
suspended cells, the centrifugation (at low speeds) of which aids removal of red blood cells
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and leaves a clear solution, the plasma. Lysing of red blood cells may prove hazardous to 
most experiments, since components released could interfere with analysis. Generally drugs 
or metabolites are not extracted from whole blood, but from plasma and serum [3].
Plasma and Seram
Drugs and metabolites present in both serum and plasma can bind to proteins in these 
samples, and by doing so they may compromise the quality of data produced, especially 
when considering HPLC and capillary electrophoresis. Thus numerous methodologies for 
the removal of protein from the sample and the release of protein-bound drugs have been 
developed. These include precipitation by heating or freeze-thawing cycles, the 
denaturation and precipitation of protein, solvent extraction, and solid phase extraction 
(SPE) [116].
Urine
Urine is relatively free from proteins and lipids and can usually be extracted with organic 
solvents, or analysed directly. Its composition is largely dependent upon diet and diuresis. 
Extraction of lipid-soluble drugs from urine can yield an extract which is relatively free 
from potentially interfering endogenous components, as such components in urine are 
water-soluble [3]. Urine that is allowed to stand, for relatively long periods of time, slowly 
loses its carbon dioxide content and becomes more alkaline due to bacterial conversion of 
urea to ammonia [3]. The alkaline conditions result in the precipitation of inorganic salts 
such as phosphates, and possible co-precipitation, or degradation of analytes. One of the 
most popular and simplest methods for analyte extraction from urine is SPE. To date there 
are various examples of SPE carried out on the urine of smokers [116,117].
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Urine analysis may also be affected by temperature. Hagan et al. [118] found that as 
storage temperature increased, cotinine levels in urine also dramatically increased, possibly 
due to hydrolysis of cotinine-N-glucuronide. This would have an adverse effect on analysis 
especially when tiying to quantify the amount of conjugated or unconjugated cotinine 
present in urine. That is, a false positive could be achieved in many cases.
Oral fluid
Oral fluid, like urine, is relatively free from interfering substances. Even though it is a 
relatively viscous material, saliva can be easily extracted with organic solvents, and can be 
analysed directly (especially when considering immunoassays). But direct introduction into 
a HPLC or GC column or a fused silica capillary may prove difficult because of the viscous 
nature of this matrix. For some drugs, levels of drug in saliva are thought to reflect the 
concentration of non-protein bound analytes in the blood (e.g. non-ionised drugs such as 
steroids readily pass from plasma to saliva). Analysis of nicotine and its metabolites has 
been reported after a simple centrifugation step followed by dilution with water. However, 
drugs may bind to mucoid proteins in saliva. The pH of saliva is approximately 7.0 to 7.8 
and any change in pH will affect the distribution of drugs in saliva, especially those bound 
to proteins. Thus it is imperative that the investigator be made aware of the pH prior to 
analysis [3].
Cerebrospinal fluid and Bile
Analysis of cerebrospinal fluids is important for centrally acting drugs, since it provides 
concentrations of the drugs and their metabolites in the vicinity of the receptor and/or 
enzyme active sites responsible for the drug’s pharmacological properties. Even though
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cerebrospinal fluids can be difficult to obtain, extraction of analytes from such fluids may 
be brought about by the same extraction procedures for serum and plasma. Bile, like 
cerebrospinal fluids, is difficult to obtain but techniques that have been developed for the 
analysis of drugs in plasma and serum are generally applicable to this type of matrix [3],
Breast milk
As for breast milk, the major problem is the presence of large amounts of fat 
(approximately 4.5 % in mature human breast milk). Treatment of this fluid with lipase 
prior to HPLC analysis has been reported for some drug analyses, but generally a fat 
removal step (e.g. washing 0.5 mL breast milk, at pH 3.0-4.0, with 10 mL w-hexane) is 
recommended. The importance of breast milk analysis is realised when one needs to 
determine if drug molecules can be transferred from mother to infant via this route [3],
Hair
Analyses of scalp hair from smokers have also revealed that inhaled nicotine becomes 
fairly concentrated in the hair shaft (an average of 15.5 pg/ mL in smokers) [3]. An average 
concentration of 2.42 jag/ mL of nicotine, from the scalp hair of 10 non-smokers, suggests 
that the use of this biological material would be ideal for the analysis of environmental 
smoke exposure. However, contamination of the exterior of the hair shaft by 
environmentally derived nicotine and various hair treatments could compromise the 
analysis [3]. A further draw back is the harsh extraction procedures that are required for 
hair analysis [119].
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1.13. Analytical methodology for the determination of nicotine and its
metabolites
Numerous methods have been used for the analysis of nicotine and its metabolites. These 
range from highly sensitive and accurate mass spectrometric methods to qualitative or 
semi-quantitative colorimetric methods. In general the more sensitive and accurate methods 
are less available and more costly. New instrumentation suitable for GC/MS determination 
of nicotine and cotinine is likely to cost about £ 31,000. State of the art mass spectrometers 
can cost in excess of £ 125,000 [115],
Gas chromatography coupled to mass spectrometric detection (GC/MS) is well suited to 
nicotine and cotinine determination and has proved to be very sensitive and accurate. 
Nicotine and cotinine are readily detected by gas chromatography coupled with nitrogen- 
phosphorus detection (GC/NPD), with excellent precision and accuracy (and 
instrumentation can cost up to $ 15,000) [115].
A polarisation fluoroimmunoassay (carried out on the Abbot TDx analyser) was able to 
discriminate active smokers from non-smokers (including passive smokers) by applying a 
cut-off at 0.5 mg/ L of total urinary cotinine [120]. Radio-immunoassays (RIA) and 
enzyme-linked immunosorbent assays (ELISA) have frequently been used for measuring 
nicotine and cotinine in plasma with good precision and accuracy. GC, HPLC and 
immunoassay methods used for the determination of nicotine and cotinine, in plasma, are 
usually applicable to urine. Colorimetric methods for measuring urine levels of nicotine, 
cotinine, and their metabolites without distinguishing individual compounds have also been 
developed [115].
Chromatographic methods (GC and HPLC), especially when coupled with mass 
spectrometry, usually provide great sensitivity and specificity. However, they are generally 
Chapter 1 Introduction 43
the most costly due to the expensive instrumentation, the need for computational 
interpretation of results, and highly trained personnel. Chromatographic methods have been 
successfully applied to pharmacokinetic studies, in which accurate measurement of low 
levels of nicotine and its metabolites are needed to determine half-lives [115].
Immunoassays
Immunoassays are fast and economical for large numbers of samples and in most cases 
have good sensitivity, accuracy, and precision. Antibodies to nicotine and its metabolites 
can be coupled to an enzyme, which reacts with a substrate to yield a coloured product (as 
in the case of ELISA) which is measured spectrophotometrically [121,122] or is 
radiolabelled (as in RIA) and read by a radiometric detectors [123-125].
Benkirane et ah [126] observed similar detection limits for both ELISA and RIA (0.1 pg/ 
mL of cotinine). For the analysis of serum and saliva, non-smoker values ranged from 0.1 
to 17 pg/ L by ELISA and 0.1 to 27.5 pg/ L by RIA, whereas smoker values ranged from 
50 to 1000 pg/ L (ELISA) and from 70 to 800 pg/ L (RIA) [126]. Comparative analysis of 
96 human sera revealed a good correlation between ELISA and RIA methods [126],
When ELISA results were compared with those obtained by GC, a correlation coefficient 
r = 0.886 was obtained [122]. For samples containing > 50 ng/ mL of cotinine, RIA gave 
results on average 60 % higher than GC [127]. This was thought to be due to RIA cross­
reactivity of cotinine antibodies with other nicotine metabolites [127], However, samples 
containing < 7 ng/ mL of cotinine gave no significant correlation [127].
Thus a major disadvantage of immunoassays is the possibility of interference by 
endogenous compounds or other drugs. It is possible for compounds with similar structures 
to interfere with immunoassays due to their having significant affinity to the antibody.
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Schepers and Walk [121] found cotinine metabolites to cross-react with antibodies used in 
certain immunoassays, which led to higher values than expected, when compared to 
chromatographic methods [128,129]. However, cross-reactivity only poses a problem if 
quantitative information about a particular substance is required (as in pharmacokinetic 
studies), but not if the assay is being used for verification of smoking status.
Colorimetric methods
Colorimetric methods for estimating nicotine and nicotine metabolite levels have been 
reported [115]. The speed of analysis and simplicity and inexpensiveness of the equipment 
used make this an attractive alternative to the chromatographic and immunoassay methods. 
In most cases a crude sample, such as urine, is used, which means no sample clean up is 
required [130-133]. The general principle behind these methods is the reaction of the 
pyridine ring of nicotine and its metabolites, with reagents that generate a coloured product 
that is measured spectrophotometrically. Probably the best known of these methods is the 
Konig reaction, in which the pyridine ring is cleaved with cyanogen bromide or chloride 
and the resulting compound is condensed with an aromatic amine [131-133]. Recently 
Chambers et ah [134] coupled this reaction mechanism to HPLC.
Pickert et al. [135] achieved a limit of detection of 0.5 mg/ L for cotinine via the Konig 
reaction. However, in the same study a fluorescence polarization immunoassay achieved 
even lower limits of detection for cotinine (0.05 mg/L) [135]. Quantitative methods, such
as the NicCheck I®, use test strips that develop a particular colour in the presence of
nicotine and its metabolites, and are commercially available [131,133].
Like immunoassays, sources of interference can compromise the effectiveness of 
colorimetric methods [115]. Drugs or endogenous substances having a pyridine ring are a
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potential source of interference [115]. Thus a false positive can be obtained from the urine 
of persons consuming large amounts of, the pyridine-containing compound, niacin [115].
Gas chromatography
Gas chromatography (GC) separates substances that are volatile enough to be vaporised. 
It consists of an injection system for introducing the sample, a column in which the 
separation occurs, a carrier gas (usually helium), and a detector. Separation occurs by 
partitioning of the substances in a mixture between the vapour phase moving through the 
system and the stationary phase. Compounds that are less volatile and/or have greater 
affinity for the column material move more slowly, bringing about separation [3].
In 1966 Beckett and Triggs [136] used GC for the determination of nicotine and cotinine 
in urine. Since then there have been numerous studies for the determination of nicotine and 
its metabolites in urine [137-139]. GC has also been used for the analysis of nicotine and its 
metabolites in blood [3], plasma [137,140-142], saliva [137], breast milk [142], and hair 
[143,144].
Hariharan and Van Noord [139] used a GC coupled to a nitrogen-specific detector (NSD), 
for the determination of nicotine and cotinine in urine from passive smokers. In this study 
the correlation coefficient for nicotine and cotinine, between GC/NSD and HPLC/UV, were 
0.934 and 0.987 respectively. Limits of detection for nicotine by GC/NSD have been 
observed well below 1 ng/ mL [139,142]. GC coupled to a nitrogen-phosphorus detector 
has also been used to determine the amount of nicotine in hair from environmental tobacco 
smoke [143]. The NPD has similar detection limits to the NSD [140,141]. Other detectors 
used for GC analysis of nicotine include UV and flame ionisation [136,137]. The suitability
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of the former has been questioned since it brings about the decay of nicotine (which is light 
sensitive).
Mass spectral analysis of nicotine and its metabolites is becoming increasingly popular. 
One of the earliest examples of mass spectrometric work done on nicotine and its 
metabolites was performed by Homing et al. in the early 1970s [3]. Here the mass spectra 
of nicotine and its major metabolites, cotinine and trans-3'-hydroxycotinine, obtained from 
extracts of smokers’ urine, were recorded. The volatile nature of compounds separated by 
GC meant that this separation technique was initially one of the most attractive and 
simplest ways of introducing samples into the mass spectrometer. It is for this reason that 
sample introduction to MS by GC has been widely employed for over thirty years. The low 
carrier gas flow rates required by capillary GC columns and the development of more 
efficient mass spectrometer pumping systems have allowed the direct placement of the 
outlet end of the column in the ionisation source with an improvement in ionisation 
efficiency [3].
GC/MS has been widely used for the determination of nicotine and up to nine of its 
metabolites. In the late 1970s Dow and Hall used glass capillaries for the development of a 
GC/MS method for the estimation of nicotine and obtained good resolution, sensitivity, and 
efficiency for both nicotine (extracted from plasma) and quinoline [3]. Nowadays capillary 
GC columns are utilised in most GC applications including the analysis of nicotine and its 
metabolites [18,146]. The advancements in computer-controlled operation of entire systems 
and the development of the quadrupole mass analyser, for rapid scanning, have ensured the 
storage of vast amounts of data produced by full scanning GC/MS. This has allowed highly 
sensitive GC/MS applications to become ever-present in the majority of analytical 
laboratories.
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The limit of detection of nicotine in biological fluids, by GC/MS, has been found at 
picogram levels [18]. The low limits of detection achieved have allowed GC/MS to be used 
for monitoring the extent of environmental tobacco smoke via urine analysis of cotinine 
[147] and to estimate the amount of nicotine in indoor air as an indicator of passive 
smoking [148].
High-pressure liquid chromatography
Partition chromatography is sub-divided into liquid-liquid or bonded phase 
chromatography. When using the bonded phase, the stationary phase is chemically bonded 
to support surfaces, which may be silica or silica based compositions. Liquid 
chromatography requires the sample to be dissolved in a solvent. High pressure is essential 
for driving the mobile phase through the tightly packed stationary phase within the column 
[149]. In reversed phase chromatography, the stationary phase is non-polar, often a 
hydrocarbon, and the mobile phase is relatively polar (such as water, methanol, or 
acetonitrile). Elution can either be performed isocratically (with a single solvent or a 
constant solvent mixture) or under a gradient (from one solvent/mixture to another) [150]. 
Chromatography of this type usually shows the most polar molecules eluting first. By 
increasing the polarity of the mobile phase, the elution time, for a particular compound, is 
also increased [151]. Reversed phase is currently the most popular of bonded phase 
packings. The most common R group of the siloxane in these coatings is a Cs (w-octyl) or 
Ci8 (n-octadecyl) chain. Differences in analyte elution times are dependent upon their 
hydrophobic interactions with the bonded reversed phase.
When using a reversed phase HPLC method for nicotine and its metabolites with a 
gradient that runs from a mostly aqueous to mostly non-aqueous composition, metabolites
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such as glucuronides and N-oxides should elute before the parent compound. Separation of 
nicotine and its metabolites has been developed using reversed phase [152], and cation 
exchange chromatography [153-155],
A high-pressure liquid chromatographic (HPLC) method for the analysis of nicotine and 
cotinine in smokers’ urine was first reported by Watson in 1977 [156], This study utilised a 
normal phase isocratic method with UV detection. The method had shorter analysis time 
(with both nicotine and cotinine eluting in under 5 minutes) when compared to the existing 
gas chromatographic methods of the day. Later on normal-phase HPLC/UV achieved 
detection limits for nicotine and cotinine of 2 ng/mL [157].
In the 1980s the use of reversed phase chromatography for the analysis of nicotine and 
other tobacco alkaloids became widespread [158]. Since the 1980s reversed phase 
HPLC/UV has been used in numerous studies for the determination of nicotine [159,160] 
and cotinine [160-163] in urine. Quantification of nicotine, cotinine and nomicotine in rat 
plasma and urine, by HPLC/UV, has also been described [163].
Recently, Nakajima et al. [164] developed a highly sensitive method for the 
determination of nicotine and cotinine in human plasma by HPLC/UV. This method 
showed detection limits of 1 ng/mL, which was reportedly enough to carry out 
pharmacokinetic studies after smoking one cigarette or chewing a piece of nicotine gum. 
Data obtained from this method showed good precision and accuracy. Nakajima et al. [165] 
also developed a HPLC/UV method for the determination ofN-glucuronidation of nicotine 
and cotinine in human liver microsomes. This was the first report of the in vitro 
determination of cotinine-glucuronide and nicotine-glucuronide in liver microsomes and 
would most probably form the basis of any future attempts to determine nicotine-
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glucuronide and cotinine-glucuronide in biological specimens. HPLC/UV has also been 
used for the analysis of nicotine in medicated chewing gums [166].
Other popular detection methods for HPLC analysis of nicotine include diode array, 
electrochemical detection, radiometric detection, colorimetric assay, and mass 
spectrometry. Diode array coupled to reverse phase HPLC has been used for the analysis of 
nicotine and its related substances in chewing gum formulations [167], and for the 
assessment of foetal exposure to tobacco smoke through the measurement of nicotine and 
cotinine in meconium with detection limits of 10 ng/ mL [168], Mahoney and Al-Delaimy 
[119] coupled reversed phase HPLC with electrochemical detection and observed limits of 
detection for nicotine to be lower than 0.05 ng/ mg of hair.
In a study by Kyerematen et al. [152] the coupling of HPLC to radiometric detection, via 
the administration of radiolabelled nicotine to animals, was used to determine the extent of 
nicotine metabolism. This radiometric assay was able to measure the concentrations of 
nicotine and twelve of its metabolites in urine and blood. The metabolism of nicotine 
proved to be complex and HPLC methods with greater resolving power were developed. Of 
these new methods a cation exchange method was shown to resolve numerous polar 
metabolites of nicotine in guinea pig urine [153] and has recently been used, with UV/vis 
detection, for the quantification of total cotinine and total 3-hydroxycotnine in the plasma 
of smokers [154]. Demetriou et al. [155] used radiometric detection with ion-exchange 
HPLC to identify and quantify nicotine and many of its metabolites in rat urine. This 
method showed good reproducibility, whilst metabolites were detected above 1.5 pM. 
Thus radiometric detection has cemented its position as a viable detection apparatus for 
HPLC analysis of nicotine.
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Colorimetric-HPLC assays have been applied to nicotine and its metabolites 
[134,169,170] and have also been used for the study of passive smoke exposure [12]. But 
as with radiometric detectors identification of particular metabolites can sometimes be 
unclear. When a situation like this arises, the coupling of HPLC to a more informative 
detector such as a mass spectrometer can and should be carried out.
The method developed by Nakajima et al. [164] for example, would be an ideal method 
for HPLC/MS (i.e. combining the selectivity of the MS with the efficient separation 
provided by HPLC). Unfortunately it requires the use of a phosphate buffer, which can 
have a detrimental effect on most MS ion sources and hence analyte detection, due to the 
readiness of this salt to form crystalline deposits that block the apertures leading to the 
mass analyser [3]. HPLC/MS requires the use of a volatile mobile phase since ions are 
sampled in the gas phase. Thus aqueous mobile phases, which tend to give the best 
separations for polar compounds and their metabolites, are rarely used, since evaporation of 
such mobile phases becomes harder. HPLC/MS is therefore somewhat compromised by its 
inability to utilise aqueous mobile phases efficiently. Thus most ionisation sources use 
volatile organic buffers, such as ammonium formate or ammonium acetate, at low 
concentrations (below 20 mM); with only the commercial Z-spray interface (developed by 
Micromass, Manchester, UK) being able to cope with harsh mobile phases such as 
potassium or sodium phosphate buffers) [3],
Liquid chromatography can be applied to a greater variety of samples than gas 
chromatography, since the latter requires the analyte to be volatilised while LC requires 
only the dissolution of the analyte in some solvent prior to separation [3]. Thus metabolites 
such as N-oxides, which are not thermally stable, cannot pass through a GC without 
decomposing [3]. Generally such metabolites are derivatised and converted back to the
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aglycone for GC analysis. Derivatisation of trans-3f-hydroxycotinine with 
bis(trimethylfluorosilyl) acetamide has also been performed for GC/MS analysis [171]. But 
derivatisation of the analyte requires extra sample work-up and therefore a direct method is 
usually preferred.
To date there have been numerous studies for the determination of nicotine and its 
metabolites in biological fluids by HPLC/MS, which include saliva [18], urine [65,172], 
and plasma [3]. Applications of liquid chromatographic-tandem mass spectrometric 
methods (LC/MS/MS) have also been extended to quantitative analysis of polar ionic 
compounds in biological fluids [173]. More importantly LC/MS/MS has been used in the 
determination of cotinine and 3-hydroxycotinine in human saliva [174], the analysis of 
nicotine and its metabolites in urine of smokers [65,174] and the analysis of cotinine in 
serum [175]. The limit of detection of both nicotine [172] and cotinine [18,175] in 
biological fluids, by HPLC/MS, has been found at picogram levels.
Capillary electrophoresis
Electrophoresis is the migration of charged electrical species when dissolved, or 
suspended, in an electrolyte (a conductive liquid medium, usually aqueous) through which 
an electric current is passed. Capillary electrophoresis (CE) is therefore the separation of 
charged compounds usually in a narrow fused silica capillary upon the application of an 
electric field. Thus cations migrate toward the negatively charged electrode (cathode) and 
anions toward the positively charged electrode (anode). The rates at which solute ions 
migrate depend on their charge-to-mass ratios. Smaller ions migrate faster than larger ions 
of the same charge and an ion with a higher charge will migrate faster than an ion with a
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lower charge, of the same size. Neutral solutes are not attracted to either electrode. The 
electrical driving force of solvent in CE is what is known as the electroosmotic flow [176].
CE can be used as an alternative method to both GC and HPLC. Like HPLC, CE can 
utilise a wide range of sample types, and with its high resolution and high number of 
theoretical plates achieved, it makes for an attractive separating device for MS coupling. 
Even though CE has been applied to nicotine analysis in tobacco products [177-180], and 
the study of neuropharmacological effects of cotinine atcholinergic nicotineic receptors of 
the superior cervical ganglion [182], there are currently no publications regarding its 
application to nicotine metabolism that we are aware of. So in this area of research CE is 
still in its infancy. Furthermore, there is only a single publication, that we are aware of, on 
the coupling of CE to MS for the determination of nicotine and metabolites [182]; and 
hence to the best of our knowledge there are no CE/MS analyses of this compound or its 
metabolites from the major biological matrices, which are saliva, urine, and blood. 
However, there are numerous publications on CE-ESI-MS (CE coupled to the MS via an 
electrospray ionisation source) [183,184], of which one ofthe latest by Stockigt et al. [185] 
features the analysis of selected alkaloid groups. Thus the potential is there for a robust 
CE/MS method to be developed for application to nicotine metabolism.
CE can offer several advantages over the more established separating techniques of GC 
and HPLC, including high separation efficiency, extremely small injection volumes, short 
analysis times, speed of method development and low reagent costs. CE may produce 
highly-efficient separations of a wide range of sample types, and the number of theoretical 
plates in CE may reach several hundred thousand. The main limitation of CE is its lack of 
sensitivity due to its low sample loadability and the short path length of the detection 
window (when UV detectors are used).
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Several techniques have been shown to yield on-column sample pre-concentration and to 
lower detection limits in CE. The most practical way to concentrate a sample is the on-line 
sample stacking approach, but the most effective way is by transient isotachophoresis [186- 
188]. Sample pre-concentration is most essential when coupling CE to MS, since the 
coaxial sheath flow interface requires a make-up flow, which dilutes the sample. Other 
ways of improving sensitivity include the use of the nanospray interface (but it is somewhat 
more difficult to achieve a stable spray with this interface) and sample pre-concentration 
via solid phase extraction (SPE).
Conclusion
The method of choice for any given application is one that is sensitive, specific, requires 
simple instrumentation/ equipment, and is economical. Colorimetric methods are amongst 
the cheapest methods for nicotine determination and are also very rapid in their analysis. If 
very high sensitivity is required, such as for studies of nicotine and its metabolites in 
biological fluids of non-smokers, mass spectrometric methods are probably most desirable; 
and for studies in which it is necessary to measure nicotine and cotinine specifically 
without interference from other nicotine metabolites, chromatographic methods, along with 
capillary electrophoretic methods, would be the most suitable. Greater selectivity and 
sensitivity are obtained from the selected-ion monitoring mode of MS and structural 
elucidation, from tandem mass spectrometry. The latter will also achieve higher 
sensitivities. However, in order to distinguish heavy smokers from non-smokers, most of 
the aforementioned methods would be applicable.
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The high temperatures exhibited in GC analysis means that thermally labile metabolites, 
such as the N-oxides, would not remain intact during GC separation of the sample. Also 
since GC requires the analyte to be volatilised, there are a limited number of compounds it 
can be applied to. Thus the use of HPLC for the determination of nicotine and its 
metabolites may prove advantageous, since it can be applied to a wider range of 
compounds. However, the high resolution and high peak efficiency obtained by CE make 
this technique an even more attractive proposition, providing the issue of sensitivity is 
addressed. By combining CE with MS a potentially highly efficient electrophoretic 
separating method, with selective mass identification and structural elucidation, can 
potentially be achieved.
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Chapter 2
The Determination o f Nicotine and its Metabolites, in 
Urine, by Solid Phase Extraction and Sample Stacking 
Capillary Electrophoresis/Mass Spectrometry.
2.1. Introduction
In the study of nicotine metabolism the application of capillary electrophoresis (CE) is 
still in its infancy. However, CE offers several potential advantages over GC and HPLC for 
the analysis of complex mixtures of metabolites, including high separation efficiencies, 
extremely small injection volumes, short analysis times, rapid method development and 
low reagent costs [1]. CE may be used to perform highly efficient separations of a wide 
range of sample types, and the number of theoretical plates in CE may reach several 
hundred thousand [2].
The main limitation of CE is its lack of sensitivity [2-18]. However, detection limits in 
CE are generally 10-100 times higher than in HPLC [4,5]. The relatively higher limit of 
detection observed in CE comes from its restricted injection volume (where typical 
injection volumes are in the nanolitre range) and the short path length for on-capillary 
detection (when coupled to a UV detector) [1,4]. Thus a major area of interest in CE is to 
improve its low concentration sensitivity without sacrificing resolution.
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Several techniques have been shown to yield on-column sample concentration and hence 
to lower detection limits in CE. These include isotachophoresis [1], sample stacking [6], 
and field amplified injection [8]. The most practical way to concentrate a sample is in fact 
the on-line sample stacking approach. The sample stacking phenomenon was first 
introduced by Tiselius, and can be achieved through the manipulation o f sample and buffer 
solutions with injection procedures common to any CE instrumentation.
In capillary zone electrophoresis (CZE) the sample is dissolved in the same buffer as the 
run buffer and hydrodynamically injected, with the width o f the solute zone being the same 
as the width o f the sample plug. Thus when a voltage is applied the sample migrates 
through the capillary, and elutes in a zone that is slightly wider than, and proportional to the 
initial width o f the sample plug (figure 2.1).
Figure 2.1. A schematic representation o f the capillary zone electrophoresis procedure for 
the separation o f cations (adapted from Baker, 1995) [9].
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Figure 2.2. A schematic representation o f the sample stacking procedure for the separation 
o f cations (adapted from Baker, 1995) [9].
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In sample stacking, however, the sample is dissolved in a lower ionic strength solution 
than the run buffer (figure 2.2). This can be a more dilute buffer or deionised water. This 
will result in the sample solution having a lower conductivity than the run buffer. Thus 
when a voltage is applied, a higher electric field strength is generated within the sample 
plug than in the run buffer due to its higher resistivity. Since electrophoretic velocity is 
proportional to electric field strength, the solute ions will migrate rapidly through the dilute 
sample plug until they reach the concentration boundary between the sample plug and the 
run buffer. The solute ions then encounter a reduced electric field strength at this boundary 
and therefore slow down, forming a narrow, stacked zone. They will then proceed through 
the capillary, under the influence o f the electroosmotic flow and their electrophoretic 
mobilities, as stacked zones that are narrower than the sample plug (figure 2.2). Neutrals
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are not stacked as they migrate under the influence of the electroosmotic flow alone. 
Anions, however, will stack at the rear of the sample plug, also as narrow zones. The thin 
solute zones are then separated by CZE [5,6].
The degree of stacking and on-column preconcentration is proportional to X the ratio of 
resistivities of the sample solution and the run buffer [7-9]
X = Cr/C s (2.1)
where Cr is the concentration of electrolyte in the run buffer and Cs the concentration of 
electrolyte in the sample buffer. Solute ions should be concentrated to an amount equal to 
X, the enrichment factor. Thus if the sample is dissolved in water X could be several 
hundred. However the expected (theoretical) A,-value may not be fully observed due to the 
laminar flow that is produced during the stacking process. The difference in electric field 
strengths, in the sample and buffer zones, results in different electroosmotic flow velocities, 
which create an electroosmotic pressure leading to this laminar flow. The laminar flow 
leads to increased solute zone width, and hence broader peaks since it produces a parabolic 
flow profile in contrast to the flat profile of CZE. The greater the difference in 
concentration between the sample and buffer zones, the broader the peaks [10]. So even 
though a sample dissolved in the most dilute buffer, water, should yield the highest 
concentration enhancement, it also gives the broadest peaks. A study carried out by Chien 
and Burgi [5] showed that the optimum situation, for minimising the effect of broadening 
and obtaining a significant concentration enhancement, was achieved by the sample 
solution having a concentration one tenth of the run buffer.
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Sample stacking can be performed by hydrodynamic (under pressure) or electrokinetic 
(under voltage) injection. In the case of the former, the sample is dissolved in a low 
conductivity buffer and the resulting solution is introduced into the capillary under 
pressure. In the case of the latter, sample stacking can be performed whether the matrix is a 
low conductivity solution or not. When dealing with a moderately high conductivity 
solution, a water plug (or solvent plug without background ions) is introduced before 
electrokinetic injection to induce sample stacking. Thus the sudden change in 
electrophoretic velocity across the water plug and the background solution is responsible 
for the focussing effect [3]. One limitation of electrokinetic injection is that there may be a 
bias towards higher mobility analytes. Thus a larger amount of higher mobility ions will be 
introduced and focussed when compared to lower mobility ions [3]. However, 
electrokinetic injection does provide sensitivity enhancements in comparison to 
hydrodynamic injection. The volume of sample solution that can be introduced to the 
capillary, by the latter, can limit the injected amount of the sample; but as analyte 
molecules are introduced electrophoretically to the capillary, by electrokinetic injection, 
this does not pose as a major problem for this injection method.
Palmer et ah [11] recently reported the separation and detection of standards of nicotine 
and ten of its metabolites using CE/ MS. However, to date there are no reported studies, to 
this author’s knowledge, on the use of CE for the determination of nicotine and its 
metabolites in “real samples”. By combining CE with mass spectrometry (MS), selective 
identification and also structural elucidation can be achieved. In this study the use of solid 
phase extraction combined with sample stacking CE/MS for the determination of nicotine 
and its metabolites in urine is demonstrated.
Chapter 2 CE/MS 11
Aims and objectives
The objective of this study was to produce a sensitive and selective CE/MS method for 
the determination of nicotine and its metabolites and the extraction of these compounds, 
from urine, by solid phase extraction.
2.2. Methods and Materials
2.2.1 Samples and Sample Preparation
Standards of nicotine and its major metabolites were obtained from P. Jacobb ID, San 
Francisco, CA, USA. Nicotine and cotinine was also obtained from Sigma-Aldrich, Dorset, 
UK. These were prepared in buffer for CZE experiments or mobile phase for HPLC or one 
tenth of the run buffer (or the appropriate solvent mixture) for sample stacking experiments.
Urine was obtained from five male smokers (aged 21 to 39 years), A to E, and stored at 
-20 °C in tissue culture flasks. Two samples, labelled Ci and C2, were collected from the 
same subject, but on different days. Prior to extraction urine samples were thawed 
overnight at 4 °C, thoroughly mixed and filtered with a 0.45 pm Supor acrodisc filter (Pall 
Corporation, Portsmouth, UK).
2.2.2 Solid Phase Extraction
Solid phase extraction (SPE) was carried out using a 100 mg C l8 cartridge (Varian Ltd,
Surrey, UK). For conditioning purposes 3 mL of methanol (Fischer Scientific, Manchester,
UK) followed by 3 mL of deionised water (Milli- Q, UK) were passed through the SPE
cartridge sequentially. Then 1 mL of sample was introduced into the cartridge followed by
6 mL of deionised water. It should be noted that for 5, 10, 15 and 20 fold pre- 
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concentrations, 5, 10, 15, and 20 mL of sample were introduced respectively. The sample 
was then eluted with 1 mL of methanol. The eluted product was dried with nitrogen gas. 
The dried product was then reconstituted with 1 mL of mobile phase for the recovery 
experiments or 1 mL buffer for CZE or 1 mL one tenth buffer (or solvent mixture) for 
sample stacking.
Solid phase extraction (SPE) was also carried out using a lg  C l8 Isolute cartridge (Jones 
Chromatography Ltd., UK). For conditioning purposes 6 mL of methanol (Fischer 
Scientific, Manchester, UK) followed by 6 mL of deionised water (Milli- Q, UK) were 
passed through the SPE cartridge sequentially. Then 100 mL of sample was introduced into 
the cartridge followed by 6 mL of deionised water. The sample was then eluted with 6 mL 
of methanol. The eluted product was dried with nitrogen gas. The dried product was 
reconstituted with 0.5 mL buffer or one-tenth buffer or solvent mixture (200 fold pre­
concentration for CE/ MS) or 1 mL mobile phase (100 fold pre-concentration for recovery 
experiments).The reconstituted product was then subjected to ultrafiltration (via a Sorval 
Tc-6 centrifuge, Sorval Instruments - Dupont, CT, USA; and Vivaspin Concentrator- 3000 
MW, Vivascience, Gloucestershire, UK) at 3950 rpm for 20 minutes.
2.2.3 Buffer and Mobile Phase Preparation
The required quantity of ammonium formate or acetate (Sigma-Aldrich, Dorset, UK) was 
dissolved in the solvent mixture (acetonitrile [Fischer Scientific, Manchester, UK]/ 
deionised water [Milli-Q, UK]); buffer pHs were adjusted with formic acid or HC1 (Sigma- 
Aldrich, Dorset, UK), as appropriate, and buffers were freshly prepared. Buffers were 
degassed prior to analysis using a Branson 1210 ultrasonic bath (Branson Ultrasonics,
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Danbury, CT, USA) and filtered through a 0.2 pm Supor acrodisk syringe filter (Pall 
Corporation, UK). The buffers prepared were 25 mM ammonium formate (10 % 
acetonitrile, 90 % deionised water), which was adjusted to pH 2.5 with formic acid, for 
CZE; and 10 mM ammonium formate (75 % acetonitrile, 25 % deionised water) adjusted to 
pH 2.5 with HC1, for sample stacking experiments.
2.2.4 Recovery Experiments
Non-smokers’ urine samples were spiked with cotinine and extracted using the SPE 
method described above. These samples were analysed by HPLC/UV and HPLC-MS using 
a VG Quattro I (Manchester UK) triple quadrupole mass spectrometer operating in 
electrospray ionisation (ESI) and selected ion monitoring (SIM) mode (which is the same 
as selected ion recording [SIR]).
The HPLC conditions were as follows; Phenomenex Luna 5p Cl 8 column, 250 x 4.6 mm 
(Phenomenex, UK), 60 % mobile phase (15 % acetonitrile, 5 % methanol and 80 % buffer 
in deionised water [10 mM ammonium acetate- pH adjusted to 4.8 with HC1]) + 40 % 
methanol; flow rate 1 mL/ min. A 50:1 split post column was employed with a flow of 20 
pL/ min being introduced into the mass spectrometer. The injection volume was 10 pL.
2.2.5 CE Separation
CE experiments were carried out in a 100 cm, 50 pm i.d. x 365 pm o.d., and a 100 cm, 75 
pm i.d. x 365 pm o.d., untreated fused silica capillary (Composite Metal Services Ltd., 
Hallow, UK). The CE system used (Crystal CE System, PrinCE Technologies, Lauerlabs, 
Emmen, Netherlands) utilizes programmable injection with pressure and voltage. 
Separations were achieved using an applied voltage o f+30 kV. Injections were performed 
Chapter 2 CE/MS 80
either hydrodynamically (25 mbar/ 0.2 min) or electrokinetically (30 kV/ 0.2min) or 
hydrodynamically + electrokinetically (HE: 25 mbar + x kV/ 0.2 min, where x is the 
voltage applied in kV). Initial conditioning of the capillary took place with 1 M NaOH, (5 
min, 2000 mbar [Sigma-Aldrich, Dorset, UK]) followed by the buffer system (7 min, 
2000mbar). The capillary was conditioned prior to each run with 1 M NaOH (2000 mbar/1 
min) followed by buffer system (2000 mbar/ 1.5 min). The buffer system was replenished 
after each run cycle.
2.2.6 CE/MS
A VG Quattro I triple quadrupole mass spectrometer (Micromass, Manchester, UK) was 
used throughout. To date, electrospray ionisation (ESI) is the most common technique for 
coupling CE to MS. In these experiments CE/ESI/MS coupling was achieved using the 
coaxial sheath-flow interface developed in-house and previously described by Palmer et al. 
[11]. The sheath liquid comprised either, 1:1 MeCN/H20 + 0.1% formic acid, or run buffer 
and was delivered by a Harvard Model 11 syringe pump (Harvard Apparatus, Edenbridge, 
UK) at a flow rate of 3 -5 pL min'1.
Positive ions were generated through the application of 3.5 kV to the probe tip, with a 
source cone voltage of 25 V. Desolvation was aided by nebulising gas (-40 L/hr) and bath 
gas (-225 L/hr).
Data was acquired by selected ion recording of the analyte protonated molecules 
employing a 1 Da window with a dwell time of 0.08 s. Data acquisition was performed by 
Masslynx3.1 (Micromass, Manchester, UK).
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2.3. Results and discussion
2.3.1 CZE/MS of nicotine and its metabolites in smokers’ urine (sample C2")
Before one can perform CZE/MS on a urine sample, an extensive clean-up strategy must 
be employed to remove the high concentration of inorganic salts present (50 to 500 mM 
sodium chloride) [19]. Direct CE analysis of urine is problematic since inorganic salts 
present in urine would increase the electrical conductivity of the sample, which could cause 
a distortion in the electric field, thereby reducing the overall efficiency of separation and 
hence leading to the observation of broad, skewed peaks, i.e., this situation would be the 
opposite to that in sample stacking. In other words when a voltage is applied to a urine 
sample a lower electric field strength will be generated within the sample plug than in the 
run buffer, due to its lower resistivity. Since electrophoretic velocity is proportional to 
electric field strength, the solute ions will migrate slowly through the dilute sample plug 
until they reach the concentration boundary between the sample plug and the run buffer. 
The solute ions will then encounter higher electric field strength at this boundary and 
therefore speed up, forming abroad zone leading to the poor peak shape.
If the inorganic salt content is too high then according to the Ohm’s law plot, the current 
will also be high and the resistance low. The zeta potential, is defined as [9]
Q = 47i5e/£ (2.2)
where 5 is the thickness of the diffuse double layer, e is the charge per unit surface area and 
s is the dielectric constant. Zeta potential, which determines the EOF velocity ( v e o f )  and 
can be described as [9]
C = veof 4 tutjI £ E  (2.3)
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where 77 is the viscosity, and E  is the electric field in (volts/cm). High electrolyte 
concentration will lead to high current according to the Ohm’s law plot [9]
E = IR (2.4)
where I  is the current and R  is the resistance. High currents will inevitably cause an 
increase in heat production via Joule heating, AT, (equation 2.4) [9]
A T= (0.239Q/4k)r2 (2.5)
where O is the power density, k  is the thermal conductivity, r is the tube radius. A rise in 
temperature will cause a reduction in viscosity, permitting even more current to flow. 
Increased heat in the capillary may lead to broader peaks, sample decomposition, or even 
boiling of the buffer, which can cause electrical discontinuity through the capillary, 
eventually bringing electrophoresis to an end [9].
It should also be noted that the high inorganic salt content of urine would be incompatible 
with the MS, due to the crystallisation of salts on the ion source. This would prevent the 
efficient transmission of ions through the MS. For these reasons the direct analysis of urine 
by CE is not practicable.
Liquid-liquid extraction and SPE are currently the most frequently applied off-line 
sample preparation techniques in bioanalysis. The polarity of the eluting solvent (e.g. 
methanol or acetonitrile) used in the latter is normally compatible with the subsequent CE 
separations and sample pre-concentration is a useful consequence of this method. If the 
elution system is aqueous or partially aqueous, then time-consuming evaporation steps 
(which can result in analyte loss) may be required.
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Hence the purpose of employing an off-line SPE method may be to remove particulate 
matter, interferences, salts and proteins and, also to enrich analytes. In this work the C l8 
SPE cartridge was used to remove inorganic salts, interferences, and to pre-concentrate 
nicotine and its metabolites from urine. The SPE procedure employed to obtain the 
recovery data summarized in table 2.1 is described in section 2.2.2.
Table 2.1. Percentage recoveiy of cotinine from 100 mg and 1 g C l8 SPE cartridges (n =
3).
C l8 SPE 
cartridge- 
type
Pre­
concentration
Initial
concentration
(pg/mL)
Final
concentration
(pg/mL)
% RSD % Recoveiy
100 mg 1 times 6.25 6.35 1.67 101.5
100 mg 5 times 6.25 31.22 0.14 99.7
100 mg 10 times 6.25 63.59 0.22 101.7
100 mg 20 times 3.13 28.15 3.59 45.1
1 g 100 times 0.63 63.86 0.07 102.2
1 g 100 times 1.25 118.34 0.07 94.7
HPLC/MS: Electrospray ionisation; 60 % mobile phase (10 mM ammonium acetate-15 % 
MeCN/5 % methanol/ 80 % deionised water) + 40%  methanol; C l8 Phenomenex Luna- 5 
pm, 250 mm; flow rate = 0.5 mL/ min, 1/50 split. The relative standard deviations (RSDs) 
were determined by the migration times of cotinine.
Table 2.1 summarises the data obtained from the LC/MS recovery experiments. For the 
100 mg SPE cartridges, percentage recoveries were calculated from a linear calibration plot 
of six points, recorded in duplicate (before and after analysis), with the R2 value for the 
calibration data being 0.9993. The 6.25 pig/ mL cotinine-spiked urine samples, for 1 to 10 
times pre-concentration, were analysed in triplicate and an overall mean percentage 
recoveiy of 100.99 % was obtained.
For the 1 g SPE cartridges, percentage recoveries were calculated from a linear 
calibration plot of eight points and recorded in duplicate (before and after analysis). The R
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value for the calibration data was 0.9993, and the 1.25 and 0.625 pg/ mL cotinine-spiked 
urine samples were analysed in triplicate and an overall mean percentage recovery of 98.42 
% was obtained.
Table 2.1 shows good reproducibility for all SPE pre-concentration steps. However, the 
20 times pre-concentration (via the 100 mg C l8 cartridge) showed very poor recovery (45 
%). This was probably due to overloading the Cl 8 cartridge with interfering components of 
urine, thereby leading to less cotinine being retained on the stationary phase. Additional 
evidence for this was that only a 17 % recovery was obtained for 50 times pre­
concentration on the 100 mg C l8 cartridge (data not shown on table 2.1). It was for this 
reason that a 1 g C l8 cartridge was used for 100 times pre-concentration.
It should be noted that the washing step of SPE (section 2.2.2. - step 4) for 1 and 5 times 
pre-concentrations required 6 mL of deionised water, whereas the 10 to 100 times pre­
concentrations required the equivalent volumes of deionised water (e.g. the introduction of 
10 mL of sample is followed by 10 mL deionised water). This particular step was employed 
for the removal of both inorganic salts and the more polar interfering components of urine.
Prior to SPE, the urine sample was filtered with a 0.45 pm acrodisc filter, the purpose of 
which was to remove any particulate matter from the urine. After SPE, evaporation, and 
sample reconstitution, the sample was then subjected to ultrafiltration, for the purpose of 
removing any proteins over 3000 MW. The removal of proteins is of great importance, as 
they tend to adhere to the inner surface of the fused silica, thereby disrupting the EOF and 
hence separation.
CE separations were carried out at low pH (2.5 to 2.8), which meant that there were few 
charged Si-O' groups present and, consequently a lower zeta potential (equation 2.2), and 
little electroosmotic flow. Thus it was essential to condition the capillary, with 1 M NaOH
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followed by the buffer system prior to each run. However, when using the coaxial probe 
arrangement for electrospray (figure 2.3), it is essential to activate the nebulising gas after 
NaOH introduction to ensure that no NaOH enters and/or is left in the nebulisation chamber 
prior to conditioning with the buffer, as NaOH and buffer contents will surely enter the 
source (where they will form crystalline deposits, which can eventually block the ion 
source) if this is not carried out.
Buffer replenishment was also carried out prior to each run to improve precision. 
Replenishment is essential as buffer pH in the inlet and outlet vials can change due to 
electrolysis of water, where protons are produced at the cathode and hydroxide ions at the 
anode. Buffer depletion could also occur as a result of electrolysis and migration of buffer 
ions. [9].
Buffer replenishment was performed by rinsing and refilling the inlet vial, which 
contained approximately 4 mL of buffer, with fresh buffer. Replenishment is essential as 
buffer pH in the inlet and outlet vials can change due to electrolysis of water, where protons 
are produced at the cathode and hydroxide ions at the anode. Buffer depletion could also 
occur as a result of electrolysis and migration of buffer ions. For MS detection no outlet 
vial was used and so buffer replenishment was only required for the inlet vial (figure 2.3).
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Figure 2.3. The coaxial probe arrangement.
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Figure 2.3 was adapted from M. Palmer (2001 PhD thesis, Sheffield Hallam University) 
[20].
When coupling the CE system to the MS, the capillary outlet was placed directly into the 
ESI interface via the coaxial probe. There was no requirement o f the capillary outlet and 
cathode to be in a reservoir, since there was sufficient electrical contact with the run buffer 
flowing out o f the fused silica capillary. The electrical contact was made via the sheath 
liquid, a large proportion o f which was the volatile solvent, acetonitrile. Acetonitrile served 
to aid evaporation, and reduce surface tension for better spray production [12].
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The sheath liquid flowed around the capillary, at 5 pL/ min. A voltage was applied to the 
stainless steel spray capillary to ensure the production of ions during electrospray. Thus 
upon the application of this voltage (3.5 kV for the VG Quattro triple quadrupole mass 
spectrometer), it was negative with respect to the anode (which is the fused silica capillary 
inlet of the CE system), which was in the CZE buffer in the high voltage region (30 kV), a 
potential difference was set up for CZE separation (based on the size-to-charge ratio of the 
analytes) [13]. Ionised solutes then exited the capillary through nebulisation into the 
electrospray ion source. Solute ions proceeded through the MS system where they were 
separated according to their mass-to-charge (M/Z) ratios and were observed as the 
protonated molecule, [M + H]+.
Because of the difference in physical size of the CE device and of the ion source (i.e. the 
height of the CE in relation to the height of the ion source, from the ground or a bench), 
there was a limit to the smallest length of fused silica capillary that could be used [13,14]. 
This was important since the longer the fused silica capillary, the longer the analysis time, 
as there is a voltage drop per centimetre of capillary. For this study a 100 cm capillary was 
used [13].
Formation of gas bubbles in the spray capillary (stainless steel) and/or the fused silica 
capillary may lead to instability in the spray. The former may result in the isolation of the 
liquid solution from the metal high voltage contact, halting the spraying process [15]. The 
latter may lead to an unstable current within the capillary. Thus the buffer system and the 
sheath liquid were degassed by sonication, in order to reduce the occurrence of gas bubbles.
CE-ESI interfacing is further complicated by the need to complete electrical paths for 
both CE and ESI systems [16]. This predicament may be worsened, since a constant voltage 
must be applied between the capillary outlet and the MS entrance, during ESI. Ideally the
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capillary outlet should be maintained at ground potential (where the electric field applied 
across the fiised silica capillary is zero volts with respect to the outlet end), as is normally 
the case in CE/UV [16]. Since this could not be achieved with the MS, the CE/MS system 
was subjected to arcing/ fluctuating currents. A second major issue in obtaining 
reproducible high quality CE/MS data using the co-axial arrangement was the drying out of 
the electrophoresis capillary outlet end. One possible approach to solving this was the 
application of a supplementary pressure to the head of the column. This ensured the 
presence of fluid at the tip at all times during CE separation.
The sheath liquid functions as the terminal buffer reservoir and is therefore a source of 
chemical background [16,17]. Thus background from the sheath liquid may interfere with 
analyte detection and raise detection limits! It may also be possible for counter ions, from 
the sheath liquid, to enter the fused silica capillary, at the outlet end, and alter the migration 
of analytes, and facilitate the loss of separation and resolution [16]. The counter ions may 
do this by forming a moving ionic boundary inside the capillary counter to the flow of 
analyte [18]. This problem is most noticeable in capillaries with low electroosmotic flows 
(EOF) [18]. The application of supplementary pressure to the fiised silica capillary and/ or 
the elevation of the CE device (to prevent siphoning) will also ensure that very few to no 
counter ions enter the capillary [17]. However, the application of a supplementary pressure 
will result in loss of resolution and peak efficiency as shown in figure 2.4.
Chapter 2 CE/MS 89
Figure 2.4. Selected ion recording (SIR) mass electropherogram of a smokers’ urine sample 
(sample C2).
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Two hundred times pre-concentration o f urine sample via SPE; the sample was 
reconstituted in buffer. 25 mM ammonium formate (90% deionised water and 10 % 
acetonitrile), which was adjusted to pH 2.5 with formic acid; sheath liquid was M eCN/ 
H2 O 1:1; 100 cm capillary + 50 pm i.d.; sheath flow rate used was 5 pL/ min; sample was 
introduced at 25 mbar for 0.2 min; CZE separation took place at 30 kV and 50 mBar 
supplementary pressure. Reproducibility was determined by the RSD o f the resolution 
(mean = 1.25) between nicotine and cotinine (RSD = 3.5 %, where n = 3). Resolution was 
calculated by R -  2(t2-fi)/(wi+w2) (equation 2.6) [9], where t is the time and w is the peak 
width.
When CZE/MS was applied to a smoker’s urine sample, (Figure 2.4) the same pattern of 
elution was observed for nicotine, nicotine-l'-N-oxide, cotinine, trans-3'-hydroxycotinine 
and 5'-hydroxycotinine as that seen by Palmer et al. [11]. However, it was evident from the 
above mass electropherogram (figure 2.4) that this separation profile resembled that o f  a
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pressure driven system rather than an electrically driven one. This had a markedly 
detrimental effect on separation efficiency.
The higher viscosity of the sample plug may have led to an intermittent spray, and/ or the 
lack of sensitivity generated by this method. Thus Figure 2.4 shows a non-optimised 
CE/MS mass electropherogram obtained from the analysis of a smoker’s urine sample (C2).
When using a coaxial probe from CE the contents of the capillary become diluted by the 
sheath flow since CE flow rates are in nL/ min whereas the sheath flow rate is in the pL/ 
min range. It was for the purpose of reducing this dilution effect that a 75 pm i.d. fused 
silica capillary was used instead of a 50 pm i.d. capillary (which was used by Palmer et ah 
[11]). Palmer et ah [11] used 100 pg/mL concentrations for nicotine and nine of its 
metabolites, whereas 50 pg/mL concentrations were used for this study.
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Figure 2.5. SIR mass electropherogram of nicotine and six of its metabolites.
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Refer to table 2.2 for peak efficiencies. 50 pg/mL nicotine, nomicotine, cotinine, nicotine- 
l'-N-oxide, 3-pyridyl acetic acid, 5*-hydroxycotinine, and cotinine-1-N-oxide were made up 
in buffer. The buffer system consisted of 25 mM ammonium formate (pH adjusted to 2.5 
with formic acid) + 10 % MeCN; sheath liquid was MeCN/ H2 O 1:1 + 0.1 % formic acid; 
100 cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate used was 5 pL/ min; 
sample was introduced 25 mbar for 0.2 min; CZE separation took place at 30 kV and 50 
mBar supplementary pressure. Reproducibility was determined by the RSD of the 
resolution (mean = 2.89) between nicotine and cotinine (RSD = 3.41 %, n = 3). Resolution 
was calculated by R = 2(t2-h)/(wi+W2) (2.6) [9], where t is the time and w is the peak width.
Figure 2.5 shows a reasonable separation of nicotine and six of its metabolites. But even 
though this method achieved an acceptable RSD it was not as robust as one would have 
liked, since only three out of eight runs were successful. This was probably due to poor 
electrical contact between the fused silica capillary and the stainless steel sheath tube 
provided by the sheath liquid, since in CE/UV the outlet vial consists of the same buffer 
system as the inlet. Because the 50 mbar supplementary pressure applied was there to
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ensure no entry of the sheath liquid and/ or air into the fused silica capillary, it was unlikely 
that the siphoning of either would have affected the robustness of the technique. What was 
observed was the degradation of the baseline at various points within the mass 
electropherogram. Unfortunately those periods of degradation tended to coincide with the 
elution of some analytes. But the migration times and separation order (for those 
metabolites observed), for the five failed mass electropherograms, were more or less 
unchanged.
The same pattern of elution was observed by Palmer et al. [11], but in our case 
cotinine- 1-N-oxide eluted at a mean time of 12.06 minutes (refer to figure 2.5, and table 
2.2) whilst Palmer et al. found it to elute at approximately 21.2 minutes. This can be simply 
explained by the use of different inner-diameter fused silica capillaries. For this study a 75 
pm i.d. fused silica capillary was used whilst Palmer et al. [11] used a 50 pm i.d. capillary. 
This meant that the supplementary pressure applied would result in a faster elution of the 
anlayte in the 75 pm i.d. capillary due to its greater i.d. That is the greater the inner 
capillary diameter the shorter the length of time it takes to fill a capillary, tc, and hence to 
elute. This is shown in equation 2.7 [9].
tc = 6900 L2/APd2 (2.7)
where L is the total capillary length, AP is the pressure in mBar, and d  is the inner capillary 
diameter. This also expressed by electrokinetic injection [9]
ginj =  U7t c / r 2( p Ep +  P e o f ) / £  (2.8)
where gjnj is the quantity of sample injected Vis the voltage, c is the sample concentration, 
t is the time duration the voltage is applied, r is the capillary radius, pEp is the 
electrophoretic mobility of the solute, and pEQF is the electroosmotic mobility.
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Table 2.2. Peak efficiencies obtained for nicotine and six of its metabolites via CZE/MS (n 
= 3). Mass electropherograms shown in figure 2.5.
Retention time Peak width 
t (min) w (min) t
Number of 
leoretical plates (N)
Nomicotine 6.28 0.22 13665
Nicotine 6.61 0.23 14168
Nicotine-l'-N-oxide 6.79 0.28 9411
Cotinine 7.89 0.63 2551
3-pyridyl acetic acid 8.27 0.51 4183
5'-Hydroxy cotinine 8.35 0.4 6996
Cotinine-N-oxide 12.06 0.53 8450
Refer to figure 2.5 for conditions. Peak efficiency was determined by N  = 16(tfw)2 
(equation 2.9) [9]; where t is the migration time and w is the peak width at the base of the 
peak.
The peak efficiencies obtained (table 2.2) were rather low in comparison to those
obtained by Palmer et al.[ 11 ]. They obtained theoretical plate numbers of 18000 and 22000
for nicotine and cotinine by sample stacking/ MS [11]. But the low theoretical plate
numbers could be attributed to the use of CZE rather than sample stacking, which was used
by Palmer et al. [11], and/ or the shorter retention times, which were evidently due to the
use of a greater inner diameter fused silica capillary. The use of a 75 pm i.d. capillary 
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rather than a 50 pm i.d. capillary would have meant that the faster flows generated within 
the capillary presumably led to the flow profile having the characteristic parabolic shape of 
a pressure driven system (when a 50 mbar supplementary pressure was applied) rather than 
the plug flow profile of an electrically driven system. The flat plug flow profile of CE has 
the advantage that all of the solute molecules experience the same velocity component 
caused by EOF regardless of their cross-sectional position in the capillary, thereby causing 
analytes to elute as narrow bands giving peaks of high efficiency.
2.3.2. Optimisation of electro spray
In order to obtain good signal to noise in CE/MS and hence good detection limits a stable 
electrospray is required. The stability of the electrospray was improved (figure 2.6) by (a) 
withdrawing the fused silica capillary into the stainless steel sheath capillary until it was 
level with the sheath capillary and (b) replacing the previously used sheath liquid i.e. 1:1 
acetonitrile/deionised water + 0.1% formic acid, with the buffer system. By withdrawing 
the fused silica capillary into the stainless steel capillary, the length of the fused silica that 
can be surrounded by the sheath capillary is maximised. Hence the maximum electrical 
contact between the sheath capillary and the fused silica capillary is obtained. A buffer 
system of 10 mM ammonium formate, 75 % acetonitrile/ 25 % deionised water was 
employed in order to improve spray formation due to its greater organic content. The use of 
this run buffer as sheath liquid improved beam stability presumably due to the 
homogeneous nature of the sheath liquid and the buffer reducing mixing effects.
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Figure 2.6. SIR mass electropherogram of nicotine and five of its metabolites obtained via 
CZE.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-1 -N-oxide, 5'-hydroxycotinine, cotinine- 
1-N-oxide,and 3-pyridyl acetic acid were made up in buffer. The buffer system consisted of 
10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place at 30 kV + 
20 mbar. Reproducibility was determined by the RSD of the resolution (mean = 4.48, n = 5) 
between nicotine and cotinine (RSD = 1.40 %).
The new CZE/MS method (figure 2.6) showed greater robustness, as five out of five runs 
were successful. The migration times were increased since a lower supplementary pressure 
of 20 mbar was used. A lower supplementary pressure was utilised primarily because of the 
reduced viscosity of the 10 mM ammonium formate buffer system due to its greater organic 
content. The order of elution was comparable to that shown by Palmer et al. [11].
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Figure 2.6 also showed improved resolution (4.48) between nicotine and cotinine when 
compared to the previous CZE/MS method (figure 2.5). Theoretical plate numbers for 
nicotine (11543 for figure 2.6) were comparable with those obtained for figure 2.5 (14168, 
from table 2.2), whereas those for cotinine were significantly higher for the new method 
(12331 for figure 2.6). This improvement in theoretical plate numbers and resolution was 
primarily attributed to the lower supplementary pressure applied, as the system became 
more electrically driven. However, the theoretical plate numbers obtained were still, on 
average, lower than those obtained by Palmer et al. [11], since they utilised sample 
stacking.
2.3.3. Sample stacking/MS of nicotine and its metabolites bv hvdrodvnamic-electrokinetic 
injection
Sample injection in CE is generally performed by hydrodynamic or electrokinetic 
injection. During hydrodynamic injection the sample vial is pressurised, forcing the sample 
into the capillary. Thus the volume of sample injected is dependent on the magnitude and 
duration of the pressure applied, the capillary dimensions, and the sample viscosity. 
Electrokinetic injection is performed by placing the capillary and the anode into the source 
inlet vial and applying a voltage over a period of time. Thus ionic solutes are injected as a 
result of their electrophoretic mobilities, with neutrals being pushed through the capillary as 
a result of the electroosmotic flow.
Electrokinetic injection provides sensitivity enhancements in comparison to 
hydrodynamic injection, since the volume of sample solution that can be introduced does
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not limit the injected amount of the sample. However, sampling bias is a major drawback of 
electrokinetic injection, since larger quantities of higher mobility solutes are injected than 
those of lower mobility. An example of this is the absence ofy-3-pyridyl-Y-oxo-butyric acid 
and cotinine-N-oxide (table 2.4), where both analytes were clearly not injected in an 
adequate amount to yield a sufficient response from the mass spectrometer for detection. In 
order to reduce such a sampling bias a combination of electrokinetic and hydrodynamic 
(HE) injection was used.
Chapter 2 CE/MS 98
Table 2.3. The measurement of standard and relative standard deviations of peak-to-peak 
resolutions between cotinine and 5-hydroxycotinine, for urine samples from five smokers, 
and cotinine and trans-3’-hydroxycotinine from a standardised mix of nicotine and eight of 
its metabolites.
Mean resolution Res SD Res % RSD
Sample stacking 
HE-injection/MS
(n = 3)
Sample A (cot-5HC) 2.59 0.12 3.15
Sample B (cot-5HC) 1.41 0.01 4.52
Sample Ci (cot-5HC) 2.21 0.10 1.02
Sample D (cot-5 HC) 2.16 0.08 3.57
Sample E (cot-5 HC) 2.18 0.08 3.85
Sample stacking
(cot-3HC, n = 5)
Hydrodynamic
injection
0.75 0.02 2.51
Electrokinetic
injection
1.26 0.01 0.80
Hydrodynamic + 
electrokinetic injection
0.77 0.02 3.15
For urine samples A to E n = 3; n = 5 for the three injection methods; where n is the 
number of repeat analyses. The resolution, R, between two adjacent peaks (cotinine and 5'- 
Hydroxycotinine for A to E and cotinine and /ra/?5-3'-hydroxycotinine for the three 
injection methods) was calculated as follows: R = 2(t2 -  fi)/(wi + M’2)  (2.6) [9]. Urine 
samples A to E were obtained from smokers.
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Figure 2.7. SIR mass electropherogram of nicotine and eight of its metabolites obtained via 
sample stacking and HE injection.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-l'-N-oxide, 5-hydroxycotinine, and 
cotinine-1-N-oxide were made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted 
of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 30 kV + 25 mbar for 0.2 min. Separation took place at 30 kV + 
20 mbar. Refer to table 2.3 for RSD.
Sample stacking was employed in conjunction with the combined injection procedure in
order to achieve the best possible sensitivity (figure 2.7). The limits of detection, by CE-
sample stacking/ MS, of nicotine and cotinine, respectively, for the three injection methods
were found to be: 1) 0.11 and 2.25 pg/ mL for the HE injection method, 2) 2.86 and 6.25
pg/ mL for hydrodynamic injection, and 3) 0.18 and 3.27 pg/ mL for electrokinetic
injection. Thus it is clear that the HE injection method yields the lowest limits of detection, 
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followed by electrokinetic, and finally hydrodynamic injection. The lowest detection limits 
yielded by the HE injection method can be explained by its ability to introduce the greatest 
quantity of sample to the capillary (see table 3.3). It should also be noted that the higher 
electrophoretic mobility of nicotine results in greater quantities of this solute being 
introduced to the capillary than cotinine. This, accompanied with the higher ionising 
potential of nicotine, ensured its lower limit of detection. However, such a bias can be 
corrected, when applying this method to biological samples, by taking account of the ratio 
of peak areas of the analyte and internal standard.
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Table 2.4. Mean peak efficiences obtained for the three injection methods (n=5) used in 
conjunction with sample stacking CE/MS.
JNumber of Theoretical plates (N)
Hydrodynamic Electrokinetic 
injection injection
Hydrodynamic + 
electrokinetic injection
Nomicotine 5911 17047 5542
Nicotine 6141 12023 3323
Nicotine-l'-N-oxide 20367 45201 5150
Cotinine 24024 11122 11894
3-Pyridyl acetic acid 19093 13086 15545
y-3 -Pyridyl-y-oxo-butyric 
acid
36415 14010
trans- 3 '-Hydroxycotinine 10622 23189 13125
5 -Hydroxycotinine 45666 162140 23130
Cotinine-N-oxide 14830 13617
Mean total 
number of 
theoretical plates
20341 40555 11704
2% Calculated using N  = 16(//w) (equation 2.9). The concentration of each analyte was 50 
pg/ mL. Refer to table 2.3 for RSD and figure 2.7 for analysis procedure.
The mean total number of theoretical plates achieved was greatest in electrokinetic 
injection (table 2.4), since during sample introduction the samples are stacked into narrow,
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discrete, zones, whereas for hydrodynamic injection solute ions are dispersed within the 
sample plug (thus stacking only takes place during separation). The HE injection method 
has the lowest mean total number of theoretical plates. This was most probably due to 
sample overload of the capillary, when both injection methods were employed. The highest 
number of theoretical plates was achieved by 5'-hydroxycotinine with the electrokinetic 
injection method yielding a theoretical plate number of 162,140 (table 2.4). However, not 
all solute ions were observed by electrokinetic injection, as the introduction of ions with 
lower mobility, such as cotinine-N-oxide and y-3 -pyridyl-y-oxo-butyric acid was 
compromised via the sampling bias exhibited by electrokinetic injection.
Efficiency, in contrast to chromatography is independent of capillary length, providing all 
the Joule heating is dissipated. Thus peak efficiency from the 90 cm CZE capillary (as used 
by Palmer et al. [11]) should be comparable to that of the 1 metre sample stacking 
capillary.
Interestingly, the HE injection method produced theoretical plate numbers of 26287, 
36805, and 88953 for cotinine, trans-3 '-Hydroxycotinine, and nicotine respectively (sample 
Ci- not shown). These were, on average, 131.6 fold greater than the number of theoretical 
plates observed by CZE/MS (sample C2). The higher number of theoretical plates would be 
attributed to the lower injected quantities of the analytes in sample Ci (a more dilute 
sample). Therefore due to the lower detection limit, and reasonable number of theoretical 
plates produced by HE injection, this method of sample introduction would be used for 
sample stacking/ MS.
Optimisation of the electrospray together with the application of sample stacking (via HE 
injection) has greatly improved peak efficiency, baseline stability, and detector response to
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the analytes (figure 2.7), and the added selectivity that SIM provides ensured the 
identification of nicotine and its metabolites in urine (figure 2.8).
2.3.4 Sample stacking/MS of smokers’ urine via HE injection
Figure 2.8. SIR mass electropherogram of a smokers urine sample (E) via sample stacking.
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The buffer system consisted of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 
% MeCN/25 % H2O; 100 cm, 75 pm i.d. fused silica capillary was used; the sheath flow 
rate was 5 pL/ min; the sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation 
took place at 30 kV + 20 mbar. Refer to table 2.3 for RSD.
When applying the optimised sample stacking/MS HE-injection method to urine samples, 
sample pre-concentration via solid phase extraction was required (with the 200 fold pre­
concentration of sample achieved). Data from a smoker’s urine (figure 2.8, sample E)
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shows the clear identification of nicotine, cotinine and the other major metabolites of 
nicotine. Since nicotine has only a half-life of approximately two hours, the relatively high 
abundance on the mass electropherogram could be attributed to the recent exposure of the 
smoker to tobacco smoke.
The relative abundance of cotinine in the five mass electropherograms obtained (see 
figures 2.8-2.10, samples Cl and D are not shown), confirms its status as the major 
metabolite of nicotine. The total ion chromatograms shown in figures 2.9 and 2.10 
demonstrate this observation clearly.
Samples Ci and D (not shown) exhibited a more extensive metabolism of nicotine, and 
having a relatively low abundance of this analyte on both mass electropherograms. The 
high abundance of 5'-hydroxycotinine with respect to trans-3 '-hydroxycotinine in all the 
mass electropherograms, with the exception of sample C2 , suggests that the major pathway 
for cotinine metabolism is via 5'-hydroxycotinine. This is further confirmed by the 
presence of 3-pyridyl acetic acid. However, it is possible that trans-3 '-hydroxycotinine 
could mainly exist in the glucuronide form. More work in this area (with respect to patient 
studies) is required.
The inter-urine sample migration times of the metabolites, among samples A to E, 
appeared to differ slightly. It was unlikely that changes in air temperature could have 
influenced the migration times, since the laboratory that housed the CE and mass 
spectrometer was climate controlled. Temperature change has been shown to indirectly 
affect both the current and the electric field strength via the power density, O. Where [9]
AT= (0.239 g /4 /ty 2 (2.4).
Thus by changing O we inevitably change the electric field (£), the current (7), and the
voltage (V) all of which can affect the separation since [9]
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O = EHm = vilnxh (2.10).
The notion that excessive Joule heating within the capillary (as a result of the high voltage 
used for separation) was the cause, was also dispelled since the current observed was stable 
at approximately 12.5 pA (with no significant fluctuations). It should also be noted that the 
buffer used to replenish the inlet vial was kept in a polystyrene cooler unit at < 5 °C, and so 
the internal capillary temperature would have been the same at the beginning of each run 
and the fact that the laboratory used was climate controlled would have prevented any 
external temperature changes from taking place.
Figure 2.9. SIR electropherogram of a smokers’ urine sample (A) obtained via sample 
stacking.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-l-N-oxide, 5-hydroxy cotinine, and 
cotinine-1-N-oxide were made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted 
of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place at 30 kV + 
20 mbar. Refer to table 2.3 for the RSD.
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Figure 2.10. SIR mass electropherogram of a smokers’ urine sample (B) obtained via 
sample stacking.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-l-N-oxide, 5'-hydroxycotinine, and 
cotinine-1-N-oxide were made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted 
of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place at 30 kV + 
20 mbar. Refer to table 2.3 for the RSD.
The probable cause for the differing inter-urine sample migration times of the metabolites
(figures 2.8, 2.9 and 2.10) was the presence of urobilins and urobilinogens in urine. The
presence of these compounds in urine may be brought about by the derivation of bilimb in
from senescent red blood cells and from other haem-containing proteins, such as
cytochromes. Bilirubin is poorly water-soluble and so undergoes glucuronidation to form 
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bilirubin diglucuronide, which is excreted into the bile. The glucronide residues are 
released in the terminal ileum by intestinal bacterial hydrolases. Free bilirubin is then 
reduced to colourless urobilinogens, which are oxidised to coloured products known as 
urobilins. Urobilins are mainly excreted in the faeces, but small proportions of urobilins 
and urobilinogens are excreted in the urine. Urobilins give urine its yellow pigment [21,22].
Since ultrafilitration of the urine sample only filters molecules of 3000 MW and over, 
urobilins and urobilinogens (584.65 MW) are still present in the filtered urine. When pre­
concentrating urine by 200 fold the concentration of urobilins increase and hence the 
viscosity increases. An increase in viscosity could cause an increase migration times, but 
not necessarily the order of elution providing the fused silica capillary is long enough for 
effective separation. In order to prove this hypothesis practically, both nicotine and 
cotinine, prepared in solutions of varying urobilinogen concentrations, would have to be 
run under the same conditions to establish whether migration time, resolution, and peak 
efficiency are affected by the increasing urobilinogen concentrations. Unfortunately due to 
time constraints this experiment was not carried out. However, the presence ofglucuronides 
may have also contributed to the varying migration times.
2.4. Conclusion
The 100 fold pre-concentrations of 1.25 pg/ mL and 625 ng/ mL of cotinine, in urine, 
showed a mean percentage recovery of 98.42 % from a lg C l8 SPE cartridge. Hence the 
200 fold pre-concentration of sample could be achieved through drying with nitrogen gas 
and reconstituting with buffer.
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A combination of hydrodynamic and electrokinetic injection was used for sample 
stacking/ MS due to the lower detection limit, and the reasonable number of theoretical 
plates achieved. Thus the sample-stacking mode of CE, when compared to CZE, was 
shown to improve peak efficiency.
LODs of nicotine and cotinine, by CE-sample stacking/ MS (via HE injection), were 
found to be 0.11 and 2.25 pg/ mL, respectively. Thus the LODs of nicotine and cotinine 
after 200 fold pre-concentration could be up to 0.55 ng/ mL and 11.25 ng/ mL, respectively. 
It should also be noted that the higher electrophoretic mobility of nicotine probably resulted 
in greater quantities of this solute being introduced to the capillary than cotinine during HE 
injection. This, accompanied with the higher ionising potential of nicotine, ensured its 
lower limit of detection. However, for quantitative analysis of biological samples, such a 
bias can be corrected by taking account of the ratio of peak areas of the analyte and internal 
standard.
The added selectivity that SIM provided ensured the clear identification of nicotine and 
its metabolites.
The same pattern of elution was observed for nicotine and its metabolites when analysing 
smokers’ urine. However, the inter-urine sample migration times of the metabolites 
appeared to differ slightly and were attributed to the presence of urobilinogens and 
urobilins. The extraction of both tetrapyrroles could be performed by acetaldehyde and 
petroleum ether. An alternative would be to use molecular imprinted polymers as a second 
phase extraction step complementary to SPE, as their added selectivity might ensure that 
only the analytes of choice were present in the sample.
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Chapter 3
Optimisation o f Hydrodynamic-Electrokinetic 
Injection and Supplementary Pressure Utilisation.
3.1. Introduction
In chapter 2 the application of a dual injection method, comprised of electrokinetic and 
hydrodynamic injection was described. The method produced lower limits of detection 
when compared to hydrodynamic or electrokinetic injection alone, but yielded a lower 
number of theoretical plates. A sampling bias was also evident in favour of nicotine. 
Therefore correction of this bias (in terms of the ratio of analyte peak area to that of the 
internal standard) is required when attempting quantitative analysis of nicotine and its 
metabolites in urine.
The most noticeable drawback of this injection method was the reduced peak efficiency, 
and increased peak broadening observed when large quantities of a concentrated sample 
were introduced. This means that for concentrated samples broader peaks are observed as 
compared to dilute ones. The relatively low peak efficiencies observed may also have been 
contributed to by the use of supplementary pressure to prevent column drying.
Aims and objectives
The objective of this study was to optimise the HE injection method (in terms of the 
voltage used) and to find the optimum supplementary pressure needed for the production of
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high quality data. This will allow ‘real’ samples containing potentially widely varying 
amounts of analyte(s) to be examined, using this method.
3.2. Methods and Materials
For CE/UV the detection window was burnt into the capillary 15 cm from the end of the 
capillary and analyses were performed at 205 nm. Inlet and outlet ends of the capillary were 
housed in run buffer vials during a run. Separations were achieved using +30 kV. Data 
acquisition was performed by DAx 6.0 software (PrinCE Technologies, Emmen, 
Netherlands) for CE/UV. Refer to section 2.2 for further methods and materials.
3.3. Results and Discussion
As previously described the degree of stacking and on-column pre-concentration is 
proportional to the ratio of resistivities of the sample solution and the run buffer, where 
solute ions are concentrated to an amount equal to X, the enrichment factor. However, this 
enrichment may not be fully observed as the difference between sample and buffer zone 
electric field strengths can generate a laminar flow, which in turn may lead to peak 
broadening. It was precisely for this reason that the sample solution, used thus far, was one 
tenth of the run buffer concentration.
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According to table 3.1, the dissolution of nicotine in the solvent mixture does not 
significantly affect peak efficiency and sensitivity when compared to dissolution in 1/10 
buffer. In fact the number of theoretical plates for cotinine was increased by approximately 
40,000 when the analyte was dissolved in the solvent mixture (table 3.1). The resolution 
between nicotine and cotinine was also slightly improved when the analytes were dissolved 
in the solvent mixture and only a minor reduction in peak asymmetry was observed (table 
3.1). Since there was no band broadening observed, solute ions analysed from here on were 
made up in the appropriate solvent mixture.
Table 3.1. Observation of the band broadening effect when the analyte is dissolved in the
solvent mixture as compared with that dissolved in 1/10 buffer (n = 5).
Resolution
(nic-cot) Amo
Aieanic(V.min) Heightnic(V)
Asymmetry
nic -A/cot
Areacot(V.min)
Heightcot
(V)
Asymmetry
cot
75% MeCN 
25% H20 10.2 66076 2.9X10-4 3.1xl0'3 10.8 138560 3.0 xlO-4 3.77 xlO'3 5.96
1/10 buffer 9.98 64282 2.9x10-4 3.4x1 O'3 8.60 95963 4.6 xlO-4 5.34 xlO'3 4.82
CE-sample stacking/UV was used to determine these measurements (at 205 nm). 50 pg/mL 
concentrations of nicotine and cotinine were used. The buffer system consisted of 10 mM 
ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm 
i.d. fused silica capillary was used, with effective length 85 cm; the sheath flow rate was 5 
pL/ min; the sample was introduced at 25 mbar for 0.2 min. Separation took place at 30 kV 
only. Subscripts (nic and cot) denote nicotine and cotinine respectively. Reproducibility 
was determined by the RSD of the retention times for nicotine dissolved in the solvent 
mixture (1.26 %) and the 1/10 buffer (0.83 %). Resolution was calculated by R -  l( t2- 
t2)/(w 1+W2) (equation 2.5) [1]. N= 5.54(thvy2)2 (equation 3.1) [1].
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3.3.1 Hvdrodvnamic-electrokinetic (HE) injection
It is important to gauge how much voltage to use when attempting HE injection as the 
combination of hydrodynamic and electrokinetic injection could lead to sample overload of 
the capillary. It is evident from figure 3.1 that there is a linear increase in peak area as a 
result of increasing the voltage applied during HE injection. This was especially true for 
nicotine, which had an R2 value o f0.994 (figure 3.1), and suggesting that increasingly more 
sample was being introduced to the capillary.
There appeared to be more nicotine loaded onto the capillary than cotinine. This was 
probably as a result of greater pre-concentration of nicotine as a result of its higher 
electrophoretic mobility.
Figure 3.1. Peak area versus applied voltage for HE 
injection of nicotine and cotinine.
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Sample stacking was performed at 205 nm. 50 pg/mL nicotine and 50 pg/mL cotinine were 
made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium 
formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm i.d. fused 
silica capillary, with effective length 85 cm; the sheath flow rate was 5 pL/ min; the sample 
was introduced at a range of voltages + 25 mbar for 0.2 min. Separation took place at 30 
kV. Error bars were a product of the standard deviation (n = 7).
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Since a fixed amount of sample is introduced into the capillary by hydrodynamic 
injection, the only other variable is the voltage applied during the electrokinetic part of this 
injection method. Equation 2.8 (ginj = F7ictr2(pEP + Peof)/£) [1] clearly illustrates the 
importance of voltage (V) as the major variable since both the EOF and the electrophoretic 
mobility of the analyte are dependent upon it. However, this linear relationship was not 
confirmed by using peak height (figure 3.2).
Figure 3.2. Peak height versus applied voltage for HE injection of 
nicotine and cotinine.
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Sample stacking was performed at 205 nm. 50 pg/mL nicotine and 50 pg/mL cotinine were 
made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium 
formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H20; 100 cm, 75 pm i.d. fused 
silica capillary, with effective length 85 cm; the sheath flow rate was 5 pL/ min; the sample 
was introduced at a range of voltages + 25 mbar for 0.2 min. Separation took place at 30 
kV. Error bars were a product of the standard deviation (n = 7).
A possible reason for this was that at higher sample concentrations, increasing peak 
broadening and/or distortion occurred, which caused changes in peak height but not area.
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Peak broadening/distortion is most evident in figure 2.9 due to HE injection at 30 kV (refer 
to figure 3.2).
Probably the only way of monitoring peak distortion is by calculating peak asymmetry. In 
this study peak asymmetry is a serious issue, since the analytes have lower mobilities than 
buffer cations causing peak tailing. Therefore at higher voltages, peak shape becomes 
increasingly asymmetric due to increased sample introduction. As a result, the distorted 
peak shape may have a significant effect on the peak height. That is, if peaks become 
increasingly broad then they will tend to lose height.
ba?eS>■>
03
Sample stacking was performed at 205 nm. 50 pg/mL nicotine and 50 pg/mL cotinine were 
made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium 
formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm i.d. fused 
silica capillary, with effective length 85 cm; the sheath flow rate was 5 pL/ min; the sample 
was introduced at a range of voltages + 25 mbar for 0.2 min. Separation took place at 30 
kV. Error bars were a product of the standard deviation (n = 7).
Figure 3.3 shows only a slight increase in peak asymmetry for cotinine from 15 kV to 30 
kV and so this increase is not significant. However, there is a more significant increase in 
peak asymmetry for nicotine from 0 to 30 kV.
Figure 3.3. Peak asymmetry versus applied voltage for HE 
injection of nicotine and cotinine.
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As the voltage was increased for HE injection, the resolution between the nicotine and the 
cotinine peak decreased (table 3.2). This is presumably related to increasing band 
broadening as there was a progressive increase in peak width from 0 kV to 30 kV, 
especially in the case of the nicotine peak (table 3.2). From .ft = 2(ft-ft)/(wi+w2), where ft is 
resolution, t is time, and w is the peak width, (equation 2.5) [1] it can be seen that an 
increase in peak width will cause a reduction in resolution.
Table 3.2. Resolution between nicotine and cotinine at various voltages for HE injection (n
=n
Voltage (kV) ft (mins) ft (mins) w\ (mins) W2 (mins) Resolution ft %RSD ft %RSD
0 9.76 12.14 0.22 0.33 8.58 0.79 0.31 ;
5 9.99 12.72 0.37 0.42 6.97 1.17 0.66
10 10.12 12.94 0.49 0.32 7.0 0.77 0.81
15 10.20 13.13 0.70 0.35 5.61 0.49 0.89
20 10.02 13.01 0.63 0.33 6.20 3.03 3.80
25 10.16 13.24 0.79 0.42 5.10 0.50 0.76
30 10.42 13.68 1.0 0.43 4.54 0.55 0.78
Sample stacking was performed at 205 nm. 50 jig/mL nicotine (ft) and 50 pg/mL cotinine 
(ft) were made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM 
ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H20; 100 cm, 75 pm 
i.d. fused silica capillary, with effective length 85 cm; the sheath flow rate was 5 pL/ min; 
the sample was introduced at a range of voltages + 25 mbar for 0.2 min. Separation took 
place at 30 kV.
Thus far the use of peak area versus increasing kV, for HE injection, has been a useful 
way of evaluating the extent of sample introduction. However, in order to confirm this 
relationship, it becomes essential to know the injected quantities of nicotine and cotinine at 
increasing voltages for this method of sample introduction.
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Table 3.3. Variation in the quantities of nicotine and cotinine injected at a range of voltages
for HE injection (n = 3).
Voltage
applied
(kV)
/m nic
min
tm  cot
min
/nm urea
min
Hue
mm/min Vcotmm/min
Vurea
mm/min Qtnl(ng)
Q in f i-
(ng) a
0 1 0 .4 9 1 4 .5 6 4 1 . 5 5 6 0 . 6 0 3 7 . 9 2 2 0 . 4 5 2 . 3 0 2 . 3 0 0 . 8 7
6 .5 1 0 .5 2 1 4 .4 5 4 1 . 5 8 6 0 . 3 6 3 8 . 3 9 2 0 . 4 4 3 . 1 7 2 . 9 4 0 . 8 7
1 0 1 0 .4 4 1 4 .4 4 4 1 . 7 9 6 1 . 0 5 3 8 . 7 9 2 0 . 3 4 3 . 6 6 3 . 2 8 0 . 8 7
2 0 1 0 .0 5 1 4 .1 9 4 0 . 0 5 6 3 .3 5 3 8 . 6 8 2 1 . 2 2 5 . 1 2 4 . 3 0 0 . 8 6
2 6 .5 1 0 .3 3 1 4 .7 4 4 4 . 1 8 6 3 .0 5 3 8 . 4 2 1 9 .2 4 5 . 9 3 4 . 8 5 0 . 8 6
3 0 1 0 .4 0 1 4 .6 3 4 2 . 1 9 6 1 . 6 0 3 7 . 9 4 2 0 . 1 5 6 . 3 9 5 . 2 0 0 . 8 7
Sample stacking was performed at 205 nm. Laboratory temperature = 20 °C. Subcripts (nic, 
cot, and urea) denote nicotine, cotinine, and thiourea respectively. HE injection was 
accomplished by introducing the sample at 25 mbar + at a range of voltages, for 0.2 min. 
Separation was carried out at 26.5 kV. Results were obtained from CE-sample stacking/ 
UV. The viscosity of the buffer system was calculated as 0.51 cP. 0inj = (F// 1 x 106) xc x 
1000 (equation 3.2); Lp = (AP  x / x d2) / (53.3 x rj x L) + (v+  vtop) x tm x (Vinj / Vsep) 
(equation 3.3); V, = (r x 1 x 106)2 x (Lp x 1 x 103) x n x 1 x 1012 (equation 3.4). Q WJ1 and 2 
are nicotine and cotinine respectively, where Qmf is the injected quantity; V,- is the injected 
volume (nL); c is the concentration in pg/ mL; Lp is the sample plug length; AP  is the 
pressure across the capillary; / is the injection time (min); d  is the capillary inner diameter 
(75 pm); t] is the viscosity of the sample solution; L  is the total length of the capillary 
(100cm); /m is the migration time; v is the velocity of the analyte or the EOF in the case of 
Vureai Vinj is the injection voltage; Vsep is the separation voltage, a  = selectivity, i.e. a  = (t2- 
tnm)f(ti-tma) (equation 3.5) [1], where t2 and t\ are migration times of adjacent peaks and /nm 
is the migration time of a neutral marker.
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Since a UV detector was used for the above study, it was necessary to try and reproduce 
the same conditions as experienced by the mass spectrometer. It should be remembered that 
the voltage used in the MS experiments was 3.5 kV at the capillary outlet. This creates a 
potential difference along the fused silica capillary of 26.5 kV, when 30 kV was applied at 
the inlet end. Thus in order to determine the correct amounts of sample injected, separation 
would have to be conducted under this potential difference.
When considering electrokinetic injection it is important to note that solutes are carried 
into the capillary by the electroosmotic flow and the electrophoretic mobility. Therefore 
both electroosmotic velocity and the electrophoretic velocity of the solute ion will have to 
be calculated, since both are dependent upon the voltage applied. Measurement of the 
former requires the introduction of a neutral marker (as neutral solutes are pulled into the 
capillary by just the EOF), such as thiourea, for measurement. Hydrodynamic injection, 
however, is mainly dependent on the length of the capillary, the capillary diameter, the 
pressure applied,and the viscosity (table 3.3).
The charge states of nicotine and cotinine within the solvent mixture at pH 7 would be 
+1 and 0 respectively. This was probably due to pyrrolidine N of nicotine having a pKa 
between 9 and 10, whilst the pyrrolidine N of cotinine has a pKa of -0.41. Therefore in 
theory there should be no increase in the amount of cotinine introduced to the capillary. 
This was observed to some extent in figure 3.1 where there was a significantly greater 
linear increase in peak area for nicotine, at increasing voltage, when compared to that of 
cotinine. In theory if cotinine was charged then it too would show a linear increase in 
amount introduced to the capillary (as shown in figure 3.4 and table 3.3). Thus the 
calculated amounts (ng) shown in figure 3.4 and table 3.3 rely on the assumption that
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cotinine is charged since the electrokinetic part of the technique is dependent on the voltage 
applied. But in practice this was not the case (refer to figures 3.1).
Figure 3.4. Injected quantity versus applied voltage for HE 
injection of nicotine and cotinine.
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Sample stacking was performed at 205 nm. 50 pg/mL nicotine and 50 pg/mL cotinine were 
made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium 
formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm i.d. fused 
silica capillary was used; the sheath flow rate was 5 pL/ min; the sample was introduced at 
a range of voltages + 25 mbar for 0.2 min. Separation took place at 30 kV only. Error bars 
were a product of the standard deviation (n = 7).
Figure 3.4 shows a linear increase in the injected quantities of both nicotine and cotinine 
relative to increased voltage for HE injection. Figure 3.4 also shows the clear sampling bias 
for nicotine with respect to cotinine for this injection method at increasing voltages. This 
confirms that greater quantities of nicotine were being introduced into the capillary than 
cotinine. The greater quantities of sample introduced into the capillary at higher voltages
for HE injection corresponds with the decline in peak efficiency (figure 3.5) and resolution 
(table 3.2).
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It is interesting to note that selectivity between nicotine and cotinine remained constant at 
all the voltages applied for HE injection (table 3.3). However this is perhaps not surprising 
as selectivity is only a measure of the distance between two solute peaks, whereas 
resolution, which is a measure of separation between two adjacent peaks, was most likely to 
succumb to the effects of increasing peak broadening at higher voltages for HE injection, 
since resolution is partly dependent upon the peak width. Thus the constant selectivity 
observed between nicotine and cotinine peaks at all the applied voltages for this injection 
method further confirmed the significance of peak broadening at higher voltages, as only 
peak-to-peak resolution was compromised at higher kV for HE injection (table 3.2).
Figure 3.5. Peak efficiency versus applied voltage (kV) for HE 
injection of nicotine and cotinine.
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Sample stacking was performed at 205 nm. 50 pg/mL nicotine and 50 pg/mL cotinine were 
made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium 
formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm i.d. fused 
silica capillary, with effective length 85 cm; the sheath flow rate was 5 pL/ min; the sample 
was introduced at a range of voltages + 25 mbar for 0.2 min. Separation took place at 30 
kV only. N  = 5.54(/Avi/2)2 (equation 3.1) [1]. Error bars were a product of the standard 
deviation (n = 7).
As expected peak efficiency was at its highest when only hydrodynamic injection was 
applied (i.e. at 0 kV on figure 3.5) and declined at higher voltages for HE injection.
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Cotinine exhibited the greatest number of theoretical plates, with the greater decline 
between 5 and 10 kV for HE injection. The number of theoretical plates declined to a lesser 
extent between 10 and 15 kV, and then began to plateau. Nicotine, on the other hand, had 
the greatest decline in theoretical plate numbers from 0 to 5 kV. However, from 5 to 30 kV, 
theoretical plate numbers for the nicotine were only diminished by approximately 15,000 
theoretical plates. Values obtained for hydrodynamic injection were in keeping with the 
theoretical plate numbers of those shown in table 2.5.
When considering the optimum peak efficiency, voltages of 10 kV and below were 
desirable for cotinine, whereas those of 5 kV and below were desirable for nicotine (figure 
3.5). However, in terms of separation, the greatest resolutions were obtained from voltages 
of 10 kV and below (figure 3.2).
3.3.2 Supplementary pressure optimisation
As already mentioned, supplementary pressure was used to prevent the outlet-end of the 
fused silica capillary from getting blocked, drying out (which can result from an influx of 
air), and to prevent siphoning effects when the CE system was coupled to the mass 
spectrometer [2,3]. Thus it was necessary for some supplementary pressure to be applied to 
the inlet end during separation.
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Figure 3.6. The effect of supplementary pressure on peak efficiency.
60000 n
50000 =.
40000 -
o  30000 "  
£  20000 -
20 30 40 50 600 10
Supplementary pressure (mbar)
♦ CZE Sample stacking
Sample stacking was performed at 205 nm. 50 pg/mL cotinine was made up in 25 % 
H2O/ 7 5  % MeCN. The buffer system consisted of 10 mM ammonium formate (pH adjusted 
to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 cm, 75 pm i.d. fused silica capillary, whose 
effective length was 85 cm; the sheath flow rate was 5 pL/ min; the sample was introduced 
at 25 mbar for 0.2 min. Separation took place at 30 kV + at a range of mbars. N  = 
5.54(r/ivi/2)2 (equation 3.1). Error bars were a product of the standard deviation (n = 7).
Figure 3.6 shows clearly the higher theoretical plate numbers exhibited by sample 
stacking with respect to CZE. This further emphasises the justification for using sample 
stacking rather than CZE. Figure 3.6 shows a steady decline in theoretical plate numbers for 
both sample stacking and CZE at increasing increments of supplementary pressure. For 
sample stacking there is a slight decrease in theoretical plate numbers between 0 and 10 
mbar of applied supplementary pressure. However, it could also be said that acceptable 
numbers of theoretical plates are achieved at 20 mbar for sample stacking. CZE exhibits no 
significant change in theoretical plate numbers between 10 and 20 mbar. But there is a 
minor increase of approximately 8000 theoretical plates from 10 to 0 mbar for CZE. This
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suggests that acceptable numbers of theoretical plates are achieved from 0 to 20 mbar 
supplementary pressure.
It should be noted that the lower theoretical plate numbers achieved in figure 3.6 may 
also have been the result of using a different capillary, which might also account for the 
lower peak-to-peak resolution observed (refer to tables 2.8 and 2.9).
The small variations in migration times observed was probably in this case accounted for 
by changes in ambient temperature, since the laboratory was not climate controlled (tables
2.8 and 2.9)
Table 3.4. The effect of varying supplementary pressure on the resolution of nicotine and 
cotinine for CZE (n = 7).
mbar
t nic
(min) t cot (min) rvnic (min) Wcot (min) Resolution t  nic % R S D f c o t% R S D
0 9.15 10.98 0.24 0.35 6.21 1.4 1.38
10 7.39 8.55 0.23 0.32 4.25 0.97 0.74
20 6.45 7.29 0.28 0.33 2.76 0.79 0.62
30 5.86 6.50 0.28 0.30 2.21 0.92 0.99
40 5.12 5.61 0.33 0.40 1.34 0.54 0.52
50 4.572 4.96 0.27 0.35 1.25 0.27 0.26
Sample stacking was performed at 205 nm. Subcripts denote nicotine and cotinine 
respectively; t and w are the migration time and peak width respectively. 50 pg/mL nicotine 
and 50 pg/mL cotinine were made up in 25 % H2O/ 7 5  % MeCN. The buffer system 
consisted of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % 
H2O; 100 cm, 75 pm i.d. fused silica capillary, with effective length 85 cm; the sheath flow 
rate was 5 pL/ min; the sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation 
took place at 30 kV + at a range of mbars..
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Table 3.5. The effect of varying supplementary pressure on the resolution of nicotine and 
cotinine sample stacking (n = 7).
mbar t nic (min) foot (min) Wnic (min) u>cot (min) Resolution fn i0 % R S D t cot % R S D
0 9.61 11.41 0.20 0.32 6.97 0.52 0.51
10 7.68 8.80 0.17 0.29 4.86 0.34 0.39
20 6.18 6.89 0.20 0.27 3.00 0.32 0.43
30 5.32 5.84 0.19 0.27 2.28 0.56 0.61
40 4.69 5.10 0.22 0.26 1.70 0.94 0.92
50 4.22 4.54 0.21 0.24 1.42 1.70 1.77
Sample stacking was performed at 205 nm. Subcripts denote (nic and cot) nicotine and 
cotinine respectively; t and w are the migration time and peak width respectively. 50 pg/mL 
nicotine and 50 pg/mL cotinine were made up in 25 % H2O/ 7 5  % MeCN. The buffer 
system consisted of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % 
MeCN/25 % H20; 100 cm, 75 pm i.d. fused silica capillary, with effective length 85 cm; 
the sheath flow rate was 5 pL/ min; the sample was introduced at 10 kV + 25 mbar for 0.2 
min. Separation took place at 30 kV + at a range of mbars.
Tables 3.4 and 3.5 both show a reduction in resolution as a result of increasing 
supplementary pressure, due to the flow profile becoming increasingly more laminar. That 
is, the flow profile increasingly resembles that of a pressure driven system. The resolutions 
exhibited by both CZE and sample stacking were very similar, with the latter exhibiting 
only a slight improvement. However, the initially recorded resolution between nicotine and 
cotinine i.e. that recorded without supplementary pressure was lower than that previously 
reported (table 3.2). This may have been due to the elevated external temperature causing a 
rise in internal capillary temperature, which probably lead to some zone spreading and 
hence a reduction in resolution.
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3.3.3 Optimised HE injection and supplementary pressure for the analysis of nicotine and 
its metabolites.
Ideally the best separations are achieved with low voltage applied for HE injection (i.e. 
10 kV) and without supplementary pressure. These conditions were then transferred to the 
mass spectrometer and the optimised coaxial probe arrangement was used throughout (refer 
to section 2.3.1).
Figure 3.7. SIR mass electropherogram of nicotine and seven of its metabolites, obtained 
via HE-sample stacking/MS with no supplementary pressure during separation.
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50 pg/mL nicotine,.nomicotine, cotinine, nicotine-l'-N-oxide, 5'-hydroxycotinine, and 
cotinine-1-N-oxide were made up in 25 % H2O/ 7 5  % MeCN. The buffer system consisted 
of 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H2O; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place at 30 kV. 
Reproducibility was determined by the RSD of the resolution (mean = 10.45; n = 3) 
between nicotine and cotinine (RSD = 3.99 %).
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The advantages of using no supplementary pressure and a lower voltage (10 kV) for HE 
injection were that extremely good separation and highly efficient peaks (with theoretical 
plate numbers of 31164 and 51066 obtained for nicotine and cotinine respectively) were 
obtained (figure 3.7). The most notable drawback of this method, however, was the 
relatively long analysis time of almost 30 minutes. Another major disadvantage of not 
using supplementary pressure was that, on numerous occasions, air entered the capillary 
outlet (as a result of siphoning) causing considerable fluctuations in the current. Thus only 
three out of eight runs were successful. Therefore some supplementary pressure was 
required to improve the robustness of this method. The lowest supplementary pressure 
considered was 10 mbar (figure 3.8).
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3.8 SIR mass electropherogram o f nicotine and seven o f its metabolites obtained via HE- 
sample stacking/MS and the application o f  10 mbar supplementary pressure during
separation.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-l'-N-oxide, 5'-hydroxycotinine, and 
cotinine-1-N-oxide were made up in 25 % H2O/7 5  % MeCN. The buffer system consisted 
o f 10 mM ammonium formate (pH adjusted to 2.5 with HC1), 75 % MeCN/25 % H20 ; 100 
cm, 75 pm i.d. fused silica capillary was used; the sheath flow rate was 5 pL/ min; the 
sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place at 30 kV + 
10 mbar supplementary pressure. Reproducibility was determined by the RSD o f the 
resolution (mean = 9.64; n = 5) between nicotine and cotinine (RSD = 4.83 %).
Figure 3.8 shows good separation, highly efficient peaks (with theoretical plate numbers 
o f 33614 and 50589 obtained for nicotine and cotinine respectively), and a reduction in the 
analysis time. This method was then considered for the analysis o f a smoker’s urine sample 
(after SPE pre-concentration).
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Figure 3.9. SIR mass electropherogram of a smoker’s urine sample obtained via HE-sample 
stacking/MS.
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Two hundred fold pre-concentration o f a smoker’s urine via SPE (made up in 25 % H20/75 
% MeCN). The buffer system consisted o f 10 mM ammonium formate (pH adjusted to 2.5 
with HC1), 75 % MeCN/25 % H20 ; 100 cm, 75 pm i.d. fused silica capillary was used; the 
sheath flow rate was 5 pL/ min; the sample was introduced at 10 kV + 25 mbar for 0.2 min. 
Separation took place at 30 kV + 10 mbar supplementary pressure. Reproducibility was 
determined by the RSD o f the resolution (mean = 10.02) between nicotine and cotinine 
(RSD = 4.01 %, n = 3).
Figure 3.9 shows the clear identification o f nicotine, cotinine, trans-3'-hydroxycotinine, 
and 5'-hydroxycotinine from a smoker’s urine. This mass electropherogram proved that the 
applied 10 kV, for HE injection, was sufficient to provide the sensitivity needed to identify 
nicotine and its metabolites. The 10 mbar supplementary pressure ensured good separation 
as well as high peak efficiency.
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An optimised voltage for HE injection was also achieved together with an optimised 
supplementary pressure for a predominantly aqueous system (figure 3.10).
Figure 3.10. SIR mass electropherogram of nicotine and five of its metabolites obtained via 
HE-sample stacking/MS.
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50 pg/mL nicotine, nomicotine, cotinine, nicotine-l'-N-oxide, 3-pyridyl acetic acid, 5'- 
hydroxycotinine, and cotinine-1-N-oxide were made up in buffer. The buffer system 
consisted of 25 mM ammonium formate (pH adjusted to 2.8 with formic acid) + 10 % 
MeCN; sheath liquid was MeCN/H20 1:1 + 0.1 % formic acid; 100 cm, 75 pm i.d. fused
silica capillary was used; the sheath flow rate used was 5 pL/ min; sample was introduced 
at 25 mbar +10 kV for 0.2 min; CZE separation took place at 30 kV and 30 mBar 
supplementary pressure. Reproducibility was determined by the RSD of the resolution 
(mean Res = 4.95) between nicotine and cotinine (RSD = 4.14, n = 3).
Figure 3.10 shows a good separation of nicotine and five of its metabolites. The migration 
times resemble those observed by Palmer et al. [4]. However, the electrical contact 
established was not maintained for long periods and only three successive runs were
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achieved. The non-homogenous nature of the sheath liquid, with respect to the composition 
of the mn buffer, appears to have weakened the electrical contact. However, there was a 
slight improvement in spray stability, which was probably due to the withdrawal of the 
fused silica capillary into the sheath tube (until they were at the same level), as compared 
with the previous arrangement (refer to section 2.3.1). Potentially the aqueous systems offer 
greater separation efficiency and sensitivity, due to their greater conductive nature.
3.4. Conclusion
Optimum peak efficiency and separation is obtained if a sample is hydro dynamically 
injected but this causes a reduction in sensitivity, since less sample is introduced into the 
capillary compared to HE-injection. This is especially true for use with the mass 
spectrometer, since this detector is concentration dependent. It is also important to note 
that the highest peak efficiencies and separations were only obtained when no 
supplementary pressure was applied during separation, but severe fluctuations in current 
(due to the influx of air at the outlet end of the ffised silica capillary) were also noticed.
Daily changes in laboratory temperature did not affect reproducibility, but appeared to 
affect peak efficiency and resolution. Thus climate-controlled laboratories should be 
welcomed for this type of analysis.
Sensitivity and throughput are also important parameters when considering the analysis of 
multiple compounds within a sample. In the case of the former the optimal voltage (e.g. 10 
kV), which is one that achieves great sensitivity enhancements without significantly 
compromising resolution and peak efficiency, is required. But the effect of HE injection on 
resolution and peak efficiency, at higher voltages, is dependent upon analyte concentration,
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prior to injection. Thus if the analyte concentration is relatively high then lower voltages 
may be applied for HE injection, but if it is low, as in the case of most biological samples, 
then higher voltages can be used.
The application of supplementary pressure during separation may increase the through­
put of analyses, but cause a reduction in resolution. There has to be a careful balance 
between obtaining high quality data and generating fast analysis times. The optimum 
appears to be 10 mbar and below, where acceptable separations and theoretical plate 
numbers are achieved. However, since separation and peak efficiency are also dependent 
upon analyte concentration, both variables should be taken into account when considering 
the supplementary pressure applied.
Higher throughput analyses could be achieved by raising the concentration of the run 
buffer (i.e. between 25 and 50 mM), which would improve separation and analyte pre­
concentration, as well as peak efficiency, and would allow for higher supplementary 
pressures to be applied.
When applying the optimised method to .a real sample (e.g. from SPE pre-concentration 
of urine), initially that sample would be spiked with a known quantity of internal standard, 
from which it would be possible to determine the relative concentrations of nicotine and its 
metabolites.
We have recently developed a counterflow transient isotachophoresis (tTTP) method, with 
MS detection, for the analysis of even lower analyte concentrations. A major advantage of 
this method was that less sample pre-concentration by SPE was required, due to the higher 
pre-concentrating capability of tUP with respect to sample stacking. Thus by using less 
sample pre-concentration via SPE lower levels of urobilinogens/urobilins will be present in
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the sample, which would mean that separation would be less hampered by changes in 
sample viscosity. This is reported in the next section.
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Chapter 4
The Determination of Nicotine and its Metabolites, in Urine, 
by Transient Isotachophoresis/Mass Spectrometry.
4.1. Introduction
The major limitation of capillary zone electrophoresis (CZE) is low concentration 
sensitivity [1]. This is due primarily to the extremely small dimensions of the fused silica 
capillary (25-150 i.d. and 40 cm -1 m length), which only allows for small sample volumes 
(usually less than 50 nL) to be loaded onto the column, as well as a drastically reduced 
path-length for the most common optical detection techniques, including UV detection [2-
4], As already mentioned, the dilution effect of the sheath liquid also reduces sensitivity 
during mass spectrometric analysis.
To greatly improve the sensitivity of CE, larger volumes of sample need to be introduced 
into the capillary [5,6]. But the introduction of a large dilute sample plug ensures that there 
is a high field strength is in the solute zone, with the field strength in the run buffer at times 
becoming extremely low. Therefore when solute ions reach the run buffer their 
electrophoretic velocities can drop to near zero. In such circumstances solute ions are not 
very well separated. In order to minimise the problems associated with injection of large 
sample volumes isotachophoresis can be employed [7].
The German chemist Kohlrausch laid down laws governing isotachophoretic separation 
in 1897, but isotachophoresis was only established as a full working method during the
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1970s. Much of the work reported since then has been on devising a theoretical description 
of the dynamics of the separation, and calculating the composition of the electrophoretic 
zones [8].
Isotachophoresis
Electrophoretic pre-concentration can be brought about through the use of continuous or 
discontinuous buffers. However, the former is mainly suitable for samples in non-ionic 
matrices. This technique does not work well for trace components present in complex ionic 
matrices because of CZE overloading, leading to poor resolution [9]. For isotachophoresis 
(TTP) the electroosmotic flow (EOF) is usually kept to a minimum (by using very low pH 
buffers) or removed entirely (by coating the capillary with a hydrophilic polymer) as the 
presence of the EOF would otherwise limit the focusing effect.
In capillary ITP the sample plug is placed between the leading and terminating buffers, in 
the capillary, and a voltage at a constant current is applied. Leading electrolyte ions have 
greater mobilities than the mobilities of ions present in the sample, whilst terminating 
electrolyte ions have the lowest mobilities [7,10,11]. For cations, the application of an 
electric field will cause cations in the leading buffer to move the fastest. At the point of 
focusing, cations in the sample arrange themselves in order of mobility, with those of the 
highest mobility next to the leading electrolyte, whilst those of the lowest mobility are next 
to the terminating electrolyte [12]. After solutes distribute themselves in the capillary, an 
equilibrium is reached and hence a steady state. In this situation all buffer and solute 
cations migrate at the same velocity, vl, the velocity of the leading cations. Hence the term 
isotacho, which means constant velocity [7]
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Vl — Pep# (4.1)
where Pep is the electrophoretic mobility, and E  is the electric field (where a different 
electric field develops in each zone) [7] E  is highest in the zone with the lowest mobility 
since
and therefore
E —ll ffiOBS
where t is the migration time and pobs is the observed mobility. The boundaries between 
each zone are extremely sharp since a solute that migrates into a different zone experiences 
a different electric field, which inevitably causes it to diffuse back into the zone with the 
appropriate electric field for its mobility [2,7]. When a steady state is reached each analyte 
moves as a discrete band according to its mobility. Bands with the highest mobility will 
elute before those of lowest mobility. During the steady state, all zones migrate with equal 
velocity, have distinct borders, and the discreteness in field strengths between each zone 
corrects diffiisional band broadening. The steady state concentrations of the compound 
zones are proportional to the concentration of the leading buffer. From the Kohlrausch 
regulating function an equation linking the concentration of solute ions to those ions of the 
leading buffer has been derived [7]. The concentration of solute ions, Cs, is related to the 
concentration of the leading ions, Cl, in the following way
where p is the electrophoretic mobility, the subscript L represents the leading ion, S 
represents the solute co-ion, and C the counter-ion. The final concentration may be given
t — //poBsE (4.2)
CdCs— [Pl/(Pl + Pc)][(ps + Pc)/ps] (4.3)
by [7]
Cs=CJc (4.4)
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where A: is a proportionality factor (between 0.2 and 1 for common electrolytes). This is 
equal to 1 when the concentration o f solute ions becomes the same as the concentration of 
ions in the leading buffer [7].
Figure 4.1. A schematic representation o f the transient isotachophoresis procedure for the 
separation o f cations (adapted from Baker, 1995) [7].
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C is the co-ion (leading electrolyte), T is the terminating ion, and S is the sample plug.
Continuation o f the separation in the CZE mode may be performed by placing the 
capillary inlet in the leading electrolyte. When the leading electrolyte catches up with the 
sample zone the field gradient will be lost and CZE separation will begin. Since ITP only 
takes place for a short period o f time the technique is termed “transient” ITP [7].
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On-line ITP can be either on-column or coupled-column in arrangement. Two 
disadvantages of the coupled column procedure are that the apparatus has to be modified 
and it is difficult to automate these procedures [13]. Since the on-column procedure 
gradually changes from ITP to CZE it is referred to as on-column transient isotachophoresis 
(tITP). In this arrangement the analysis is conducted such that both ITP pre-concentration 
and CZE separation proceed in the same capillary [14,15].
Interfacing a CE-tlTP system to a triple quadrupole mass spectrometer would ensure the 
provision of structural information on compounds after separation and enables the clear 
identification of selected analytes within complex mixtures [16].
Aims and Objectives
The aim of this study was to produce a highly sensitive transient isotachophoretic/MS 
method that was complementary to the CE-sample stacking/MS method used for the 
analysis of nicotine and its metabolites in urine (chapters 2 and 3). The optimised method 
should yield limits of detection comparable to that observed by HPLC/MS, and with a 
separation efficiency to match that of CE-sample stacking/MS.
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4.2 Methods and Materials
4.2.1 Samples and Sample Preparation
Standards of nicotine and its major metabolites were prepared in the appropriate solvent 
mixtures (made up to 1 mM acetic acid) for tITP experiments.
Urine was obtained from five male smokers (aged 21 to 39 years), la  to 5a, and stored at 
-20 °C in tissue culture flasks. Urine samples were also obtained from eleven subjects (lb 
to 1 lb), five of whom were non-smokers (7b to 1 lb). Prior to extraction urine samples were 
thawed overnight at 4 °C, thoroughly mixed and filtered with a 0.45 pm Supor acrodisc 
filter (Pall Corporation, Portsmouth, UK).
4.2.2 Solid Phase Extraction
Solid phase extraction (SPE) was carried out using a 100 mg C l8 cartridge (Vanan, Ltd, 
Surrey, UK). For conditioning purposes 3 mL of methanol followed by 3 mL of deionised 
water (Milli- Q, UK) were passed through the SPE cartridge sequentially. Then 1 mL of 
sample was introduced into the cartridge followed by 6 mL of deionised water. It should be 
noted that for 2 and 10 fold pre-concentrations, 5 and 10 mL of sample were introduced 
respectively. The sample was then eluted with 1 mL of methanol. The eluted product was 
dried with nitrogen gas. The dried product was then reconstituted with 1 mL of mobile 
phase for recovery experiment or 1 mL of solvent mixture for tITP.
4.2.3 Buffer and Mobile Phase Preparation
A suitable quantity of ammonium salt (Sigma-Aldrich, Dorset, UK) was dissolved in the 
solvent mixture (acetonitrile [Fischer Scientific, Manchester, UK]/ deionised water [Milli-
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Q, UK]) as the leading buffer; L-alanine was dissolved the appropriate solvent mixture 
(acetonitrile/ deionised water [Milli-Q, UK]) as the terminating buffer; buffer pH’s were 
adjusted with formic, acetic acid orHCl (Sigma-Aldrich, Dorset, UK), as appropriate, and 
were freshly prepared. Buffers were degassed prior to analysis using a Branson 1210 
ultrasonic bath (Branson Ultrasonics, Danbury, CT, USA) and filtered through a 0.2 pm 
Supor acrodisk syringe filter (Pall Corporation, Portsmouth). The buffers prepared were 10 
mM ammonium formate (10 % acetonitrile, 90 % deionised water), which was adjusted to 
pH 2.5 with formic acid; 10 mM ammonium acetate (in deionised water) adjusted to pH 2.5 
with acetic acid; 10 mM ammonium formate (75 % acetonitrile, 25 % deionised water) 
adjusted to pH 2.5 with HC1; 10 mM L-alanine (dissolved in the appropriate solvent 
mixture) adjusted to pH 2.5 with either acetic acid or HC1 depending on the composition of 
the leading buffer system.
4.2.4 THP Separation
TUP was carried out in either a 65 (50 or 75 pm i.d. x 365 pm o.d) or a 100 cm (75 pm 
i.d. x 365) pm o.d., untreated fused silica capillary (Composite Metal Services Ltd., 
Hallow, UK). The CE/UV system used (Crystal CE System, PrinCE Technologies, 
Lauerlabs, Emmen, Netherlands) utilizes programmable injection with pressure and voltage 
control. The detection window was burnt into the fused silica capillary 15 cm from the end 
for CE/UV and analyses were performed at 205 nm. Separations were achieved using +30 
kV. Data acquisition was performed by DAx 6.0 software (PrinCE Technologies) for 
CE/UV. Injections were performed either hydrodynamically (25 mbar/ 0.2 min) or 
hydrodynamically + electrokinetically (HE: 25 mbar + x kV/ 0.2 min). Initial conditioning 
of the capillary took place with 1 M NaOH (5 min / 2000 mbar [Sigma-Aldrich, Dorset,
Chapter 4 TIIP/MS 141
UK]) followed by the buffer system (7 min/ 2000 mbar). The capillary was conditioned 
prior to each run with 1 M NaOH (2000 mbar/ lmin) followed by buffer system (2000 
mbar/1.5 min). The buffer system was replenished after each run cycle.
4.2.4a TITP separation steps for a 65 cm. 50 u.m i.d. capillary using 10 mM ammonium 
acetate (100 % deionised water! as the leading buffer; 10 mM L-alanine (100 % deionised 
water) as the terminating buffer
1) Leading buffer (capillary inlet): + 1000 mbar and 30 kV for 0.3 min.
2) Sample (capillary inlet): + 75 mbar and 0 kV for 1.85 min (approximately 10 cm 
injection plug).
3) Terminating buffer (capillary inlet): + 75 mbar for 0.185 min (approximately 1 cm 
injection plug).
4) Terminating buffer (capillary inlet), tlTP step: -36.0 mbar and 30 kV, for 0.2 min.
5) Terminating buffer (capillary inlet), counterflow (counterflow step 5 [CF5]): - 75 
mbar for 0.90 min.
6 ) Leading buffer ( capillary inlet): CZE separation -30 kV only (unless otherwise 
stated) for x min (where x is the number of minutes).
4.2.4b TITP separation steps for a 65 cm. 75 pm i.d. capillary using 10 mM ammonium 
acetate HOP % deionised water) as the leading buffer: 10 mM L-alanine (100 % deionised 
water) as the terminating buffer
7) Leading buffer (capillary inlet): + 1000 mbar and 30 kV for 0.3 min.
8 ) Sample (capillary inlet): + 75 mbar and 0 kV for 0.82 min (approximately 10 cm 
injection plug).
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9) Terminating buffer (capillary inlet): + 75 mbar for 0.08 min (approximately 1 cm 
injection plug).
10) Terminating buffer (capillary inlet), tITP step: -18.0 mbar and 30 kV, for 0.2 min.
11) Terminating buffer (capillary inlet), counterflow (CF5): - 75 mbar for 0.64 min.
12)Leading buffer (capillary inlet), CZE separation: -30 kV only (unless other wise 
stated) for x min (where x is the number of minutes).
4.2.4c TITP separation steps for a 100 cm. 75 pm i.d. capillary using 10 mM ammonium 
formate (90 % acetonitrile/ 10 % deionised water! as the leading buffer: 10 mM L-alanine 
TIP % ACN/ 90 % deionised water! as the terminating buffer
1) Leading buffer (capillary inlet): + 1 000 mbar and 30 kV for 0.3 min.
2) Sample (capillary inlet): + 75 mbar and x kV for 1.26 min (approximately 1 0  cm 
injection plug).
3) Terminating buffer (capillary inlet): + 75 mbar for 0.126 min (approximately 1 cm 
injection plug).
4) Terminating buffer (capillary inlet): tITP - -28 mbar and 30 kV, for 0.2 min.
5) Terminating buffer (capillary inlet), counter-flow (CF5): - 75 mbar for 0.64 min.
6 ) Leading buffer (capillary inlet): +75 mbar for 0.64 min.
7) Leading buffer (capillary inlet), CZE separation: + 50 mbar and 30 kV (unless 
otherwise stated) for x min (where x is the number of minutes).
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4.2.4d TUP separation steps for a 100 cm. 75 urn i.d. capillary using 10 mM ammonium
formate (75 % acetonitrile / 25 % deionised water) as the leading buffer: 10 mM L-alanine 
(75 % ACN/ 25 % deionised water) as the terminating buffer
1) Leading buffer ( capillary inlet): + 1000 mbar and 30 kV for 0.3 min.
2) Sample (capillary inlet): + 75 mbar and x kV for 0.64 min (approximately 10 cm 
injection plug).
3) Terminating buffer (capillary inlet): + 75 mbar for 0.06 min (approximately 1 cm 
injection plug).
4) Terminating buffer (capillary inlet), tITP step: -14.0 mbar and 30 kV, for 0.2 min.
5) Terminating buffer (capillary inlet), counterflow (CF5): - 75 mbar for 0.32 min.
6 ) Leading buffer ( capillary inlet), CZE separation: + 30 mbar and 30 kV (unless 
otherwise stated) for x min (where x is the number of minutes).
4.2.5 CE/MS
CE/ESI/MS coupling was achieved using the coaxial sheath-flow interface via a VG 
Quattro I triple quadrupole mass spectrometer (Micromass, Manchester, UK). The sheath 
liquid comprised either; 1:1 MeCN/ELO + 0.1% formic acid, or run buffer and was 
delivered by a Harvard Model 11 syringe pump (Harvard Apparatus, Edenbridge, UK) at a 
flow rate of 3-5 pl/min. Refer to section 2.2.6 for a full description of experimental 
parameters.
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4.3 Results and discussion
On column tITP allows injection of larger volumes of dilute sample solution than can be 
achieved with sample stacking or CZE [7]. Recently Toussaint et al. [3] described the 
application of a counter-flow pressure during ITP to keep the focused sample stationary 
near the inlet end of the capillary, prior to CZE separation. Counter-flow pressure increases 
the amount of sample that can be loaded onto the system and may also improve the CZE 
separation path length (i.e. a further counter flow may be applied in order to bring the 
sample plug back to the inlet end of the capillary). A counter-flow pressure can be 
automatically applied by commercial equipment, such as the Crystal CE system, which 
enables pressure fine-tuning. There is no significant loss of efficiency upon the generation 
of an optimised counter-flow within the capillary due to the self-correction of diffusion 
band broadening during U P [3].
This approach was adopted rather than pre-concentration through a hydrophilic polymer 
coated capillary, since counter-flow tITP offered ease of method development and was 
relatively inexpensive to utilise. TITP is easily automated, with the instrumentation 
required being relatively simple. However, the volume of sample injected will influence the 
resolution. Thus the larger the sample volume, the shorter the effective length for CZE 
separation [17].
Counter-flow tITP is based on the measurements of the electrophoretic and hydrodynamic 
migration rates of the analyte during ITP-CZE. Thus by knowing the migration of the 
sample in the capillary during ITP, a counter-flow pressure can be applied to keep the 
sample stationary at the capillary inlet prior to the CZE separation [3].
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A strong EOF requires a high counter-flow balance. But if this counter flow is too high 
then it may result in the loss of analytes. EOF velocity ( v e o f )  is given by [17]
v e o f  =  F e o f  E  (4.5)
where peof is the electroosmotic mobility and E  is the electric field strength. A high 
counter-flow pressure may also disturb the focusing process, causing loss of analytes. Thus 
a lower counteiflow pressure provides greater sensitivity [17],
In order to reduce veof both the electric field strength and the electroosmotic mobility 
may be reduced [17]. One way of doing this is to use a relatively low pH for both the 
leading and terminating buffers.
Since the EOF is brought about through the force exerted on any charged particle in an 
electric field, this force may be balanced by the frictional counterforce of the fluid 
surrounding the particle. Because these two forces are equal, a steady state velocity, Vss 
achieved where [2 ]
Vss -  qE/f (4.6)
where q is the charge, E  is the electric field strength, and/is the frictional coefficient.
Figure 4.2 shows a schematic representation of the counter-flow tTTP procedure used for 
all analyses. Prior to sample injection the capillary was filled with the leading buffer (figure 
4.2).
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Figure 4.2. Schematic representation o f the counter-flow tITP-CZE procedure for the 
separation o f cations.
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Figure 4.2 was adapted from Toussaint et al. [3]. Where L is the leading electrolyte, T is 
the terminating electrolyte, and S is the sample plug. A is the conditioning step; B is the 
introduction o f the sample followed by the terminating buffer; C is the counter-flow tITP 
step; D is a further counter-flow step; E is CZE separation. Refer to section 4.2.4 for the 
conditions o f each step.
A 10 cm sample plug was introduced to the column, followed by a 1 cm plug o f 
terminating buffer. During the tITP step (C) the higher mobility solute ions initially move 
towards the boundary with the leading electrolyte, until a steady state is reach, whereas 
lower mobility solute ions lag behind. Thus it is essential for the leading electrolyte co-ion 
(ammonium) to have a higher electrophoretic mobility than the sample ions, and for the 
terminating electrolyte co-ion to have the lowest mobility o f all [3].
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Toussaint et al. [3] used this approach for the enantiomeric separation o f  clenbuterol. 
They incorporated 40 mM dimethyl-p-cyclodextrin into their leading electrolyte, which 
was 10 mM ammonium acetate, with a terminating electrolyte o f 10 mM p-alanine (both at 
pH 2.5). This was the method initially attempted for the separation o f nicotine and its 
metabolites. However, no cyclodextrins were used since chiral separations were not 
required and the p-alanine was replaced with L-alanine.
Instead o f finding the optimum counter flow pressure through the use o f migration 
studies, a slightly different approach was utilised. The only variable considered was the 
time for tITP to take place. By varying the time for tITP it was possible to gauge the 
optimum time by monitoring the quality o f the data produced. Thus the number of 
theoretical plates for cotinine was used as a marker for the optimisation o f this variable.
Figure 4.3. Number o f  theoretical plates obtained for cotinine in tITP as
a function o f tITP time.
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Error bars were a product o f the standard deviation (n = 5). Refer to section 4.2.4a for 
procedure. A 65 cm capillary + 50 pm i.d. was used, with a detection window at 50 cm and 
a wavelength o f 205 nm. N  = 5.54(//wi/2)2 (equation 3.1) [1], where N  is the number o f 
theoretical plates, t is the migration time and w\/2 is the peak width measured at half the 
peak height.
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Figure 4.3 shows that the optimum time for tITP to take place was 0.25 minutes and 
below, since the highest numbers of theoretical plates were observed at these lower times. 
As there was no significant difference in theoretical plate numbers between 0.25 and 0.05 
minutes, a time of 0.2 minutes was considered suitable for tITP. When tU P was employed 
for longer periods there was a rapid decline in the numbers of theoretical plates from 0.5 to 
5 minutes.
However, these results were extremely surprising as it is generally considered that the 
longer the tTTP process the greater the stacking effect. Therefore what was observed may 
have been the result of the breakdown of the tUP process, which would inevitably have led 
to considerable band broadening, and hence a reduction in peak efficiency. This could only 
have occurred if the counter flow pressure applied was not sufficient to keep the solute 
zone stationary during tTTP focusing. In other words the counter-flow pressure applied was 
not adequate for the maintenance of the steady state for longer periods. Thus only for short 
periods of time (e.g. 0.2 mins) would this counter-flow provide the necessary steady state 
for tITP focusing. This is understandable as the original method was designed for 
clenbuterol, which when particularly complexed to a cyclodextrin has a lower charge-to- 
size ratio than cotinine, and hence a lower mobility through the capillary. However, what 
seemed to have been a problem, in the end, proved to be an advantage as the short time for 
tITP would inevitably lead to shorter analysis times.
A switch was made from using a 50 pm i.d. to a 75 pm i.d. fused silica capillary, as the 
latter produced peak heights and areas 19.3 (n =5; RSD [based on the retention time of 
cotinine] = 1.52 %) and 2.16 times (n =5; RSD [based on the retention time of cotinine] = 
1.22 %) greater than the former. The reason for this signal enhancement was the increase in 
path-length for UV detection. The 75 pm i.d. capillary was used for the remaining studies.
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Figure 4.4. An electropherogram showing the signal enhancement o f 25 pg/ mL cotinine by 
tITP/UV as compared with sample stacking/UV.
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Refer to section 4.2.4b for tITP procedure. For sample stacking (refer to section 2.2 for 
procedure) the sample was injected for 0.2 min. at 25 mbar (8 mm plug); for tITP the 
sample was injected for 0.82 min at 75 mbar (10 cm plug). Wavelength = 205 nm; 65 cm 
capillary + 75 pm i.d.; detection window at 50 cm. Reproducibility was determined by the 
migration time for sample stacking (RSD = 2.46 %, where n = 5) and tITP (RSD = 2.89, 
where n = 5).
When tITP was compared to sample stacking for the analysis o f 25 pg/mL o f cotinine, a 
ten-fold increase in peak area was observed (figure 4.4). The introduction o f a greater 
quantity o f sample (10 cm sample plug), for tITP, brought about this increase. That is the 
greater mass o f  analyte in the capillary produced a greater response at the detector [2].
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The focusing of analyte bands in the capillary caused this enhancement via stacking. Thus 
a decrease in the peak width will result in an increase in the peak height, greater signal-to- 
noise ratio, and hence lower detection limits. Since the stacking process significantly 
reduces peak width, large sample volumes, such as that used to produce figure 4.4, can be 
injected without a significant loss of separation efficiency [11]. This results in a greater 
mass of analyte that can be introduced to the capillary and therefore a greater response at 
the detector [2].
In order to test the effect of tTTP on separation efficiency, the method was used for the 
analysis of five nicotine metabolites and the internal standard, NN-diethylnicotinamide.
Figure 4.5. TITP/ UV of five nicotine metabolites and NN-diethylnicotinamide.
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Refer to section 4.2.4b for tITP procedure. 1 = Nomicotine 2 pg/mL; 2 = Norcotinine 
2 pg/mL; 3 = Cotinine 1.25 pg/mL; 4 = 3HC 2 pg/mL; 5 = 5HC 2 pg/mL; 6 = NN- 
diethylnicotinamide 5 pg/mL. The sample was injected for 0.82 min at 75 mbar (10 cm 
plug). Wavelength = 205 nm; 65 cm capillary + 75 pm i.d.; detection window at 50 cm. 
Reproducibility was determined by the migration time of cotinine (RSD = 1.12, where n =
5).
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Figure 4.5 shows the clear separation o f five nicotine metabolites with no significant loss 
in separation efficiency, clearly establishing the success o f counter-flow tITP. Hence the 
analysis o f real samples could now be attempted. The sensitivity enhancements provided by 
tITP meant that pre-concentration, by SPE, could be kept to a minimum (i.e. two times pre­
concentration via a 100 mg C l8 cartridge- refer to table 2.1). This, it was anticipated, 
would also have the advantage that urobilinogen/ urobilin concentrations would not be high 
enough to influence viscosity and hence the separation.
Figure 4.6. TITP/UV electropherograms o f  spiked and unspiked smoker’s urine.
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Refer to section 4.2.4b for tITP procedure. Wavelength = 205 nm; 65 cm capillary + 75 pm 
i.d.; detection window at 50 cm. Reproducibility was determined by the migration time o f 
cotinine for spiked (RSD = 0.78, where n = 5) and unspiked (RSD = 0.56, where n = 5) 
samples.
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Figure 4.6 shows the clear identification of cotinine from a smoker’s urine, which had 
been subjected to only two times pre-concentration by SPE. This extraction procedure was 
significantly less time consuming than the two hundred fold pre-concentration of urine as 
less volume was required. A further five samples collected from five different smokers 
were also analysed (not shown). It was therefore evident that this method could provide the 
sensitivity required for use with the coaxial sheath flow interface for ESI-MS.
When coupling tUP to the MS, the fused silica capillary was withdrawn into the stainless 
steel sheath capillary until it was level with the sheath capillary, as this approach was 
successful in stabilising the electrospray when the predominantly aqueous buffer mixture 
was used (refer to figure 3.10). The buffer systems used were 10 mM ammonium formate 
and 10 mM L-alanine in 90 % MeCN and 10 % H2O, at pH 2.5 (HC1) (ammonium formate 
was used because it tended to produce a more stable spray than ammonium acetate).
Initially coupling tTTP to the MS proved to be extremely difficult. The main problem 
encountered was an influx of sheath liquid (MeCN/ H20  1:1 +0.1 % formic acid) in the 
outlet end of the fused silica capillary during the further counter-flow step (figure 4.2- step 
D). This was probably due to components of the sheath liquid disrupting CE separations by 
setting up transient moving boundaries migrating towards the injection side of the capillary. 
The solution to this problem was to push the sample plug approximately 5 cm forward, 
from the inlet, in order to remove the 5 cm sheath liquid plug at the outlet. It should also be 
noted that during the tITP step the sheath flow rate was increase to 25 pL/ min to ensure 
that no air entered the capillary. Once these practical issues were addressed tITP/MS was 
used to analyse nicotine and its metabolites in the urine of smokers (figures 4.7 and 4.8).
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Figure 4.7. SIR mass electropherogram of a smoker’s urine sample (1) via tUP.
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Refer to section 4.2.4c for tITP procedure. Two times pre-concentration o f urine sample via 
SPE; the sample was reconstituted in 90 % deionised H2O/IO % MeCN. 10 mM ammonium 
formate or 10 mM L-alanine (90% deionised water and 10 % acetonitrile), which were 
adjusted to pH 2.5 with HC1; sheath liquid was MeCN/ H2 O 1:1; 100 cm capillary + 75 pm 
i.d.; sheath flow rate used for separation was 5 pL/ min.
In figure 4.7 nicotine, nomicotine and cotinine are clearly observed. From the above 
electropherogram it is clear that good separation and peak efficiency were achieved. 
However, under the conditions used baseline stability was still an issue.
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Figure 4.8. SIR mass electropherogram of a smoker’s urine sample (2) via tITP.
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Refer to section 4.2.4c for tITP procedure. Two times pre-concentration o f urine sample via 
SPE; the sample was reconstituted in 90 % deionised H2O/IO % MeCN. 10 mM ammonium 
formate or 10 mM L-alanine (90% deionised water and 10 % acetonitrile), which were 
adjusted to pH 2.5 with HC1; sheath liquid was MeCN/ H2 O 1:1; 100 cm capillary + 75 pm 
i.d.; sheath flow rate used for separation was 5 pL/ min.
For smoker’s urine (2) (figure 4.8) nicotine and cotinine were clearly observable. Once 
again good separation and peak efficiency were achieved despite the application o f 50 mbar 
supplementary pressure. However, spray stability could not be maintained for long periods.
In order to improve the stability o f the electrospray, it was essential to raise the organic 
content o f the buffer systems used. Thus a buffer composition o f 75 % MeCN and 25 % 
deionised H2O was employed. The previously used sheath liquid, i.e. 1:1 
acetonitrile/deionised water + 0.1% formic acid, was also replaced with the buffer system.
Chapter 4 TITP/MS 155
The use of this run buffer as sheath liquid significantly improved beam stability (figure
4.9). The sheath flow rate was also raised to 25 pL/ min during tITP to ensure that no influx 
of air occurred.
HE injection was now incorporated into the sample introduction step for tITP/MS (refer 
to section 4.2.4b for method). This ensured that even greater sensitivity enhancements were 
achieved. The optimum voltage used was 7.5 kV at the inlet, with a potential difference of 
4 kV when the capillary voltage is taken into account of (figure 4.9). A low voltage was 
used to prevent overloading. The limits of detection (which was a linear representation of 
yB +  3 sb , i.e. three times the signal/noise ratio) for nicotine and cotinine obtained by this 
method were 30 ng/ mL and 330 ng/ mL respectively; whereas the limits of quantitation 
(which was a linear representation of ys + 1 O sb) for nicotine and cotinine were 90 ng/ mL 
and 1.14 pg/mL respectively. Limits of detection for both nicotine and cotinine were 
considerably lower than those obtained by HE injection-sample stacking/MS. It should also 
be noted that greater sensitivity enhancements might also be achieved, for HE injection- 
tlTP/MS, by increasing buffer concentrations, as this would amplify the focusing effect 
during tITP. The injection of larger volumes of sample could also be considered.
The HE injection-tITP/MS method was employed for the analysis of nicotine and six of 
its metabolites (figure 4.9).
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Figure 4.9. SIR mass electropherogram o f nicotine and six o f its metabolites via HE 
injection-tlTP.
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Refer to section 4.2.4d for tITP procedure. Two times pre-concentration o f urine sample via 
SPE; the sample was reconstituted in 25 % deionised H2O/7 5  % MeCN. 10 mM ammonium 
formate or 10 mM L-alanine (25% deionised H2O and 75 % acetonitrile), which were 
adjusted to pH 2.5 with HC1; sheath liquid was the leading buffer; 100 cm capillary + 75 
pm i.d.; sheath flow rate used for separation was 5 pL/ min. Reproducibility was 
determined by the resolution (mean = 7.30) between nicotine and cotinine (RSD = 4.19 %, 
where n = 5).
Figure 4.9 shows good separation and peak efficiency (theoretical plate numbers o f 36290 
and 36100 were achieved for nicotine and cotinine respectively) by HE injection-tlTP/MS. 
This was further emphasised by the separation o f trans-3'-hydroxycotinine from 5'- 
hydroxycotinine. The low supplementary pressure applied ensured that this system was 
more electrically driven as opposed to pressure driven. Five repeat analyses were carried 
out, confirming the stable nature o f the electrospray. Good reproducibility was also 
obtained. Since no problems were experienced with the further counter-flow step (figure
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4.2- step D) there was no requirement for the application of additional pressure to the inlet 
prior to analysis.
Unfortunately, however, there was only enough time to utilise this method for the 
analysis of a single smoker’s urine sample (figure 4.10).
Figure 4.10. SIR mass electropherogram of a urine sample from a smoker via HE injection- 
tHP.
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Refer to section 4.2.4d for tUP procedure. Ten times pre-concentration of urine sample via 
SPE; the sample was reconstituted in 25 % deionised H2O/ 7 5  % MeCN. 10 mM ammonium 
formate or 10 mM L-alanine (25% deionised H2O and 75 % acetonitrile), which were 
adjusted to pH 2.5 with HC1; sheath liquid was the leading buffer; 100 cm capillary + 75 
pm i.d.; sheath flow rate used for separation was 5 pL/ min. Reproducibility was 
determined by the migration time (RSD = 3.22 %, where n = 3).
Figure 4.10 shows the clear identification of nicotine, but not the presence of any of its 
metabolites. With only 10-fold pre-concentration via a 100 mg Cl 8 SPE cartridge, it might 
have been better to pre-concentrate the urine up to say 50-fold via a 1 g Cl 8 SPE and dilute
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down if sample overload of the capillary was experienced. Presumably more metabolites 
could have been identified this way. But again this would have been more time consuming.
Initially problems were experienced, with an influx of air at the outlet end of the fused 
silica capillary, during the further counter-flow step (figure 4.2- step D). But only when the 
sample plug was pushed approximately 5 cm forward, from the inlet, after the further 
counter-flow step, could the analysis proceed. This was surprising as there was no 
requirement for this step when nicotine and six of its metabolites were analysed (figure
4.9).
However, the above mass electropherograms suggest that HE injection-tITP/MS could be 
used as a complementary technique to HE injection-sample stacking/MS. That is, if urine 
concentrations are too low to be detected by HE injection-sample stacking/MS, then HE 
injection-tlTP/MS might be employed.
4.4. Conclusion
When coupling tTTP to the MS, the fused silica capillary was withdrawn into the stainless 
steal sheath capillary until it was level with the sheath capillary, as this approach was 
successful in stabilising the electrospray to some extent. Leading and terminating 
electrolytes, in 90 % MeCN and 10 % H2O, produced a spray that was stable for only short 
periods when a sheath liquid consisting of 1:1 MeCN/H2 0  + 0.1% formic acid was used.
However, the use of leading and terminating electrolytes, in 75 % MeCN and 25 % H2O, 
with the former as the sheath liquid produced a more stable electrospray. Reproducible high 
quality data was obtained when HE injection was coupled to tITP/MS. Limits of detection 
for both nicotine and cotinine were considerably lower than those obtained by HE 
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injection-sample stacking/MS. This suggests that HE injection-tUP/MS could be used to 
complement HE injection-sample stacking/MS.
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Chapter 5
In-vitro Study of Placental Metabolism of Nicotine via 
BeWo Cell Lines
5.1 Introduction
Glycogen stores in the endometrium (uterine wall) are only sufficient to nourish the 
embiyo during its first weeks. Thus in order to sustain the growing embryo/foetus for the 
duration of its intrauterine life, the “placenta”, a specialised organ of exchange between the 
maternal and foetal blood, is rapidly developed [1].
The development o f placental tissue 
The placenta is derived from both trophoblastic (foetal) and decidual (maternal) tissue. 
By day 12 of implantation, the trophoblastic layer becomes two cell layers thick and is 
called the chorion. The chorion forms an extensive network of cavities within the decidua, 
and as decidual capillary walls are eroded by chorionic tissue, these cavities become filled 
with maternal blood. Anticoagulants present in the chorion prevent the clotting of this 
maternal blood. Finger-like projections of chorion extend further into the maternal blood 
after which the developing embryo sends out capillaries into these chorionic projections to 
form placental villi. The foetal portion of the placenta is then anchored to the endometrium 
via the extension of some villi across the blood filled spaces [1]. The thin layer of chorionic 
tissue that surrounds the embryonic capillaries of the placental villi ensure that the
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embryonic/foetal blood is kept separate from the maternal blood in the intervillus spaces. 
The placenta can therefore be visualised as an entire system of interlocking maternal 
(decidual) and foetal (chorionic) structures [1].
Placental junction
During intrauterine life, the placenta may perform the functions of the digestive system, 
the respiratoiy system and kidneys. The syncytiotrophoblast layer of the placenta may also 
be involved in the synthesis of steroid and peptide hormones, which are required for normal 
foetal growth and development [2]. The trophoblastic layer facilitates the .transfer of 
nutrients (from the mother’s digestive system) and oxygen (from the mother’s respiratoiy 
system) from the maternal blood into the foetal blood, and carbon dioxide (eliminated via 
the mother’s lungs) and other waste material from the foetal blood into the maternal blood 
(eliminated via the mother’s kidneys) [1].
Substances may traverse the placental barrier by special mediated transport systems in the 
placental membranes or by simple diffusion. However, not all substances that traverse the 
placental barrier are beneficial as nutrients, as the many drugs, environmental pollutants, 
other chemical agents, and microorganisms, that may be present in the mother’s blood 
stream could potentially all pass through the placental barrier. These may have devastating 
effects on the growing foetus or an infant’s development after birth. Similarly newborns 
can become addicted during gestation by their mothers’ use of an abusive drug and could 
therefore suffer withdrawal symptoms afterbirth [1].
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The presence o f cytochrome p450 in the placenta cell lines
Xenobiotics entering the body reach the placenta via the circulation together with 
nutrients and endogenous substrates. Physio-chemical properties of compounds, such as 
lipid solubility, molecular weight, and charge state, influence transport across membranes 
such as the placenta. The rate of transport of chemical compounds across the placenta may 
also depend on the potential for metabolism within the placenta [3]. Metabolism of the 
parent compound could produce metabolites, which are potentially more permeable through 
the placental barrier.
As previously described (section 1.6.1), the cytochrome p450 enzyme system plays an 
important role in nicotine metabolism. The CYP2A6, 2B6, and 2D6 isoenzymes have all 
been shown to play active roles in the conversion of nicotine to cotinine, with the 2A6 form 
predominating in this activity. Hakkola et al. [4] described the various CYPs present in 
placenta that had been identified via RT-PCR: at first trimester placentae expressed at 
mRNA level were CYP1 Al, 1A2, 2C, 2D6, 2E1, 2F1, 3A4, 3A5, 3A7, and 4B1 and at full 
term CYP1A1, 2E1, 2F1, 3A3/4, 3A5, and 3A7. Of these, of note is CYP2D6, which is 
reported to convert nicotine to cotinine. However, there was no detection of this CYP2D6 
mRNA “at term” [3,4], and in fact Glover et ah [5] reported no CYP2D6 activity in human 
placentae at all. Koskela et ah [6] were only able to detect significant amounts of CYP2A6 
mRNAs in liver tissues and nasal mucosa but not the placenta. These data suggest that both 
CYP2A6 and 2B6 are not present in the placenta, and that CYP2D6 may only exist in 
extremely small amounts.
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The BeWo cell line
Problems with culturing human cytotrophoblasts include the spontaneous differentiation 
to syncytiotrophoblasts in primary culture, and the inability of the syncytialised 
trophoblasts to form a confluent and consistent monolayer. Thus an alternative culture 
system for studying transplacental transport and metabolism in vitro is generally required 
[7]. The BeWo cell line is one such alternative.
The BeWo cell line is a human choriocarcinoma- derived cell line that is used as a model 
to study the mechanisms of transplacental passage of nutrients and metabolites [8], and is 
therefore used as a model for trophoblasts [9]. The BeWo cell line is particularly attractive 
for this purpose since it is relatively stable, easy to maintain by passage, and grows to a 
confluent monolayer in a relatively short period of time [10,11]. More importantly the 
BeWo cell displays many of the morphological and biochemical properties common to 
normal trophoblasts and has been shown to exhibit the various relevant transport 
mechanisms for transcelluar transport [2,8-14]. Furthermore these cells can be induced to 
differentiate into cells resembling syncytiotrophoblasts [15] in vitro by pharmacological 
agents such as forskolin [2,15-19] or methotrexate [16,20].
The presence o f cytochrome p450 in BeWo cell lines
Recently Avery et al. [21] described the presence of inducible CYP1 Al and 1A2 in the 
BeWo cell line. Results indicated high activity associated with liver microsomes, 
sometimes comparable activities in human placenta microsomes prepared from smokers, 
and relatively low activities in human placenta microsomes from non-smokers and in the 
primary cultures of cytotrophoblasts isolated from non-smokers, with the BeWo cell lines 
exhibiting the lowest activities relative to all other microsomes. However, compared to
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primary cultures of normal trophoblasts the CYP activity of the BeWo was far more 
sensitive to typical inducers (e.g. 3-methylcholanthrene). These results suggest major 
cytochrome p450 forms present in human placenta are present and inducible in BeWo cells, 
and that this cell line is a potential model of drug metabolism in the human trophoblast 
[21].
Aims and objectives
The objective of this study was to characterise the metabolic activity of CYPs (e.g. 
CYP2D6) in the placenta, with respect to nicotine, from a representative in-vitro human 
trophoblast-like cell line, BeWo. In order to study nicotine metabolism within the BeWo 
cell line, the monolayer was exposed to nicotine and the relevant metabolites were 
identified by HPLC/MS and CE/UV.
Chapters BeWo Study 166
5.2 Methods and Materials
5.2.1 Cell culture
Media type 1 consisted of 500 mL HAM F12 nutrient mixture (Sigma-Aldrich, Dorset, 
UK), 60 mL foetal calf serum (Gibco, Invitrogen Corporation, Paisely, Scotland, UK), 5 
mL glutamine (Gibco, Invitrogen Corporation, Paisely, Scotland, UK), and 5 mL 
penicillin/streptocillin (Gibco, Invitrogen Corporation, Paisely, Scotland, UK) (American 
Type Culture Collection [ATCC] requirements). Media type 2 consisted of 40 mL HAM 
F I2 nutrient mixture, 10 mL foetal calf serum, 1 mL glutamine, and 1 mL 
penicillin/streptocillin.
BeWo cells (in 10 % media type 1/1 % dimethylsulfoxide) were stored in liquid nitrogen, 
in 1 mL aliquots. The 1 mL aliquots were allowed to thaw at room temperature prior to use. 
5 mL media (type 1 or 2) was added to an aliquot of BeWo cells, in a 50 mL Falcon tube 
(BD Biosciences, Lab ware Europe, Pont De Claix, France), and centrifuged at 1000 g for 5 
minutes. A pellet was observed and the supematent removed. The Falcon tube was tapped 
vigorously until the pellet was broken up. 9 mL of media (type 1 or 2) was then introduced 
to the Falcon tube and mixed thoroughly, after which the 9 mL BeWo mixture was split 
into three 250 mL Falcon flasks (BD Biosciences, Labware Europe, Pont De Claix, 
France). To each flask 27 mL of media (type 1 or 2) was added. BeWo cells were incubated 
at 37 °C and in 5 % carbon dioxide (Hera Cell, Heraeus Instruments -  Kendo laboratory 
products, Germany). The media (type 1 or 2) was replaced every other weekday (with 30 
mL media) until the monolayer was 60 to 80 % confluent. It should be noted that the BeWo 
cell lines were epithelial human choriocarcinoma and obtained from the ATCC (Manassas, 
VA, USA); and the dimethylsulfoxide (DMSO) was from Sigma-Aldrich (Dorset, UK).
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BeWo cells were split as follows: the media (type 1 or 2) was first removed from the 
flask, and the cells were washed three times with 20 mL PBS (Dubelco’s, UK) (removing 
20 mL each time); 2 to 3 mL trypsin/EDTA (Gibco, Invitrogen Corporation, Paisely, 
Scotland, UK) solution was added to the flask and swirled, in order to break up the 
monolayer; 20 mL of media (type 1 or 2) was then added to the flask and swirled to remove 
any remaining adherent cells; the contents of the flask were then poured off into a Falcon 
tube and centrifuged at 1000 g for 5 minutes; after the removal of the supernatant, the 
Falcon tube was tapped in order to break up the pellet; 10 mL of media (type 1 or 2) was 
then added to the Falcon tube and the contents were thoroughly mixed; after which the 10 
mL BeWo mixture was split into three 250 mL Falcon flasks, followed by the addition of 
media (type 1 or 2) to give a final volume of 30 mL; the flasks were then incubated as 
normal.
When the monolayer was 60 to 80 % confluent, treatment with trypsin/EDTA and re­
suspension of BeWo cells (as previously described) in 26 mL media (type 1 or 2) was 
carried out. 1 mL of the BeWo mixture was then added to each well of a 24 well plate. The 
cells were incubated overnight under normal conditions. The following day the media was 
replaced with one containing 10 i^M forskolin (Sigma-Aldrich, Dorset, UK) (made up in 
ethanol) and incubated overnight. Timed experiments or concentration experiments or 
inhibition experiments with nicotine and/ or cotinine were then carried out (see section 4.3). 
Reactions were stopped when transferring 0.5 mL of BeWo supernatant (from each well) 
into Ependorff tubes containing 0.5 mL methanol (Fischer Scientific, Manchester, UK). 
The samples were then centrifuged at 1000 to 2000 g for 5 minutes and the supernatant 
removed (Tc-6 centrifuge, Sorval Instruments - Dupont, CT, USA). The plates were then 
discarded in biohazard waste bins.
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Haemocytometry requires a precision-made glass counting chamber consisting of a thick 
glass slide with a depressed central area that is converted into a volumetric chamber when 
overlaid by a glass cover slip. To facilitate counting the chamber has a ruled grid, with four 
comer squares and a central square each 1 mm2. At x 10-magnification, the numbers of 
cells within the 5 squares were counted. That is, the number of cells x 5 = x x 104 cells/ 
mL.
5.2.2 HPLC/UV and HPLC/MS
Sample preparation was as described in section 4.2.1. These samples were analysed by 
HPLC/UV and HPLC-MS using a VG Quattro I (Micromass, Manchester, UK) triple 
quadrupole mass spectrometer (in the selected-ion monitoring (SIM) mode) and an LCQ 
iontrap (TheimoFinnigan, Hemel Hempstead, UK) mass spectrometer (full-scan) both of 
which were operating in electrospray ionisation (ESI).
The HPLC/MS conditions were as follows; column Phenomenex Luna (Phenomenex, 
UK) 5p Cl 8 column [250 x 4.6 mm], mobile phase 15 % acetonitrile, 5 % methanol and 80 
% buffer in deionised water (10 mM ammonium acetate- pH adjusted to 4.8 with HC1) + 40 
% methanol; flow rate 1 mL/ min. A 50:1 split post column was employed with a flow of 
20 pL/ min being introduced into the mass spectrometer. The injection volume was 5 pL. 
HPLC/UV used the above mobile phase for separation with detection at 260 nm.
5.2.3. CE/UV and CE/MS
For CE/UV the detection window was burnt into the capillary 15 cm from the end of 
the capillary and analyses were performed at 205 nm. Inlet and outlet ends of the capillary 
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were housed in run buffer vials during a run. Separations were achieved using +30 kV. 
Data acquisition was performed by DAx 6.0 software (PrinCE Technologies, Emmen, 
Netherlands) for CE/UV. Samples obtained from cell culture were dried via nitrogen gas 
and reconstituted in the solvent mixture for both sample stacking and tUP. Refer to 
sections 2.2, 3.2, and 4.2 for the relevant sample stacking, and tITP/MS methodologies.
5.3 Results and Discussion
5.3.1. In-vitro Study of Placental Metabolism of Nicotine via BeWo Cell Lines 
Nicotine was introduced to the BeWo cell line via media type 1 and would presumably, 
be taken up by the cells via passive diffusion and/or the various other cellular transport 
systems. Once inside the cell, nicotine would be expected to undergo metabolism 
depending on the availability of the relevant CYPs (refer to figures 5.1 - 5.4).
Chapter 5 BeWo Study 170
Figure 5.1. A graph showing the amount o f  nicotine recovered versus the amount of 
nicotine incubated with BeWo cells at various incubation times.
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Analyses were performed on a LCQ ion trap mass spectrometer. HPLC/MS: 
Electrospray ionisation; 10 mM ammonium acetate (15 % MeCN/5 % M eOH/ 80 % 
H 20) + 40 % MeOH; C l8 Phenomenex Luna- 5mm, 250 mm, 1/50 split. Linear 
regression was used to determine the slope and the intercept, which in turn was used to 
determine analyte concentration.
Figure 5.1 shows the reduction in nicotine levels within the media over time. The 
recovered nicotine concentrations should have been approximately half o f  their injected 
amounts since 500 pL o f methanol was added to 500 pL o f supernatant from each well. 
This was more or less true for 50 and 100 pg/mL concentrations o f nicotine, after 30 
minutes incubation, since the recovered amounts were 23.44 and 51.96 pg/mL respectively. 
Presumably this was due to a short incubation time for nicotine uptake by the cells. 
However, the 500 and 1000 pg/mL concentrations o f nicotine showed reductions o f 36.74 
% and 53.67 % respectively. Therefore after 30 minutes incubation there was a mean 76.82 
% recovery among all injected concentrations o f nicotine. Thus higher concentrations o f
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nicotine may be required to ‘initially’ facilitate the uptake and/or metabolism o f this 
compound.
After three hours incubation a mean recovery o f 64.4 % was observed among all nicotine 
concentrations. But only after 24 hours did we observe a near-complete reduction in 
nicotine levels. This suggested that nicotine uptake by the differentiated BeWo cells was 
near completion and/or that it was being extensively metabolised. The latter was further 
emphasized by the production o f cotinine after 24 hours for all injected amounts o f  nicotine 
(Figure 5.2). However, the near complete reduction o f  nicotine could also be a result of 
nicotine-induced expression o f the relevant CYP gene, between 3 and 24 hours incubation, 
since the greatest reduction occurred within this time period. The expression o f  this gene 
would lead to the production o f the necessary CYP required for metabolism.
Figure 5.2. A graph showing the amount o f cotinine recovered as a result o f the 
amount o f nicotine incubated with BeWo cells at various incubation times.
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Analyses were performed on a LCQ ion trap mass spectrometer. HPLC/MS: 
Electrospray ionisation; 10 mM ammonium acetate (15 % MeCN/5 % M eOH/ 80 % 
H 20) + 40 % MeOH; C l8 Phenomenex Luna- 5mm, 250 mm, 1/50 split. Linear 
regression was used to determine the slope and the intercept, which in turn was used 
to determine analyte concentration.
Chapter 5 BeWo Study 172
The 1000 pg/mL concentrations of nicotine, at all incubation times, failed to yield any 
cotinine (figure 5.2). A possible reason for this was that the cells may have lost their 
functions due to nicotine toxicity at such a high concentration. In order to test this 
hypothesis, a further study on cell viability versus nicotine concentration should have been 
carried out. Unfortunately time did not permit us to do so.
The occurrence of nicotine metabolism suggests the presence of the appropriate CYPs. 
Thus it is most probable that the appropriate mechanisms for nicotine metabolism were 
present. If other relevant machinery for metabolism were present, then the various 
metabolites produced would be excreted from the cells by those same cellular uptake 
mechanisms. The excreted metabolites would then permeate the media, which would in 
turn be sampled for analysis. For this reason a second set of samples (media type 1) were 
analysed for a wider range of nicotine metabolites (figure 5.3).
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Figure 5.3. SIR mass chromatogram of 500 pg/mL nicotine incubated with BeWo cells
for 24 hours.
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It should be noted that the sample was spiked with 10 pg/mL NN-diethylnicotinamide, 
which was the internal standard. Analyses were performed on a VG Quattro quadrupole 
mass spectrometer. HPLC/MS: Electrospray ionisation; 10 mM ammonium acetate (15 % 
MeCN/5 % MeOH/ 80 % H20) + 40 % MeOH; C l8 Phenomenex Luna- 5mm, 250 mm, 
1/50 split. Reproducibility was determined by the RSD of the resolution (mean = 2.8, n = 3) 
between nicotine and cotinine (RSD = 1.22 %).
The amount of nicotine recovered (via linear regression) was 4.3 pg/mL. Thus up to 
98.28 %, of nicotine, had been taken up by the BeWo cells (figure 5.3). However, only 0.89 
pg/mL of cotinine was detected, indicating that either a substantial amount was present in 
the cells, or that it was extensively metabolised. In parallel to this study, the incubation of 
500 pg/mL cotinine for 24 hours, with the BeWo cells, also took place. In this case 42.86 
pg/mL of cotinine was recovered (via regression analysis), which meant that 82.86 % was 
taken up by the cells.
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It would therefore have been best to sample the monolayer as well as the supernatant, 
since many metabolites could still have been trapped within the cells. This would have 
given a better picture of the extent to which metabolism had progressed. The main reason 
for sampling the supernatant was to provide an easy way of determining nicotine 
metabolism. Sampling the monolayer would have required the use of trypsin/EDTA 
solution to break up the monolayer, which would have been very time consuming if 
manually done. But it appears that this is probably the only way of ascertaining the true 
extent of metabolism.
The number of metabolites detected suggest that the required mechanisms were in place 
for both nicotine and cotinine metabolism to occur in the BeWo cells (figure 5.3).
A third set of samples (media type 2) were analysed by CE/UV (figure 5.4). For the 
purpose of CE analysis the sample was dried with nitrogen gas and reconstituted with 
buffer. However, it might have been better to remove the supernatant from each well and 
extract the contents by SPE (as previously described in section 2.3.1). This would have 
aided sample clean-up, but would also have been more time consuming.
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Figure 5.4. CE-sample stacking/UV analysis of 250 pg/mL nicotine incubated with BeWo
cells for 24 hours.
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The sample was reconstituted in 1 mL o f 25 % H2O/7 5  % MeCN. The sample was spiked 
with 16 pg/mL of cotinine.The buffer system consisted o f 10 mM ammonium formate (pH 
adjusted to 2.5 with HC1), 75 % MeCN/25 % H20 ; 100 cm, 75 pm i.d. fused silica capillary 
was used; the sample was introduced at 10 kV + 25 mbar for 0.2 min. Separation took place 
at 30 kV. Reproducibility was determined by the retention time (n = 3) between o f  cotinine 
(RSD was 2.40 and 1.7 for non-spiked and spiked electropherograms respectively).
Figure 5.4 shows the distortion/ broadening o f  the nicotine peak due to sample overload 
on the capillary. Nicotine concentrations would in fact be 125 pg/mL after dilution o f 
supernatant collected from BeWo cells with methanol (refer to section 3.3.1). Unfortunately 
no quantitative analysis was carried out to ascertain the extent o f nicotine metabolism. But 
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in any case figure 5.4 shows that not all of the nicotine was metabolised, as a substantial 
amount was still present. This could have been due to the fact that the third set of samples 
were not as well differentiated as the first and second sets and hence did not metabolise 
nicotine to the same extent. Unfortunately we were not able to carry out fluorescent 
staining to capture (by photo) the extent of differentiation.
The high concentrating power of HE injection appears to have brought about the 
considerable overload of nicotine as shown by the distortion of the nicotine peak. But even 
though, the presence of cotinine was still observed. Hence the application of CE/MS for 
this study should be considered.
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5.3.2 CE/MS versus HPLC/MS
Table 5.1. HPLC/MS versus CE/MS.
Resolution 
nic-cot (RSD)
LOD
pg/ mL
LOQ
jig/ mL
Sample stacking 
-HE injection-MS
Nicotine 0.11 0.37
Cotinine
3.74“ (4.17) to 9.64b (4.83)
2.25 7.5
TTTP-HE injection 
-MS
Nicotine 0.03 0.09
Cotinine
7.30° (4.19)
0.34 1.14
HPLC/MS
Nicotine 0.04 0.14
Cotinine
2.23 (3.06)
0.07 0.22
1) ‘a’ denotes the use of 30 kV + 25 mbar (0.2 min) for HE injection, and separation at 30 
kV + 20 mbar; 2) ‘b’ denotes the use of 10 kV + 25 mbar (0.2 min) for the optimised HE 
injection, and separation at 30 kV + 10 mbar; 3) ‘c’ denotes the use of 7.5 kV + 75 mbar 
(0.64 min) for HE injection, and separation at 30 kV + 10 mbar.
Table 5.1 shows the lowest limits of detection (which was a linear representation of ye + 
3 s b )  and consequently the limits of quantitation (which was a linear representation of ye + 
1 0 sb )  to be found in all cases for nicotine. Transient isotachophoresis exhibited the lowest
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limits of detection and quantitation for nicotine, but not for cotinine. This was due to the 
higher mobility of nicotine, which ensured its greater pre-concentration with respect to 
cotinine especially as the sample was introduced by HE injection, as in the case of sample 
stacking. But, HPLC/MS exhibited the lowest detection and quantitation limits for cotinine. 
Thus overall HPLC/MS demonstrated the lowest limits of detection and quantitation.
Of the three methods described, HPLC showed the poorest resolution. One of the main 
problems with HPLC method development, for this particular analysis, was trying to 
separate 5'-hydroxycotinine from trans-3'-hydroxycotinine. The structural isomeric nature 
of these compounds made them extremely difficult to separate, even in the presence of 
cyclodextrins (12.5 mM a,p or y - from the authors previous work, not shown). Further 
more, 5'-hydroxycotinine was shown to co-elute with 3-pyridyl-y-oxomethylbutyramide 
(which shares the same molecular weight), and was not separated by cyclodetrins (figure 
5.5). The transfer of this technique, from UV to MS analysis, weakened the data 
qualitatively, as transfer to the MS required the mobile phase to be more volatile and hence 
less polar. This speeded up analysis significantly and reduced the time for effective 
separation.
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Figure 5.5. A chromatogram of nicotine and nine of its metabolites by HPLC/UV.
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HPLC/UV was carried out at 260 nm. A 5 pL injection volume was used throughout. C l8 
Phenomenex Luna- 5mm, 250 mm, was used.. 1= solvent front (3.84 min); 2 = 3-pyridyl 
acetic acid (4.18 min); 3 = nomicotine (4.79 min); 4 = cotinine-N-oxide (5.32 min); 5 = 
nicotine; 6 = nicotine l'-N-oxide; 7 = 5'hydroxycotinine (9.16 min); 8 = 3-pyridyl-y-oxo-N- 
methylbutyramide; 9 = 3-pyridyl-y-oxo-butyiic acid (9.82 min); 10 = cotinine (10.26 min); 
11 = NN-diethylnicotinamide (11.51 min). 10 mM ammonium acetate (15 % MeCN/5 % 
MeOH/ 80 % H20), adjusted to pH 4.8 with HC1. Reproducibility was determined by the 
migration time of the NN-diethylnicotinamide (RSD = 1.02, n = 5).
Clearly the structures of these compounds could have been elucidated by MS/MS, but the 
intention was to provide a simple way of identifying these metabolites through separation.
Resolution was shown to be greatest in the CE methods (table 5.1), since both sample 
stacking/MS and tJTP/MS were previously shown to have separated 5'-hydroxycotinine 
from trans-3'-hydroxycotinine (sections 2.3.1, 3.3.1 and 4.3.1). The numbers of theoretical 
plates observed via the mass spectrometer for cotinine were highest in HE-sample
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stacking/MS (50589), followed by HE-tlTP/MS (36100), and finally HPLC/MS (8000). 
However, the greater robustness of HPLC/MS made this technique very easy to couple to 
the MS. The fact that two separate electrical systems were used for CE/MS meant that the 
coupling of the two devices did not always provide us with a robust technique. Since 
subsequent fluctuations in the current (brought on by a variety of factors- refer to section
2), arcing, and base line dropouts, at times made both CE/MS techniques difficult to 
operate. The large volumes of dilute sample introduced by ATP/MS made this technique 
even more difficult to implement than sample stacking/MS. However, changes to interface 
characteristics, such as the use of the buffer system as the sheath liquid and the withdrawal 
of the capillary into the sheath tube (until they were both level), greatly improved spray 
stability. Overall HPLC/MS was the most reliable technique used for this analysis, but the 
major improvements to the coaxial interface performance, has made CE/MS an attractive 
alternative.
5.4 Conclusion
It is clear from our data that nicotine metabolism was observed. It is therefore probable 
that CYP mediated processes play an important role in nicotine metabolism in the placenta. 
However, there was much CYP activity unaccounted for, since in the second and third sets 
of BeWo cells the amount of cotinine and hence other major metabolites recovered, was 
still relatively low. Thus in order to ascertain the true extent of metabolism, the monolayer 
together with the supernatant should have been sampled.
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The consequences of CYP activity in human placenta, with respect to nicotine, could lead 
to the transport of pharmacologically active metabolites (such as nomicotine) to the 
developing foetus. It may also lead to the transport of teratogenic byproducts (which may 
result in reduced placental oxidative capacity and birth defects). However levels of CYP in 
the placenta are currently unknown and so despite these processes a large proportion of 
nicotine may pass to the foetus unchanged. This in effect may cause other problems, such 
as nicotine addiction in the newborn.
Overall HPLC/MS was the most reliable technique used for this analysis, but the major 
improvements to the coaxial interface performance, has made CE/MS an attractive 
alternative.
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Chapter 6
Conclusion
The overall aims of this work were to produce a sensitive, highly selective, and simple 
CE-sample stacking/MS assay for the measurement of nicotine and its metabolites in urine, 
to develop a highly sensitive transient isotachophoretic/MS method, that yields detection 
limits comparable to that observed by HPLC/MS and with a separation efficiency to match 
that of CE-sample stacking/MS, and finally to characterise the metabolic activity of 
cytochrome P450 (e.g. CYP2D6) in the placenta, with respect to nicotine, from a 
representative in-vitro human trophoblast-like cell line, BeWo, via HPLC/MS and CE/UV.
Analyses of urine samples were accompanied by sample clean up via SPE to ensure the 
appropriate removal of inorganic salts. Consequently a two hundred fold pre-concentration 
of urine, via SPE, was achieved through drying with nitrogen gas and reconstituting with 
buffer (for CZE) or the solvent mixture (for sample stacking). The removal of inorganic 
salts enabled the transfer of this sample medium to the mass spectrometer.
The stability of the electrospray was greatly improved by (a) withdrawing the fused silica 
capillary into the stainless steel sheath capillary until it was level with the sheath capillary 
and (b) replacing the previously used sheath liquid i.e. 1:1 acetonitrile/deionised water + 
0.1% formic acid, with the buffer system (10 mM ammonium acetate, 75 % MeCN/ 25% 
H20, adjusted to pH 2.5 with HC1).
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Sensitivity and throughput are important parameters when considering the analysis of 
multiple compounds within a sample. The former was brought about by the use of HE- 
sample stacking and is especially important for use with the mass spectrometer, since this 
detector is concentration dependent. It should also be noted that the dilution effect, brought 
about by the sheath liquid, requires the use of a sensitive method for MS analysis.
The HE injection method used for CE-sample stacking/ MS brought about lower 
detection limits (LODs of nicotine and cotinine, by CE-sample stacking/ MS (via HE 
injection), were found to be 0.11 and 2.25 pg/ mL, respectively) when compared to sample 
stacking/MS via hydrodynamic or electrokinetic injection alone. The hydrodynamic part of 
HE injection also ensured that lower mobility analytes would always be injected, thus 
reducing the sampling bias observed by electrokinetic injection.
The added selectivity that SIM provided ensured the clear identification of nicotine and 
its metabolites. The same pattern of elution was observed for nicotine and its metabolites 
from smokers’ urine. However, the inter-urine sample migration times of the metabolites 
appeared to differ slightly and were possibly attributed to the presence of urobilinogens and 
urobilins.
When high voltages (e.g. 20 to 30 kV) were used for HE injection, lower numbers of 
theoretical plates and reduced separation efficiency were observed. Thus the optimal 
voltage (e.g. 10 kV) was one that achieved great sensitivity enhancements without 
significantly compromising resolution and peak efficiency. However, the effect of HE 
injection on resolution and peak efficiency, at higher voltages, is dependent upon analyte 
concentration, prior to injection. The greater quantities of sample introduced into the 
capillary at higher voltages for HE injection correspond with the decline in peak efficiency
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and resolution. Thus an optimal voltage for HE injection can be selected to suit analyte 
composition.
It is also important to note that the highest peak efficiencies and separations were only 
obtained when no supplementary pressure was applied during separation, but severe 
fluctuations in current (due to the influx of air at the outlet end of the fused silica capillary) 
were also noticed.
The application of supplementary pressure during separation appeared to increase the 
throughput of analyses, but caused a reduction in resolution. Therefore there had to be a 
careful balance between obtaining high quality data and generating fast analysis times. The 
optimum appeared to be 10 mbar and below, where acceptable separations and theoretical 
plate numbers were achieved.
Daily changes in laboratory temperature did not affect reproducibility, but appeared to 
affect peak efficiency and resolution. Thus climate-controlled laboratories should be 
welcomed for this type of analysis.
A counterflow transient isotachophoresis (ATP) method was developed, with MS 
detection, for the analysis of even lower analyte concentrations. A major advantage of this 
method was that less sample pre-concentration by SPE was required, ensuring that 
separation would be less hampered by changes in sample viscosity.
Limits of detection for both nicotine (0.03 pg/ mL) and cotinine (0.34 pg/ mL), via HE- 
tTTP/MS, were considerably lower than those obtained by HE injection-sample 
stacking/MS, suggesting that HE-tlTP/MS could be used complement to HE injection- 
sample stacking/MS.
When HPLC/MS and CE/UV were used to analyse cytochrome p450 activity in the 
human trophoblast-like BeWo cell line, it was clear from our data that nicotine metabolism
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was observed. Thus it is probable that CYP mediated processes play an important role in 
nicotine metabolism in the placenta. However, there was much CYP activity unaccounted 
for as only the supernatant and not the monolayer was sampled. Hence the other major 
metabolites recovered were still in relatively low amounts. A better representation of 
metabolism could be obtained by sampling the monolayer together with the supernatant.
When compared to HPLC/MS both HE-sampIe stacking/MS and HE-tlTP/MS exhibited 
higher resolutions and peak efficiencies; with HE-tJTP/MS exhibiting comparable limits of 
detection and quantitation to those obtained by HPLC/MS with respect to nicotine, but not 
cotinine. Overall HPLC/MS was the most reliable technique used for this analysis, but the 
major improvements to the coaxial interface performance and sensitivity enhancements, has 
made CE/MS an attractive alternative.
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Chapter 7
Future work
• For the removal of urobilinogens and urobilins from urine, extraction by petroleum 
ether or acetaldehyde may be explored. A simpler way may be to pass urine through 
a C2 or C 3 SPE cartridge prior to performing SPE through a Cig cartridge.
• If problems associated with molecular imprinted polymers could be overcome (such 
as the leaching of template from the sorbent), then this approach could also be 
explored, in combination with SPE, for the extraction of nicotine and its 
metabolites.
• Improve throughput of HE-sample stacking/MS and HE-tlTP/MS analysis. In the 
case of the former the buffer pH could be raised to increase the EOF, which would 
result in faster analysis times. High throughput could also be achieved by increasing 
the concentration of the run buffer, which would improve separation, thus allowing 
for an increase in supplementary pressure applied.
• Improve sensitivity of HE-sample stacking/MS and HE-tlTP/MS. By increasing the 
concentration of the run buffers an enhanced stacking effect should result, and 
hence lower limits of detection be achieved. In terms of the latter, injection of larger 
volumes of sample injected could be explored.
• Transfer HE-sample stacking/MS and HE-tlTP/MS of urine to a patient study.
• Explore the use of capillary LC/MS, micro-LC/MS, and CE/MS for the BeWo 
study.
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• To sample both the supernatant and the monolayer to obtain a better representation 
of nicotine metabolism within the BeWo cell.
• To cany out inducer/pro motor and inhibitor studies for further characterisation of 
CYP activity in BeWo cells.
• Finally to use MS/MS for the structural elucidation of the protein in question.
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Abstract
The combination o f capillary electrophoresis (CE) and mass spectrometry (MS) with solid-phase extraction (SPE) has been used for the 
identification of nicotine and eight of its metabolites in urine. The recovery7 of cotinine from cotinine-spiked urine, by Cl 8 SPE, was found to 
be 98%. Smokers urine (200 ml) was preconcentrated 200-fold via SPE prior to analysis. The sample stacking mode o f  CE, when compared 
to capillary zone electrophoresis, was shown to improve peak efficiency by 132-fold. Tire combination of hydrodynamic and electrokinetic
injection was studied with sample stacking/CE/MS. The on-column limits o f  detection (LOD) o f  nicotine and cotinine, by this technique, 
were found to be 0.11 and 2 .25 jxg/ml, respectively. Hence, LODs o f  nicotine and cotinine in urine after 200-fold preconcentration were 0.55 
and 11.25 ng/ml, respectively.
© 2003 Elsevier B.V. All rights reserved.
Keywords: Sample stacking; Nicotine, metabolites
1. Introduction
Smoking is generally accepted as the major preventable 
cause o f mortality and morbidity in the western world. It 
is the major cause o f cancer mortality in the UK, and may 
contribute to the causation o f many other disease states in­
cluding atherosclerosis. Thus, smoking cessation may be the 
most effective strategy for reducing the incidence o f cancer, 
cardiovascular disease and strokes. It appears that although 
smoking prevalence is declining within the developed world, 
it is on the increase in most parts o f the developing world [1J.
The tobacco alkaloid, nicotine, is mainly responsible 
for its addictive properties [2,3J. Nicotine accounts for ap­
proximately 90% o f the alkaloid fraction in commercial 
tobacco, Nicotiana labaewn, and is a major component o f  
the particulate phase o f tobacco smoke. The presence o f  
nicotine in biological fluids, in humans, is primarily due 
to exposure to tobacco smoke, the consumption o f  certain 
nicotine-containing fruits, such as aubergines, making a
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negligible contribution |4J. In humans approximately 86% 
of systemically absorbed nicotine is metabolised to cotinine. 
The half-life o f cotinine is approximately 10-fold greater 
than that o f nicotine [5] and hence cotinine can be found 
in greater concentrations than the more rapidly metabolised 
nicotine [4]. Cotinine has therefore been widely used as the 
marker o f  choice for tobacco consumption (Fig. 1).
Currently, the most common analytical techniques em­
ployed for the determination o f nicotine and its related 
metabolites in biological fluids are gas chromatography-mass 
spectrometry (GC-MS) [5,6], high-pressure liquid chro­
matography (HPLC), radio immunoassy (RIA), enzyme- 
linked immunosorbent assay (ELISA) [4,7,8] and col­
orimetric techniques [8J. O f these, GC-MS is the most 
sensitive and specific method, but is labour-intensive [9]. 
HPLC methods (including LC-MS) have been used, but 
require extensive method development due to the low sep­
aration efficiencies obtained. Immunoassay techniques are 
relatively sensitive but cannot discriminate between several 
active analytes because o f specificity limitations due to 
cross reactivity with similar molecules [4,8].
In this area o f research the application o f  capillary elec­
trophoresis (CE) is still in its infancy. However, CE offers
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Fig. 1. The major mammalian pathways o f  nicotine metabolism.
several potential advantages over GC and HPLC for the 
analysis o f  complex mixtures o f  metabolites; including high 
separation efficiencies, extremely small injection volumes, 
short analysis times, rapid method development and low 
reagent costs [10]. CE may be used to perform highly ef­
ficient separations o f  a wide range o f  sample types, and 
the number o f  theoretical plates in CE may reach several 
hundred thousand [11].
The main limitation o f  CE is its lack o f  sensitivity 
[11-18]. Detection limits in CE are generally 10-100 
times higher than in HPLC [13,14]. The relatively higher 
limit o f  detection observed in CE comes from its re­
stricted injection volume (where typical injection volumes 
are in the nanolitre range) and the short path length for 
on-capillary detection (when coupled to a UV detector) 
[10,12]. Thus, a major area o f  interest in CE is to im­
prove its low concentration sensitivity without sacrificing 
resolution.
Several techniques have been shown to yield on-column 
sample concentration and to lower detection limits in CE. 
These include isotachophoresis [10], sample stacking [15], 
and filed amplified injection [17]. The most practical way to 
concentrate a sample is in fact the on-line sample stacking 
approach. The sample stacking phenomenon was first intro­
duced by Tiselius; and can be achieved through the manip­
ulation o f  sample and buffer solutions with injection proce­
dures common to any CE instrumentation (Fig. 2).
Palmer et al. [4] recently reported the separation and de­
tection o f standards o f nicotine and 10 o f  its metabolites 
using CE/MS. To date, there are no reported studies, to our 
knowledge, on the use o f  CE for the determination o f  nico­
tine and its metabolites in clinical samples. Its use has been
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Fig. 2. A comparison of (a) capillaiy zone electrophoresis and (b) sample 
stacking. In sample stacking the use of an injection solvent of lower 
ionic strength than the run buffer results in solute ions forming a narrow 
stacked zone on application of a voltage. This improves both sensitivity 
and peak shape.
reported, however, for the quantitative determination o f both 
nicotine in tobacco [19J and tobacco alkaloids (including 
nictotine) in single plant cells [20] The limits o f detection 
(LOD) reported were, for nicotine in tobacco 286 fg (using 
electrochemical detection) [19] and for nicotine in plant cells 
0.013 pmol (i.e. 2.1 pg) (using ultraviolet detection) [20].
By combining CE with mass spectrometry (MS) se­
lective identification and also structural elucidation, can 
be achieved. In this study, we demonstrate the use of 
solid-phase extraction (SPE) combined with sample stacking 
CE/MS for the determination o f nicotine and its metabolites 
in urine.
2. Experimental
2.1. Samples and sample preparation
Standards o f nicotine and its major metabolites were 
kindly donated by Dr. Peyton Jacob o f the Department 
o f Medicine and Drug Dependence Research Centre, San 
Francisco General Hospital Medical Centre. These were 
prepared in buffer for CE experiments or mobile phase for
HPLC or one-tenth of the run buffer for sample stacking 
experiments.
Urine was obtained from five male smokers, labelled A-E, 
and stored at —20 °C in tissue culture flasks. Two samples, 
labelled, Cj and C2 were collected from the same subject, 
but on different days. Prior to extraction urine samples were 
thawed overnight at 4 °C thoroughly mixed and filtered with 
a 0.45 pm  Supor Acrodisc filter.
2.2. Solid-phase extraction
Solid-phase extraction was carried out using a 1 g C 18 Iso­
lute cartridge (Jones Chromatography Ltd.). For condition­
ing purposes 6 ml o f methanol followed by 6 ml o f deionised 
water (Milli-Q) were passed through the SPE cartridge se­
quentially. Then, 100 ml o f sample was introduced into the 
cartridge followed by 6 ml o f deionised water. The sample 
was then eluted with 6 ml o f methanol. The eluted product 
was dried under nitrogen gas. The dried product was re­
constituted with 0.5 ml buffer (200-fold preconcentration for 
CE/MS) or 1 ml mobile phase (100-fold preconcentration for 
recovery experiment). The reconstituted product was then 
subjected to ultrafiltration (via a Sorval Tc centrifuge and 
Vivaspin Concentrator 3000 MW) at 3950 rpm for 20min.
2.3. Buffer preparation
A suitable quantity o f ammonium formate (Sigma- 
Aldrich) was dissolved in the solvent mixture (acetoni- 
trile/deionised water (Milli-Q)); buffer pHs were adjusted 
with formic acid or HC1 (Sigma-Aldrich), as appropriate, 
and were freshly prepared. Buffers were degassed prior to 
analysis using a Branson 1210 ultrasonic bath (Branson U l­
trasonics, Danbury, CT, USA) and filtered through a 0.2 pm  
syringe filter (Supor Acrodisk). The buffers prepared were 
25 mM ammonium formate (10% acetonitrile, 90 deionised 
water), which was adjusted to pH 2.5 with formic acid, for 
CZE; and 10 mM ammonium formate (75% acetonitrile, 
25% deionised water) adjusted to pH 2.5 with HC1, for 
sample stacking experiments.
2.4. Recovery experiments
Non-smoker’s urine (100 ml) was spiked with cotinine (at
1.25 and 0.625 pg/ml) and subsequently extracted using the 
SPE method described above. These samples were analysed 
by LC-MS using a VG Quattro I (Manchester, UK) triple 
quadrupole mass spectrometer operating in electrospray ion­
isation (ESI) and selected ion monitoring (SIM) mode.
The HPLC conditions were as follows: column Phe- 
nomenex Luna 5 pi C18 column (250 mm x  4 .6 mm), mo­
bile phase 15% acetonitrile, 5% methanol and 80% buffer in 
deionised water (10 mM ammonium acetate, pH adjusted to 
4.8 with HC1); flow rate 1 ml/min. A 50:1 split post column 
was employed with a flow o f 20 pl/min being introduced 
into the mass spectrometer. The injection volume was 10 pi.
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2.5. CE separation
CE was carried out in a 100 cm, 75 |xm i.d. x  365 pm o.d., 
untreated fused silica capillary (Composite Metal Services 
Ltd., Hallow, UK). The CE system used (Crystal CE Sys­
tem, Prince Technologies, Lauerlabs, Emmen, The Nether­
lands) utilizes programmable injection with pressure and 
voltage. Separations were achieved using + 30  kV (a field 
strength o f  350V/cm). Injections were performed either 
hydrodynamically (25 mbar/0.2min) or electrokinetically 
(30kV/0.2m in) or hydrodynamically +  electrokinetically 
(25 mbar +  30 kV/0.2 min). Initial conditioning o f the cap­
illary took place with 1 M NaOH (5 min) followed by the 
buffer system (7 min). The capillary was conditioned prior 
to each run with 1 M NaOH (2000mbar/l min) followed by 
buffer system (2000 mbar/1.5 min). The buffer system was 
replenished after each run cycle.
2.6. CE/MS
A VG Quattro I triple quadrupole mass spectrometer was 
used throughout. To date, electrospray ionzation (ESI) is 
the most common technique for coupling CE to MS. In 
these experiments, CE/ESI/MS coupling was acheived using 
the co-axial sheath-flow interface developed in-house and 
previously described by Palmer et al. [4]. The sheath liquid 
comprised either; 1:1 MeCN/TUO + 0.1%  formic acid, or 
run buffer and was delivered by a Harvard Model 11 syringe 
pump (Harvard Apparatus, Edenbridge UK) at a flow rate 
of 3-5 pl/min.
Positive ions were generated through the application o f  
3.5 kV to the probe tip, with a source cone voltage o f 25 V. 
Desolvation was aided by nebulising gas (~401/h) and bath 
gas (~2251/h). Capillaries employed for CZE/MS were 
50 |xm i.d. x  375 pm o.d. and 100cm in length.
Data was either acquired by selected ion recording o f  
the analyte protonated molecules employing a 1 Da window 
with a dwell time o f 0.08 s or in full scan mode from 70 to 
200 Da in 0.5 s.
3. Results and discussion
Table 1 summarises the data obtained from the LC/MS re­
covery experiments. Percentage recoveries were calculated 
from a linear calibration plot o f eight points, recorded in du­
plicate. The R2 value for the calibration data was 0.9993. The
1.25 and 0.625 pg/ml cotinine-spiked urine samples were 
analysed in triplicate and an overall mean percentage recov­
ery o f 98% was obtained.
Fig. 3(a) shows non-optimised CE/MS mass electrophero- 
grams obtained from the analysis o f a standard mixture of 
the major nicotine metabolites and Fig. 3(b) the correspond­
ing optimised separation for comparison. We have found that 
several factors are important in obtaining reproducable high 
quality eleetropherograms when using the co-axial CE/MS 
electrospray interface (Table 2).
In order to obtain good signal to noise in CE/MS and 
hence good detection limits a stable electrospray is required. 
We were able to improve the stability o f the electrospray 
over our earlier work [4] by: (a) withdrawing the fused silica 
capillary into the stainless steel sheath capillary until it was 
level with the sheath capillary and (b) replacing the previ­
ously used sheath liquid, i.e. 1:1 acetonitrile/deionised water 
+  0.1% formic acid, with the buffer system. By withdraw­
ing the fused silica capillary into the stainless steel capillary, 
the length o f the fused silica that can be surrounded by the 
sheath capillary is maximised. Hence, the maximum electri­
cal contact between the sheath capillary and the fused silica 
capillary is obtained. The use o f the run buffer as sheath liq­
uid improved beam stability presumably due to the homo­
geneous nature o f the sheath liquid and the buffer reducing 
mixing effects.
A second major issue in obtaining reproducible high qual­
ity CE/MS data using the co-axial arrangement is drying 
out o f the electrophoresis capillary. One possible approach 
to solving this is the application o f a supplementary pres­
sure to the head o f  the column [21], In our earlier work 
[4], a supplementary pressure o f 50 mbar was in fact em­
ployed but used in conjunction with sample stacking to im­
prove sensitivity and peak shape. If we examine Fig. 3a a 
CZE separation where a supplementary pressure o f 50 mbar 
is used without sample stacking. It can be seen this has a 
markedly detrimental effect on separation efficiency. This is 
presumably since the flow profile now has the characteristic 
parabolic shape o f a pressure driven system rather than the 
plug flow profile o f an electrically driven system. Careful 
arrangement o f  the relative height o f  the buffer reservoir and 
the CE/MS probe allowed us to reduce the supplementary 
pressure to 20 mbar. Best results were obtained when the 
buffer reservoir was approximately 1 cm above the CE/MS 
probe. Combining all o f the slight modifications to our pre­
vious methodology with sample stacking gives stable and 
reproducible high quality eleetropherograms (Fig. 3b).
Table 1
Percentage recovery of cotinine from a 1 g C18 SPE cartridge (n =  3)
Unknown concentration (pg/ml) R.S.D. Recovery (%)
0.625 pg/ml cotinine 100 times preconcentration (Isolute Ig  C l8) 63.86 0.07 102.17
1.25pg/ml cotinine 100 times preconcentration (Isolute Ig  C l8) 118.34 0.07 94.67
Mean 98.42
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Table 2
A study of the reproducibility of the developed sample stacking CE/MS separation method
Mean resolution Resolution S.D. Resolution R.S.D. (%)
Sample stacking
Sample A (cot-5HC) 2.59 1.17 x 10_I 3.15
Sample B (cot-5HC) 1.41 1.44 x 10~2 4.52
Sample Ci (cot-5HC) 2.21 9.78 x 10~2 1.02
Sample D (cot-5HC) 2.16 7.70 x 10~2 3.57
Sample E (cot-5HC) 2.18 8.39 x 10~2 3.85
CZE
Sample C2 (cot-5HC) 2.36 6.10 x 10~2 2.57
Sample stacking (cot-3HC)
Hydrodynamic injection 0.75 1.89 x 10~2 2.51
Electrokinetic injection 1.26 9.98 x 10“3 0.80
Hydrodynamic +  electrokinetic injection 0.77 2.42 x IQ-2 3.15
The resolution, R, between two adjacent peaks (cotinine and S'-hydroxycotinine for A-E and cotinine and trans-3'-hydroxycotimne for the three injection 
methods) was calculated as follows: R =  2(t2 — t \)/ (w\  +  wj); where ty and ti,  and uq and W2 are the retention times and peak widths of adjacent 
peaks, respectively. For smokers urine samples A-E, n =  3; n =  5 for CZE; n =  5 for injection methods; where n is the number of repeat analyses.
Sample injection in CE is generally performed by hydro- 
dynamic or electrokinetic injection. During hydrodynamic 
injection (HE) the sample vial is pressurised, forcing the 
sample into the capillary. Thus, the volume o f sample in­
jected is dependent on the magnitude and duration o f the 
pressure applied, the capillary dimensions, and the sample 
viscosity. Electrokinetic injection is performed by placing 
the capillary and the anode into the source inlet vial and ap­
plying a voltage over a period o f time. Thus, ionic solutes 
are injected as a result o f their electrophoretic mobilities, 
with neutrals being pushed through the capillary as a result 
o f the electro-osmotic flow.
Electrokinetic injection provides for sensitivity enhance­
ments in comparison to hydrodynamic injection, since the 
volume o f sample solution that can be introduced does 
not limit the injected amount o f the sample. However, 
sampling bias is a major drawback o f electrokinetic injec­
tion, since larger quantities o f higher mobility solutes are 
injected than those o f lower mobility. An example o f sam­
pling bias was observed in this work. When electrokinetic
injection was employed, 7-3-pyridyl-y-oxo-butyric acid and 
cotinine-iV-oxide were not detected presumably since they 
were not injected in an adequate amount to yield a sufficient 
response from the mass spectrometer for detection. In order 
to eliminate this effect the combination o f electrokinetic and 
hydrodynamic injection was employed. The injected quan­
tities o f  nicotine and cotinine for the HE method were 0.83 
and 0.74 ng, respectively. O f this 0.29 ng of both nicotine 
and cotinine was contributed by the hydrodynamic injection 
element (Table 3) and hence electrokinetic injection con­
tributes 0.54 and 0.45 ng o f both nicotine and cotinine, re­
spectively. That is 65% of the nicotine HE load and 61% of  
the cotinine HE load.
Sample stacking was employed in conjunction with the 
combined injection procedure in order to achieve the best 
possible sensitivity. The limits o f detection, by CE-sample 
stacking/MS, o f nicotine and cotinine, respectively, for 
the three injection methods were found to be; (1) 0.11 
and 2.25 |ig/m l for the HE injection method; (2) 2.86 and
6.25 p-g/ml for hydrodynamic injection; and (3) 0.18 and
Table 3
Sample injection data calculated for CE-sample stacking/MS
Injected quantity (ng) Injected volume (nl) Sample plug length (mm) Mean migration time (min) tm R.S.D. (%)
Hydrodynamic +  electrokinetic 
Nicotine 0.83 132.04 29.89 10.27 1.52
Cotinine 0.74 118.15 26.74 12.24 2.08
Thiourea 0.51 18.6 82.17 24.58 4.04
Uracil 0.51 18.48 81.65 24.41 3.70
Hydrodynamic
Nicotine 0.29 45.98 10.40 9.59 3.77
Cotinine 0.29 45.98 10.40 11.2 3.83
Thiourea 0.29 45.98 10.40 22.2 3.05
Uracil 0.29 45.98 10.40 22.1 2.71
The viscosity o f the buffer system was calculated as 0.51 cP. {2,nj =  (Vj/1 x 106) x c x 1000; Lp =  (A P x f x d2)/(  53.3 x i ) x L )  +  ( « x / x  (Vjnj/ V^p); 
Vi =  (r x 1 x 10<v)2 x (L p  x 1 x 103) x n  x 1 x 1012; where Qmj is the injected quantity; Ki„j the injected volume; c  the concentration in pg/ml; Lp the 
sample plug length; AP  the pressure across the capillary; t the injection time; d  the capillary inner diameter; t] the viscosity of the sample solution; L 
the total length of the capillary; v the velocity of the analyte in mm/min; K[nj the injection voltage; and the separation voltage.
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Fig. 4. SIR mass eleetropherograms of a smoker’s urine (sample E); all conditions as Fig. 3b.
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3.27 (Jig/ml for electrokinetic injection. Thus, it is clear to 
see that the HE injection method yields the lowest limits 
of detection, followed by electrokinetic, and finally hydro- 
dynamic injection. The lowest detection limits yielded by 
the HE injection method can be explained by its ability 
to introduce the greatest quantity o f  sample to the capil­
lary (Tabic 3). It should also be noted that the higher elec­
trophoretic mobility o f nicotine results in greater quantities 
of this solute being introduced to the capillary than coti­
nine. This, accompanied with the higher ionising potential 
o f nicotine ensured its lower limit o f detection. Comparison 
o f the limit o f detection obtained for nicotine by HE injec­
tion o f 0.11 jxg/ml, i.e. 14.5 pg on-column (Table 3) with the 
reported literature values of, for nicotine in tobacco 286 fg 
[19] (using electrochemical detection) and for nicotine in 
plant cells 0.013 pmol (i.e. 2.1 pg) [20] (using ultraviolet de­
tection), shows that the sensitivity o f our CE/MS method is 
comparable with that o f CE with ultraviolet detection.
Optimisation o f the electrospray together with the appli­
cation o f sample stacking (via HE injection) has greatly im­
proved peak efficiency, baseline stability, and detector re­
sponse to the analytes (Fig. 3b); and the added selectivity 
that SIM provides ensures the clear identification o f nico­
tine and its metabolites. The order o f  elution is comparable 
to that shown by Palmer et al. [4J.
When applying this method to urine samples, sample pre- 
concentration via solid-phase extraction was required (with 
the 200-fold preconcentration o f sample achieved). Data 
from a smoker’s urine (Fig. 4) shows the clear identifica­
tion o f nicotine, cotinine and the other major metabolites 
of nicotine. Since nicotine has only a half-life o f approxi­
mately 2 h, the relatively high abundance on the mass elec- 
tropherogram could be attributed to the recent exposure of 
the smoker tobacco smoke.
Samples Ci and D (not shown) exhibited a more exten­
sive metabolism o f nicotine and hence had a relatively low 
abundance o f this analyte on both mass eleetropherograms. 
The high abundance o f 5'-hydroxycotinine with respect to 
/rans-3'-hydroxycotinine in all the mass eleetropherograms, 
with the exception o f sample C2 , suggests that the major 
pathway for cotinine metabolism is via 5'-hydroxycotinine. 
This is further confirmed by the presence o f 3-pyridyl acetic 
acid. However, it is possible that tran.s,-3,-hydroxycotinine 
could mainly exist in the glucuronide form. More 
work in this area (with respect to patient studies) is 
required.
The inter-urine sample migration times o f  the metabo­
lites appeared to differ slightly. The probable cause be­
ing, the presence o f urobilins and urobilinogens in urine. 
The presence of this compound in urine may be brought 
about by the derivation o f bilirubin from senescent red blood 
cells and from other haem-containing proteins, such as cy­
tochromes. Bilirubin is poorly water-soluble and so under­
goes glucuronidation to form bilirubin diglucuronide, which 
is excreted into the bile. The glucronide residues are released 
in the terminal ileum by intestinal bacterial hydrolases. Free
bilirubin is then reduced to colourless urobilinogens, which 
are oxidised to coloured products known as urobilins. Uro­
bilins are mainly excreted in the faeces, but small propor­
tions o f urobilins and urobilinogens are excreted in the urine. 
Urobilins give urine its yellow pigment. Since ultrafiltra­
tion o f the urine sample only filters proteins o f 3000 MW 
and over, urobilins and urobilinogens (584.65 MW) are still 
present in the filtered urine. When preconcentrating urine by 
200-fold the concentration o f urobilins increase and hence 
the viscosity increases. Thus, an increase in viscosity will 
increase migration times, but not the order o f elution pro­
viding the fused silica capillary is long enough for effective 
separation.
4. Conclusions
The 100-fold preconcentrations o f 1.25 |xg/ml and 
625 ng/ml o f cotinine, in urine, showed a mean percentage 
recovery o f 98% from a l g  C l8 SPE cartridge. Hence, 
the 200-fold preconcentration o f sample could be achieved 
through drying w'ith nitrogen gas and reconstituting with 
buffer.
A combination o f hydrodynamic and electrokinetic injec­
tion was used for sample stacking/MS due to the lower de­
tection limit, and the reasonable number o f theoretical plates 
achieved. Thus, sample stacking mode o f  CE, when com­
pared to CZE was shown to improve peak efficiency by a 
mean o f 131.6-fold.
LODs o f nicotine and cotinine, by CE-sample stack­
ing/MS (via HE injection), were found to be 0.11 and
2.25 p.g/ml, respectively. Thus, the LODs o f  nicotine and 
cotinine after 200-fold preconcentration would be 0.55 and
11.25 ng/ml, respectively.
The added selectivity that SIM provided ensured the clear 
identification o f nicotine and its metabolites.
The same pattern o f elution was observed for nicotine and 
its metabolites from smoker’s urine. However, the inter-urine 
sample migration times o f  the metabolites appeared to dif­
fer slightly and were attributed to the presence o f urobilino­
gens and urobilins. The extraction o f  both tetrapyrroles by 
acetaldehyde and petroleum ether, from urine, is currently 
under investigation.
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